

BEFORE THE ADMINISTRATIVE LAW JUDGE  
THE HONORABLE KELLY ESKEW  
APPOINTED BY THE INDIANA HORSE RACING COMMISSION

2017 AUG -4 3:16

INDIANA HORSE RACING COMMISSION STAFF,  
Petitioner,

v.

JOHN MCCREARY,  
Respondent

)  
)  
) ADMINISTRATIVE  
) HORSE COMPLAINT  
) NO. 217002  
)  
)  
)  
)

**NOTICE OF OPPORTUNITY TO PRESENT BRIEFS AND ORAL ARGUMENT**

This matter is pending before the Indiana Horse Racing Commission (“Commission”) on the Recommended Administrative Penalty against John McCreary. On July 17, 2017, the Administrative Law Judge (“ALJ”) designated by the Commission, Kelly Eskew, issued her Recommended Order Granting Commission Staff’s Motion for Summary Judgment (“Recommended Order”) in this case. On July 28, 2017, McCreary filed his objections to the Recommended Order.

Notice is hereby given that the Commission will afford both parties an opportunity to present briefs concerning the filing of McCreary’s objections and the merits of this case. Any briefs filed by McCreary or the Commission Staff must be received in the offices of the Commission by noon on August 18, 2017. The Commission will accept electronic filing at [hnewell@hrc.in.gov](mailto:hnewell@hrc.in.gov). No late filings will be accepted and/or considered.

The Commission will also consider oral argument at its meeting on August 25, 2017. The oral argument will be limited to ten minutes per side.

SO ORDERED, 4<sup>th</sup> day of August 2017.

THE INDIANA HORSE RACING COMMISSION



By: \_\_\_\_\_

Philip C. Borst  
Chairperson  
Indiana Horse Racing Commission

Copies forwarded by electronic mail sent on July 27, 2017:

Lea Ellingwood  
General Counsel  
Indiana Horse Racing Commission  
1302 North Meridian, Suite 175  
Indianapolis, Indiana 46202  
lellingwood@hrc.in.gov

John McCreary  
8080 Knapp Rd.  
Indianapolis, IN 46259  
John\_mccreary@comcast.net

BEFORE AN ADMINISTRATIVE LAW JUDGE  
APPOINTED BY THE INDIANA HORSE RACING COMMISSION

INDIANA HORSE RACING COMMISSION  
STAFF,

Petitioner,

v.

JOHN MCCREARY

Respondent.

In Re: Administrative Complaint No. 217002

2017 JUN 16 AM 12  
COMMUNICATIONS SECTION

**INDIANA HORSE RACING COMMISSION STAFF'S MOTION FOR  
SUMMARY JUDGMENT AND MEMORANDUM IN SUPPORT THEREOF**

The Indiana Horse Racing Commission Staff (hereinafter the "Commission Staff"), by counsel, pursuant to Ind. Code § 4-21.5-3-23, respectfully submits its Motion for Summary Judgment requesting that the Administrative Law Judge (hereinafter the "ALJ") issue a recommended Order in favor of the Commission Staff that affirms the violation found in and the sanctions proposed by Administrative Complaint No. 217002 (the "Complaint" or "Admin. Compl."). In support of this motion, the Commission Staff designates: (1) the Affidavit of IHRC Executive Director Michael Smith (with attached exhibits); (2) the Affidavit of Petra Hartmann, Drug Testing Services Director, Industrial Laboratories (with attached exhibits); and (3) the Affidavit of Scott Stanley, University of California – Davis Laboratories (hereinafter "U.C. Davis") (with attached exhibits). The Commission Staff respectfully submits that there is no genuine issue of material fact with respect to the matters referenced in the Administrative Complaint. In support of its motion, the Commission Staff submits the following Memorandum.

**I. INTRODUCTION**

The Indiana Horse Racing Commission has been established by the Indiana Pari-Mutuel Wagering on Horse Races Act (the "Horse Racing Act"), codified at Ind. Code § 4-31 *et seq.*

The Horse Racing Act provides that the purpose of the article is to “permit pari-mutuel wagering on horse races in Indiana **and to ensure that pari-mutuel wagering on horse races in Indiana will be conducted with the highest of standards and the greatest level of integrity.**” Ind. Code § 4-31-1-2 (emphasis added).

The Indiana Legislature provided specific direction to the Commission with respect to the illegal medication and/or drugging of racehorses. Chapter 12 of the Horse Racing Act makes clear that (unless specifically authorized by the Commission) there is an absolute prohibition against allowing a horse that has “drugs [and] medications or substances foreign to the natural horse” in its system to compete in a race without suffering an appropriate sanction. Ind. Code §§ 4-31-12-1, 4-31-12-2(a). That sanction includes the mandatory forfeiture of any purse that was earned as a result of the horse’s performance. Ind. Code § 4-31-12-13(b)(1). This absolute prohibition and the related legislative forfeiture directive have been incorporated into the applicable Commission regulations at 71 IAC 8.5-1-2.

In addition, the Commission has delegated to its Executive Director the authority to issue an administrative complaint in order to propose the assessment of administrative sanctions when it has been determined that a licensee has committed a violation of the Horse Racing Act or of applicable Commission regulations. 71 IAC 10-3-20. Mike Smith, the Commission’s Executive Director, issued the Complaint at issue to John McCreary on or about January 31, 2017.

## **II. UNDISPUTED MATERIAL FACTS**

John McCreary (“McCreary”) was licensed as a trainer by the Commission in 2016 and was at all times subject to the jurisdiction of the IHRC. (Affidavit of Mike Smith [“Smith Aff.”], ¶ 7.) McCreary was the trainer of American Purr, a Quarter Horse racehorse that competed in the first race at Indiana Grand on September 10, 2016. (Smith Aff., ¶ 5, 7.) American Purr placed first in the race, and was awarded a purse of \$8,800. (Smith Aff., ¶ 5.)

Following the race, and pursuant to 71 IAC 8.5-2-3, post-race blood and urine specimens were taken from American Purr. (Smith Aff., ¶ 12.) The American Purr specimen, labeled Sample No. E200939, was sent to Industrial Laboratories Company (“Industrial”), a Commission-approved laboratory, for analysis pursuant to the Commission’s regulations. (Smith Aff., ¶ 14.) On September 29, 2016, Industrial reported to the Commission Staff that Sample No. E200939 tested positive for mepivacaine in blood, a therapeutic substance under the regulations governing medication of Quarter horses that may not exceed the “level of detection” (“LOD”) in blood or serum. (Smith Aff., ¶ 15, Hartmann Aff. ¶ 7). McCreary, upon being notified of the positive test results and advised of his rights to have the split sample sent to an independent laboratory approved by the Commission, requested split sample testing. ( Smith Aff., ¶16) Specifically, McCreary requested a split sample of American Purr’s blood and urine be tested by U.C. Davis, a Commission-approved split laboratory. On November 7, 2016, the split sample, Sample No. E200939, was sent to U.C. Davis for analysis pursuant to the Commission’s regulations. U.C. Davis received the samples on November 8, 2016. (Stanley Aff. ¶4.) On December 15, 2016, U.C. Davis reported to Commission Staff that Sample No. E200939 tested positive for mepivacaine. (Stanley Aff. ¶7.)

Mepivacaine is a therapeutic substance, with a threshold limit, that is classified by the ARCI Uniform Classification Guidelines for Foreign Substances and Recommended Penalties and Model Rule, Version 12.00 revised on or about April 8, 2016 (hereinafter “ARCI Uniform Guidelines”), as a Class 2 drug with a category “B” penalty classification (“Class 2-B foreign substance”). (Smith Aff., ¶¶ 18; Smith Aff., Ex. 2). 71 IAC 8.5-1-7, which, in relevant part, was in full force and effect at all times relevant to this case, directs the Commission to consider and impose penalties consistent with the ARCI Uniform Guidelines. Within a given substance’s

ARCI penalty classification, the primary factors in determining the severity of a licensed trainer or owner's penalty are the number and recency of any past violations. (Smith Aff., ¶ 11). McCreary had no similar substance violations within the past 365 days at the time the Commission Staff received the test results from Industrial. (Smith Aff., ¶ 20; Smith Aff. Ex 8). Taking all of these facts into consideration, the Commission Staff recommended that McCreary be fined \$500 and be suspended for fifteen (15) days in addition to loss of purse (for first place finisher American Purr) from Race 1 held at Indiana Grand on September 10, 2016. (Smith Aff., ¶ 19; Smith Aff. Ex 2). This penalty is warranted because the recommended sanctions follow the ARCI recommended guidelines for category "B" penalty classifications. Specifically, for a first offense, the ARCI-recommended Category B penalty is a minimum 15-day suspension and \$500 fine, absent mitigating circumstances. (Smith Aff., ¶¶ 18-20; Smith Aff., Ex 2). The Commission Staff's recommended penalty imposed the minimum recommended sanctions proposed under the ARCI Guidelines. In addition, forfeiture of the purse is required pursuant to applicable Indiana statutes and regulations. Ind. Code § 4-31-12-13(b)(1); 71 IAC 8.5-1-2(b).

### **III. PROCEDURAL HISTORY**

Mike Smith, as the Executive Director of the Commission, is charged with the responsibility and authority for the implementation, administration, and enforcement of the Horse Racing Act, Ind. Code § 4-31 *et. seq.* See also 71 IAC 2-5-1(a). As previously stated, on January 31, 2017, Mr. Smith issued Administrative Complaint No. 217002 recommending that McCreary be assessed an administrative penalty of a fifteen (15) day suspension, fined Five Hundred Dollars (\$500), that American Purr be disqualified from the first race at Indiana Grand on September 10, 2016, and that the (first place win) purse at issue be forfeited and redistributed. This case was subsequently assigned to Administrative Law Judge Kelly R. Eskew ("ALJ Eskew").

#### IV. ARGUMENT

##### A. Summary judgment standard in administrative proceedings.

Ind. Code § 4-21.5-3-23 provides that “[a] party may, at any time after a matter is assigned to an administrative law judge, move for a summary judgment in the party’s favor as to all or any part of the issues in a proceeding.” Ind. Code § 4-21.5-3-23(a). The administrative law judge “shall consider a motion filed under subsection (a) as would a court that is considering a motion for summary judgment filed under Trial Rule 56 of the Indiana Rules of Trial Procedure.” *Id.*

Indiana Trial Rule 56(C) provides that summary judgment is appropriate when there are no genuine issues of material fact and when the moving party is entitled to judgment as a matter of law. Ind. R. Trial P. 56(C); *Parker v. Ind. State Fair Bd.*, 992 N.E.2d 969, 976 (Ind. Ct. App. 2013). “A genuine issue of material fact exists where facts concerning an issue which would dispose of the litigation are in dispute or where the undisputed facts are capable of supporting conflicting inferences on such an issue.” *Parker*, 992 N.E.2d at 976 (internal citations omitted). “The party moving for summary judgment bears the burden of making a *prima facie* showing that there is no genuine issue of material fact and that he or she is entitled to a judgment as a matter of law.” *Id.* “Once the moving party meets these two requirements, the burden shifts to the non-moving party to show the existence of a genuine issue of material fact by setting forth specifically designated facts.” *Id.* Here, the Commission has shown that it is entitled to summary judgment in these proceedings because there can be no dispute that: (1) a horse racing in Indiana is prohibited from having foreign substances in excess of established thresholds in its system at the time of a race; (2) American Purr had a foreign substance in excess of established thresholds in its system at the time of the race; (3) its trainer, John McCreary, is responsible for the presence

of this substance under the applicable law and regulations; and (4) the sanction recommended to be imposed by the Commission Staff on McCreary is reasonable and appropriate.

**B. A horse racing in Indiana is prohibited from having foreign substances in excess of established thresholds in its system at the time of the race, and American Purr's samples were found to contain such a substance.**

A horse participating in a race in Indiana is prohibited from carrying in its body any foreign substance that is not specifically authorized by Commission regulations. *See* Ind. Code § 4-31-12-2. Certain foreign substances allowed are allowed as therapeutic substances, as long as they do not exceed the given threshold limits. 71 IAC 8.5-1-4.2. The Commission regulations direct the Executive Director to consider the ARCI Uniform Guidelines in both classifying a therapeutic substance and when imposing penalties and proposing sanctions for exceeding the threshold limit. 71 IAC 8.5-1-7. According to the ARCI Uniform Guidelines in effect at the relevant times in 2016, mepivacaine is a Class 2 drug with a “B” penalty classification. (Smith Aff., ¶ 18; Smith. Aff., Ex. 2) The Commission regulation that authorizes the presence of mepivacaine in a horse as a therapeutic substance, sets the maximum level, in blood or serum, at the time of a race as the LOD. Accordingly, the mere detection of mepivacaine in blood or serum is considered violation under the Commission’s regulations and its presence in American Purr on September 10, 2016, constitutes an unquestionable violation of the Commission’s threshold levels’ rule. 71 IAC 8.5-1-4.2(15).

A finding at a Commission-approved laboratory that a test sample taken from a horse contains a drug or its metabolites or analogs creates a presumption that the “procedures of collection, preservation, transfer to the laboratory, and analysis of the sample are correct and accurate.” 71 IAC 8.5-2-1(2). Moreover, the presence of **“any quantity” of a drug or drug metabolite in excess of the allowable limits**, such as mepivacaine, supports a finding of a positive test and compels the attendant consequences. 71 IAC 8.5-3-3(g) (emphasis added). In



other words, it is not relevant under the Commission's regulations how someone might characterize the amount of the drug that was present upon testing (i.e., minimal, moderate, substantial, etc.) or what the precise quantity of the drug was that may have been found in the horse's system.

The finding of a drug positive also creates a presumption that the foreign substance was in the horse's body at the time the race was run. 71 IAC 8.5-1-2(a). Positive laboratory results are *prima facie* evidence that the foreign substance has been administered to the horse in violation of the Commission's rules. 71 IAC 8.5-2-1. In addition, a positive test creates a *prima facie* case that the trainer (or his or her agents) responsible for the care and custody of the horse was negligent in the handling or care of the horse. 71 IAC 8.5-1-2(a). This is consistent with the regulation that imposes a duty on a trainer to "prevent the administration of any drug or medication or other prohibited substance that may cause a violation of these rules." 71 IAC 5.5-3-2(b). Stated another way, a claim that the mepivacaine may have entered American Purr's body via the act of a third person are unavailing because McCreary, as the trainer, was responsible for the condition of his horse regardless of any acts of third persons. 71 IAC 5.5-3-2(a).

After obtaining and testing the samples of American Purr's blood and urine (in accordance with the procedures set forth in 71 IAC 8.5-2-3(b)) following the September 10, 2016 Indiana Grand race, the Commission's approved laboratory, Industrial, confirmed the presence of mepivacaine in American Purr's blood and U.C. Davis confirmed the presence of mepivacaine in the split sample. (Smith Aff., ¶¶ 15, 17). These facts lead to the inevitable conclusion of a positive test result for the presence of mepivacaine, which establishes the Commission's *prima*

*facie* case that such illegal foreign substance was in American Purr's body at the time it ran the races, in violation of Indiana law and the Commission's rules.

**C. The recommended sanctions imposed upon McCreary are both reasonable and appropriate.**


Indiana law mandates the forfeiture of a purse when any therapeutic substance exceeding the threshold limit is detected in a horse participating in a race. *See* I.C. 4-31-12-13; 71 IAC 8.5-1-4.2(15). Furthermore, the ARCI Uniform Guidelines' recommended minimum penalty for a first violation (in any jurisdiction within 365 days) involving a Class 2-B foreign substance, such as mepivacaine, is a suspension of at least fifteen (15) days and a minimum \$500 fine (absent mitigating circumstances). (Smith Aff., ¶ 19; Smith Aff., Ex. 2) The actual sanction the Commission Staff has recommended to be imposed upon McCreary is just that: a fifteen (15) day suspension, a \$500 fine (and the loss of the purse, as required by Indiana law). This Commission Staff recommended penalty is clearly reasonably related to the minimum recommended penalties for a first offender, and, accordingly, cannot be determined to be unreasonable. The ARCI Uniform Guidelines contemplate and are consistent with the sanctions recommended here.

**V. CONCLUSION**

As the trainer of American Purr, McCreary is responsible for a violation of 71 IAC 8.5-1-4.2(15) that prohibits a horse from carrying any therapeutic substance in its body exceeding the threshold limit, based upon a positive drug test. The presence of mepivacaine in the samples of American Purr as measured by Industrial Laboratories is a *prima facie* violation of 71 IAC 8.5-2-1 which prohibits a race horse from carrying a substance, in violation of Commission rules, in its body during a race. In the absence of "substantial evidence" that a third person was responsible for the administration, McCreary (as trainer) is responsible. 71 IAC 5.5-3-2(a) and (b); 71 IAC 8.5-2-1.

**WHEREFORE**, the Indiana Horse Racing Commission Staff respectfully requests that the Administrative Law Judge enter an Order granting Summary Judgment in favor of the Commission Staff, thereby adopting the sanctions proposed by the Commission Staff and imposing the recommended penalty for McCreary of a fifteen (15) day suspension, a Five Hundred Dollar (\$500) fine, and the forfeiture and redistribution of the first place purse for the first race at Indiana Grand on September 10, 2016.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Lea Ellingwood', written over a horizontal line.

Lea Ellingwood, # 22346-49

INDIANA HORSE RACING COMMISSION  
1302 N. Meridian Street, Suite 175  
Indianapolis, IN 46202  
Tel: (317) 232-0397  
Fax: (317) 233-4470  
lellingwood@hrc.in.gov

*Attorney for Indiana Horse Racing Commission Staff*

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing has been served via electronic mail and deposited in the U.S. mail, first-class postage prepaid, on the 16<sup>th</sup> day of June, 2017, to:

John McCreary  
8080 Knapp Rd.  
Indianapolis, IN 46259  
[John\\_mccreary@comcast.net](mailto:John_mccreary@comcast.net)

The Honorable Kelly R. Eskew  
Administrative Law Judge  
1309 East 10<sup>th</sup> Street, HH4080D  
Bloomington, IN 47401  
[HorseRacingALJ@gmail.com](mailto:HorseRacingALJ@gmail.com)



---

Lea Ellingwood

BEFORE AN ADMINISTRATIVE LAW JUDGE  
APPOINTED BY THE INDIANA HORSE RACING COMMISSION

2017 JUN 14 A 10:18

INDIANA HORSE RACING  
COMMISSION STAFF,  
Petitioner,

INDIANA  
HORSE RACING COMMISSION

v.

In Re: Administrative Complaint No. 217002

JOHN MCCREARY,

Respondent.

**AFFIDAVIT OF MIKE SMITH**

Comes now the undersigned, and being duly sworn upon his oath, alleges and says as follows:

1. I am an adult, over eighteen (18) years of age, of sound mind, have personal knowledge of and am competent to testify as to the matters contained herein.
2. I am the Executive Director of the Indiana Horse Racing Commission (the "Commission"). I commenced my duties on February 1, 2016. The Executive Director is the highest ranking member of the Commission Staff.
3. As Executive Director of the Commission, I am a custodian of records that are maintained by the Commission in the ordinary course of its business.
4. As Executive Director, I have familiarity with the foreign substance screening program.
5. My review of information relating to the first race conducted at Indiana Grand on September 10, 2016 reveals that American Purr finished first and was

awarded an \$8,800.00 purse. The Program for Race 1 at Indiana Grand is attached to this Affidavit as Exhibit 1.

6. At all times relevant, American Purr was owned by Bennett Racing Stable (Diane Bennett) of whom were licensed by the Commission as owner.
7. At all times relevant, American Purr was trained by John McCreary, who was licensed by the Commission as a trainer.
8. Participation in pari-mutuel racing in Indiana is a privilege, and not a right.
9. Any horse participating in a pari-mutuel race is subject to 71 IAC 8.5-2-3(b), and can be selected for post-race blood and urine analysis.
10. Commission regulations dictate that the Judges shall consider the classification level of the violation as currently established by the Uniform Classification Guidelines of Foreign Substances and Recommended Penalties and Model Rule published by the ARCI, and impose penalties and disciplinary measures consistent with the recommendations therein. 71 IAC 8.5-1-7. The version of the ARCI Uniform Guidelines in effect at the time of the September 10, 2016 race at issue is attached to this Affidavit as Exhibit 2.
11. The primary factors in determining the severity of a licensed trainer or owner's penalty are the number and recency of any past violations.
12. Blood and urine samples were collected from American Purr after the September 10, 2016 race.

13. The blood (serum) of American Purr was assigned Sample No. E200939. The sample tag is attached to this Affidavit as Exhibit 3. The Commission Test Barn Report is attached to this Affidavit as Exhibit 4.
14. Pursuant to Commission regulations, the blood and urine of American Purr was sent to The Industrial Laboratories Company in Wheat Ridge, Colorado (“Industrial”) on September 10, 2016. The Chain of Custody Form reflecting the shipment is attached to this Affidavit as Exhibit 5.
15. On September 15, 2016, Industrial Laboratories identified Sample No. E200939 as being positive for mepivacaine in the serum, The Affidavit from Industrial Laboratories showing the positive findings is attached to this Affidavit as Exhibit 6.
16. McCreary was notified of the positive tests and requested that a split sample be tested.
17. On December 15, 2016, University of California - Davis identified Sample No. E200939 as being positive for mepivacaine in the serum. The positive letter relating to the positive findings is attached to this Affidavit as Exhibit 7.
18. Mepivacaine is a Class 2 drug with a Category “B” penalty. Exhibit 2, pg. 6.
19. The Uniform Guidelines recommend a minimum of a 15-day suspension, a \$500.00 fine (per violation) in addition to loss of purse for the September 10, 2016 race. Exhibit 2, pg. 29.

20. McCreary had not been sanctioned for any other incident taking place within the past 365 days of the September 10, 2016 race. John McCreary's USTA ruling report is attached to this Affidavit as Exhibit 8.
21. IHRC Chairman Tom Weatherwax directed that the matter be heard by Administrative Law Judge Kelly Eskew ("ALJ Eskew") and was forwarded to her for consideration.
22. Attached Exhibits 1 through 8 reflect entries, reports, records and/or data compilations that were made at or near the time of the occurrence of the matters set forth in each of the records, by or from information transmitted by a person with knowledge of the existence of the matters recorded therein.
23. Attached Exhibits 1 through 8 and the entries, reports, records and/or data compilations that they reflect are, and were, kept in the course of regularly conducted business activities of the Commission.
24. Attached Exhibits 1 through 8 and the entries, reports, records and/or data compilations that they reflect are, and were, made and gathered as a part of the regular business practice and activity of the Commission.
25. I certify the authenticity of Exhibits 1 through 8 pursuant to the provisions of Indiana Rules of Evidence 803(6) and 803(8).


Further Affiant Sayeth Not.



I affirm under the penalties for perjury that the foregoing representations are true and correct to the best of my knowledge.

6-13-17

Date




Mike Smith

STATE OF INDIANA )

) SS:

COUNTY OF MARIION )

Before me the undersigned, a Notary Public in and for said County and State, personally appeared Mike Smith and acknowledged the execution of the foregoing instrument this 13<sup>th</sup> day of June, 2017.

  
\_\_\_\_\_  
Notary Public

Lisa Ellingwood  
\_\_\_\_\_  
Printed Name

My Commission Expires:

8/6/23

County of Residence:

Hamilton

HORSE IN TODAY

Table listing horses and their connections for the day's races, including names like 'A First Down Legacy', 'Big Tymn Connection', etc.

TRAINER IN TODAY

Table listing trainers and their win percentages for the day's races, including names like 'Almanza, Julio', 'Barraza, Felix', etc.

COMPARATIVE RANKINGS

Table comparing horses across various metrics: Wins At Distance, Last 3 Finishes, Lifetime Wins, In The Money, J/T Meet Wins, Class Rating, Avg Last 3 Speed, Best Overall.


Daily Double / Exacta / Trifecta / 50 Cent Trifecta / Superfecta / 10 Cent Superfecta / 50 Cent Pick 3 (Races 1-2-3)

1

Indiana Grand Race Course

Purse \$16,000. (\$3,200 from the IQHBDF) For REGISTERED INDIANA BREDS Maidens, Two Years Old. Weight, 120 Lbs. THREE HUNDRED YARDS

2yo MAIDEN



Track Record: Tre Boss(4), 127 lbs.; :15.24 (4-18-11)


equibase.com/QR

Table for horse #1: Coors N Cowboys (QH) B. Includes pedigree, owner (Amy Youngblood and Deborah A. Smith), trainer (Randy M. Smith), and race results.

Table for horse #2: Legally Separated (QH) B. Includes pedigree, owner (Skys The Limit Racing), trainer (Tim Eggleston), and race results.

Table for horse #3: A Hare in My Corona (QH) S. Includes pedigree, owner (Dicky Wayne Benton), trainer (Dicky Wayne Benton), and race results.

Continued on next page Saturday, September 10, 2016 IND Race 1



**4** **Rainbow Moose**(QH)**S** Sor g. 2 (Jan 17, 2014) Life: 5 0 1 0 \$4,125 Dirt: 5 0 1 0 \$4,125  
 Yellow EDUARDO GALLARDO (143-18-17-13 3%) 34% Palm Beach (Mr Jess Perry) - Elegant Winner (Runaway Winner) 2016: 5 0 1 0 \$4,125 Wet Dirt: 1 0 0 0 \$250  
 Br: Sheri Miller (IN) 2015: 0 0 0 0 \$0 Turf: 0 0 0 0 \$0  
 Own: Ronald G. Brown Ind Dirt: 5 0 1 0 \$4,125 Wet Turf: 0 0 0 0 \$0  
 Tr: Ronald G. Brown (208-16-35-19 8%) 34% Distance: 1 0 0 0 \$250 Synthetic: 0 0 0 0 \$0  
 Blue, Blue "RB" on White Ball, White Chevrons on Sleeves L 120  
 Class Rating: 32  
 12Aug16 Ind10 ft 330Y hw<sup>13</sup>:18316;17254 2 **ESK** - SPEEDSALES - 36k 57-48 8 8 97 1/2 -- 97 96 Beltran J A 122 bl 29.80 Powerfull Stone126 1/2 Sheza Classy Bay124nk Kids Bright Image121 1/2 trailed 9  
 02Aug16 Ind9 ft 350Y nw :18716;17927 2 **SMdn** 16000 66-23 9 10 8 1/2 -- 94 94 1/2 Beltran J A 124 bl 4.60 Louisiana Sixes124 1/2 Flyhichicky120nk Solo Cup121nk betwn,altered in late 10  
 28Jun16 Ind12 ft 350Y tw<sup>14</sup>:18448;18436 2 **SMdn** 16000 74-42 7 5 5 1/2 -- 1hd 2hd Beltran J A 122 bl 4.00 Hez Stone Runner127hd Rainbow Moose122hd A Hare in Hy Corona122hd surged, outfinished 10  
 04Jun16 Ind5 my<sup>5</sup> 300Y nw :16198;16087 2 **EFtr** 5000 74-38 7 3 -- -- 4 1/2 4 1/2 Beltran J A 120 bl 26.40 Rockin Tokyo125ns Streaking Jazz123nk Im a Jackson125nk late interest 9  
 13May16 Ind9 ft 250Y nw :15581;13574 2 **SMdn** 16000 10--- 6 8 -- -- 99 1/2 9 1 1/2 Collins H 127 L 17.90 Jes a Spitfire124 1/2 Run Run Corona121 1/2 Heza Quarter Captain120nk awk st,lost path early 9  
 Work(s): 25 May 16 Ind 220Y ft :12.60 b g 11/11 7 May 16 Ind 220Y ft :12.32 b g 11/15 15 Apr 16 Ind 220Y ft :12.03 b g 8/23  
 Trainer (Last 365 days): All: 43 14% \$0.95 Dist/Surf: 43 14% \$0.95 2YOs: 14 14% \$1.39 MdnSpecial: 11 0% \$0.00 With Jockey: 2 0% \$0.00

**5** **American Purrr**(QH)**B** Sor g. 2 (Mar 13, 2014) Life: 3 0 0 0 \$6,880 Dirt: 3 0 0 0 \$6,880  
 Green GIOVANI VAZQUEZ-GOMEZ (84-7-14-13 8%) 40% American Runaway (Ocean Runaway) - This Cat Purrs (First Wrangler) 2016: 3 0 0 0 \$6,880 Wet Dirt: 2 0 0 0 \$350  
 Br: Dianne S Bennett (IN) 2015: 0 0 0 0 \$0 Turf: 0 0 0 0 \$0  
 Own: Bennett Racing Stable (Dianne Bennett) Ind Dirt: 3 0 0 0 \$6,880 Wet Turf: 0 0 0 0 \$0  
 Tr: John McCreary (50-4-3-3 8%) 20% Distance: 2 0 0 0 \$6,780 Synthetic: 0 0 0 0 \$0  
 Blue and White, White "B" L 120  
 Class Rating: 55  
 13Aug16 Ind4 sy<sup>5</sup> 350Y hw<sup>5</sup>:18586;17962 2 **EFtr** 5000 70-40 2 6 5 3 -- 64 64 VazquezGomez 6 127 fl 7.40 Wrs Whoseyourdaddy124 1/2 First Cucuy125 1/2 Hh Kentucky Krome126 1/2 bumped, no menace 10  
 18Jun16 Ind9 ft 300Y nw :15844;15681 2 **SIJAGUARSTKS** - 131k 86-67 1 5 -- -- 5 1/2 4 1/2 Oxendine S L 122 fl 14.70 Dn Dis Prospect124nk Cb Come Fly With Mel25 1/2 Chics Dirty Secret120nk lacked closing kick 9  
 04Jun16 Ind7 my<sup>5</sup> 300Y nw :15850;15629 2 **EFtr** 5000 86-58 7 3 -- -- 52 4 1/2 Oxendine S L 123 fl 9.30 Dna Dales Prospect125 1/2 Flyhichicky120 1/2 Dashin to Fame125hd drifted in, mild gain 8  
 Work(s): 23 Jul 16 Ind 220Y ft :11.96 b g 6/9 17 May 16 Ind 220Y ft :11.69 b g 8/15 7 May 16 Ind 220Y ft :11.53 b g 6/15 23 Mar 16 RP 250Y ft :13.84 h g 15/96 5 Mar 16 RP 220Y ft :13.24 h g 66/77  
 Scratch(es): 19 Jul 16 Ind10 350Y ft Mdn 16000; Also-Eligible  
 Trainer (Last 365 days): All: 57 7% \$2.05 Dist/Surf: 57 7% \$2.05 2YOs: 33 9% \$2.09 MdnSpecial: 29 7% \$1.76 With Jockey: 14 0% \$0.00

**6** **Big Tymin Connection**(QH)**B** Sor g. 2 (Feb 26, 2014) Life: 4 0 0 0 \$1,820 Dirt: 4 0 0 0 \$1,820  
 Black RODNEY A. PRESCOTT (530-66-66-58 12%) 36% Bigtime Favorite (Chicks Beduino) - Ms Disconnect (Reckless Dash) 2016: 4 0 0 0 \$1,820 Wet Dirt: 1 0 0 0 \$150  
 Br: Randy Haffner (IN) 2015: 0 0 0 0 \$0 Turf: 0 0 0 0 \$0  
 Own: Teresa A. and Mark W. Myers Ind Dirt: 4 0 0 0 \$1,820 Wet Turf: 0 0 0 0 \$0  
 Tr: Randy Haffner (98-11-8-7 11%) 27% Distance: 0 0 0 0 \$0 Synthetic: 0 0 0 0 \$0  
 Blue, Blue "HF" on White Diamond, White Diamonds on Sleeves L 120  
 Class Rating: 34  
 13Aug16 Ind6 sy<sup>5</sup> 350Y nw :16699;18058 2 **EFtr** 5000 66-32 9 9 7 1/2 -- 54 5 3/4 Prescott R A 120 bl 5.90 Beach Zoomer124 1/2 Zoomin B Cartel124 1/2 Jazz C Gal122 1/2 no menace 9  
 02Aug16 Ind9 ft 350Y nw :18421;17927 2 **SMdn** 16000 74-37 6 7 3 1 -- 42 5 3/4 Prescott R A 120 bl 8.70 Louisiana Sixes124 1/2 Flyhichicky120nk Solo Cup121nk close early, weakened 9  
 28Jun16 Ind12 ft 350Y tw<sup>14</sup>:18496;18436 2 **SMdn** 16000 72-39 1 7 6 1 -- 5 1/2 4nk Prescott R A 120 bl \*1.20 Hez Stone Runner127hd Rainbow Moose122hd A Hare in Hy Corona122hd solid finish, missed 10  
 Previously trained by Rechy Chaz 2016 (as of 06/08): (32-6-5-4 19%) 47%  
 08Jun16 Ind10 ft 250Y tw<sup>11</sup>:14017;13549 2 Mdn 13000 73-25 9 9 -- -- 62 1/2 5 3/4 Prescott R A 120 L 4.30 Wrs Against the Wind124 1/2 Designed by a Bully124 1/2 Jewel of an Episode125 1/2 no menace 10  
 Work(s): 28 May 16 Ind 220Y ft :11.24 b 2/11 18 May 16 Ind 220Y ft :12.31 b g 8/10  
 Trainer (Last 365 days): All: 88 11% \$1.72 Dist/Surf: 88 11% \$1.72 2YOs: 30 10% \$2.37 MdnSpecial: 32 12% \$1.07 With Jockey: 79 12% \$1.91

**7** **Sheza Rare Treasure**(QH)**B** Ch f. 2 (Apr 10, 2014) Life: 2 0 0 0 \$315 Dirt: 2 0 0 0 \$315  
 Orange SANTIAGO MENDEZ (40-4-0-2 10%) 15% Rare Jet Extremes (Sixarun) - First Down Treasure (First Down Dash) 2016: 2 0 0 0 \$315 Wet Dirt: 1 0 0 0 \$75  
 Br: Roger L Lewis (IN) 2015: 0 0 0 0 \$0 Turf: 0 0 0 0 \$0  
 Own: Roger L Lewis Ind Dirt: 2 0 0 0 \$315 Wet Turf: 0 0 0 0 \$0  
 Tr: Roger L Lewis (22-0-0-0 0%) 0% Distance: 1 0 0 0 \$75 Synthetic: 0 0 0 0 \$0  
 Blue, White Horse and Rider, White Stars on Sleeves L 120  
 Class Rating: 11  
 19Jul16 Ind10 ft 350Y nw :16965;18100 2 **SMdn** 16000 59-21 1 4 7 1/2 -- 74 1/2 7 1/2 Galvan J 125 bl 59.30 Jess Jace124nk My Man Shan120 1/2 Keen Liaison122nk brshd,slight bmp 1/16 10  
 04Jun16 Ind10 gd<sup>5</sup> 300Y nw :16943;15647 2 **EFtr** 5000 49--- 5 4 -- -- 77 1/2 7 1/2 FonsecaSolo F 120 bf 25.60 Fly N Sixes122 1/2 Zoomin B Cartel124 1/2 Six Packin Stoil123 1/2 trailed 7  
 Work(s): \*23 Aug 16 Ind 220Y ft :11.73 b g 1/3 30 Jul 16 Ind 220Y ft :12.32 b g 9/14 15 Jul 16 Ind 220Y ft :12.66 b g 2/4 24 May 16 Ind 220Y ft :12.59 b g 15/16 17 May 16 Ind 220Y ft :13.20 b g 15/15  
 Trainer (Last 365 days): All: 33 0% \$0.00 Dist/Surf: 33 0% \$0.00 2YOs: 10 0% \$0.00 31-60Days: 10 0% \$0.00 MdnSpecial: 3 0% \$0.00 With Jockey: 3 0% \$0.00

**8** **Im a Jackson**(QH)**S** Sor f. 2 (May 12, 2014) Life: 3 0 0 1 \$935 Dirt: 3 0 0 1 \$935  
 Pink CESAR G. ESQUEDA (123-19-12-16 15%) 38% La Jollaroird (Streakin La Jolla) - Corona Capri (Corona King) 2016: 3 0 0 1 \$935 Wet Dirt: 1 0 0 1 \$500  
 Br: Alonzo Jackson (IN) 2015: 0 0 0 0 \$0 Turf: 0 0 0 0 \$0  
 Own: Alonzo Jackson Ind Dirt: 3 0 0 1 \$935 Wet Turf: 0 0 0 0 \$0  
 Tr: Anthony F. Cunningham (162-22-12-21 14%) 34% Distance: 3 0 0 1 \$935 Synthetic: 0 0 0 0 \$0  
 Black, Turquoise Stripes L 120  
 Class Rating: 26  
 26Jul16 Ind9 ft 300Y cw<sup>4</sup>:16273;15635 2 **SMdn** 16000 72-28 8 7 -- -- 84 1/2 7 1/2 Esqueda C G 126 fl 9.50 First Cucuy124 1/2 Run Run Corona122nk Sheza Classy Bay124nk broke out,bumped rival 10  
 24Jun16 Ind11 ft 300Y tw<sup>6</sup>:16663;16040 2 Mdn 13000 59-8 2 2 -- -- 83 1/2 8 3/4 Collins H 126 fl \*1.40 Kruger123nk Hez So Rare120 1/2 Sheza Classy Bay124hd came in st,bumped rival 9  
 04Jun16 Ind5 my<sup>5</sup> 300Y nw :16141;16087 2 **EFtr** 5000 76-41 5 7 -- -- 3 1/2 3nk Esqueda C G 125 fl 4.80 Rockin Tokyo125ns Streaking Jazz123nk Im a Jackson125nk brushed early,closing 9  
 Work(s): 18 May 16 Ind 220Y ft :11.96 b g 4/10 12 May 16 Ind 220Y ft :12.15 b g 9/24  
 Scratch(es): 30 Aug 16 Ind9 350Y ft Mdn 16000; Also-Eligible 19 Jul 16 Ind10 350Y ft Mdn 16000; Also-Eligible  
 Trainer (Last 365 days): All: 246 13% \$1.73 Dist/Surf: 246 13% \$1.73 2YOs: 92 10% \$0.59 31-60Days: 65 17% \$3.46 1stTimeBlink: 2 50% \$2.20 BlinksOn: 2 50% \$2.20 MdnSpecial: 109 12% \$2.08 With Jockey: 157 15% \$1.44

**9** **Up Town Jazz**(QH)**B** Br g. 2 (Apr 3, 2014) Life: 2 0 1 1 \$4,800 Dirt: 2 0 1 1 \$4,800  
 Turquoise BERKLEY R. PACKER (91-21-18-19 23%) 64% Jazz Be First (Bono Jazz) - Corona Ina Tincan (Chilled Corona) 2016: 2 0 1 1 \$4,800 Wet Dirt: 0 0 0 0 \$0  
 Br: Todd Holder (IN) 2015: 0 0 0 0 \$0 Turf: 0 0 0 0 \$0  
 Own: Todd Holder Ind Dirt: 2 0 1 1 \$4,800 Wet Turf: 0 0 0 0 \$0  
 Tr: Randy M. Smith (202-34-36-36 17%) 52% Distance: 2 0 1 1 \$4,800 Synthetic: 0 0 0 0 \$0  
 Black, Red "S", Red and White Bands on Sleeves L 120  
 Class Rating: 53  
 09Aug16 Ind9 ft 300Y nw :15964;15950 2 **SMdn** 16000 82-55 2 6 -- -- 2nk 2hd Jackson S 120 bl 2.60 Six Packin Stoil127hd Up Town Jazz120ns High Storm Warning121nk drifted to rail,missed 10  
 07Jun16 Ind10 ft 300Y tw<sup>12</sup>:16280;16148 2 **SMdn** 16000 72-51 3 6 -- -- 31 3 3/4 Jackson S 122 bl 2.60 Prairies Hot Secret124 1/2 Doc Oh Mighty120ns Up Town Jazz122 1/2 inchng up, missed pic 8  
 Work(s): \*5 Aug 16 Ind 220Y ft :10.97 b 1/8 31 May 16 Ind 220Y ft :12.32 b g 9/10 24 May 16 Ind 220Y ft :11.88 b g 5/16 11 May 16 Ind 220Y gd :12.39 b g 2/2  
 Trainer (Last 365 days): All: 270 19% \$1.22 Dist/Surf: 270 19% \$1.22 2YOs: 109 22% \$1.55 31-60Days: 66 21% \$1.23 MdnSpecial: 76 20% \$1.09 With Jockey: 129 25% \$1.20

**10** **Sixes Royal Opener**(QH)**S** Sor g. 2 (Mar 5, 2014) Life: 0 0 0 0 \$0 Dirt: 0 0 0 0 \$0  
 Purple JOSE L. SANTOS (0-0-0-0 0%) 0% Sixes Liaison (Sixes Royal) - Eyem Yur Huckleberry (Mr Eye Opener) 2016: 0 0 0 0 \$0 Wet Dirt: 0 0 0 0 \$0  
 Br: Brian L. Gunder (IN) 2015: 0 0 0 0 \$0 Turf: 0 0 0 0 \$0  
 Own: Brian L. Gunder Ind Dirt: 0 0 0 0 \$0 Wet Turf: 0 0 0 0 \$0  
 Tr: Raul A. De La Mora (12-0-0-2 0%) 17% Distance: 0 0 0 0 \$0 Synthetic: 0 0 0 0 \$0  
 Hunter Green, White Circled "G" L 120  
 Class Rating: n/a  
 Work(s): 1 Sep 16 Ind 220Y ft :12.67 b g 2/6 29 Aug 16 Cgr 220Y ft :11.96 b g 6/9 9 Jun 16 Cgr 220Y ft :12.30 b 3/5 23 May 16 Cgr 220Y ft :11.70 b 2/4 16 May 16 Cgr 220Y ft :11.80 b 2/6  
 Trainer (Last 365 days): All: 28 7% \$1.10 Dist/Surf: 28 7% \$1.10 1stTimer: 4 0% \$0.00 2YOs: 10 10% \$0.58 MdnSpecial: 9 11% \$0.64 With Jockey: 2 0% \$0.00

**ALSO ELIGIBLES - Horses below may run if any late scratches occur.**

**11 Hqh Storm Warning (QH) [B]** Sor f. 2 (Apr 27, 2014) Life: 2 0 0 1 \$1,840 Dirt: 2 0 0 1 \$1,840  
 Red Storm Cat (Mr Jess Perry) - Hqh Cash Rebate (Twaynas Dash) 2016: 2 0 0 1 \$1,840 Wet Dirt: 0 0 0 0 \$0  
 Br: Ronald E Haynes (IN) 2015: 0 0 0 0 \$0 Turf: 0 0 0 0 \$0  
 Own: Ronald E. Haynes Ind Dirt: 2 0 0 1 \$1,840 Wet Turf: 0 0 0 0 \$0  
 Tr: Karin Yike (12-0-0-2 0%) 17% Distance: 2 0 0 1 \$1,840 Synthetic: 0 0 0 0 \$0

8-1 *Burgundy, Gold Sleeves* L 120 Class Rating: 32  
 09Aug16 Ind9 ft 300Y nw :15969;15950 2 [Mdn] 16000 82-55 6 1 -- -- 3nt 3hd Bolanos L 121 bfl 89.40 Six Packin Stoltz127hd Up Town Jazz120ns Hqh Storm Warning121nt stnbl'd st, inchng up 10  
 05Jul16 Ind10 ft 300Y nw :16663;15960 2 [Mdn] 16000 59-8 2 5 -- -- 74 74 Bolanos L 121 bfl 35.80 Heza Quarter Captain120ns Six Packin Stoltz122 1/2 Streaking Jazz1241 jostled, shiftd in early 10  
 Works: 23 Jul 16 Ind 220Y ft :11.43 b g 2/9 11 Jun 16 Ind 220Y ft :11.61 b g 2/5 24 May 16 Ind 220Y ft :12.58 b 14/16  
 Trainer (Last 365 days): All: 14 0% \$0.00 Dist/Surf: 14 0% \$0.00 2YOs: 7 0% \$0.00 31-60Days: 3 0% \$0.00 MdnSpecial: 8 0% \$0.00 With Jockey: 5 0% \$0.00

**12 American Cowgirl 42 (QH) [B]** Sor f. 2 (Mar 25, 2014) Life: 1 0 0 0 \$100 Dirt: 1 0 0 0 \$100  
 American Runaway (Ocean Runaway) - Royal Mergana (Royal Shake Em) 2016: 1 0 0 0 \$100 Wet Dirt: 1 0 0 0 \$100  
 Br: Mike Campbell (IN) 2015: 0 0 0 0 \$0 Turf: 0 0 0 0 \$0  
 Own: Michael L. Campbell Ind Dirt: 1 0 0 0 \$100 Wet Turf: 0 0 0 0 \$0  
 Tr: Matt Frazier (38-7-5-5 18%) 45% Distance: 0 0 0 0 \$0 Synthetic: 0 0 0 0 \$0


20-1 *White, Blue Emblem, Blue Stripes on Sleeves* L 120 Class Rating: 46  
 13Aug16 Ind3 sy<sup>5</sup> 350Y hw<sup>8</sup> :18517;17570 2 [Ftr] 5000 72-46 9 10 74 1/2 -- 65 1/2 Jackson S 120 bl 45.00 Cb Come Fly With Me124 1/2 Tres Seis Delight1261 Jess Jace124nk drifted 9-14path 10  
 Works: 6 Aug 16 Ind 220Y ft :12.44 b 13/14 3 Aug 16 Ind 220Y ft :12.22 b g 11/20  
 Trainer (Last 365 days): All: 124 11% \$1.05 Dist/Surf: 124 11% \$1.05 2YOs: 18 6% \$0.46 MdnSpecial: 45 11% \$0.62 With Jockey: 24 4% \$0.62  
 B-Bute; L-Lasix; LT-First time on Lasix; LX-Off Lasix; [B] - Denotes Indiana Sired; [B] - Denotes Indiana Bred  
 Equipment Change: Im a Jackson will race with Blk-On

**Selections: 9-1-5-11**

Association of Racing Commissioners International, Inc.  
Drug Testing Standards and Practices Program  
Model Rules Guidelines



# Uniform Classification Guidelines for Foreign Substances and Recommended Penalties and Model Rule



Version 12.00

**Association of Racing Commissioners International, Inc.  
Uniform Classification Guidelines for Foreign Substances**

**Table of Contents**

Preamble to the Uniform Classification Guidelines of Foreign Substances .....	ii
Notes Regarding Classification Guidelines .....	ii
Classification Criteria .....	iii
Classification Definitions.....	iv
Drug Classification Scheme.....	vi
Alphabetical Substance List.....	1
Listing by Classification .....	12
Non-Classified Substances.....	27
Recommended Penalty and Model Rule.....	28
Recent Document Revisions .....	32

## Preamble to the Uniform Classification Guidelines of Foreign Substances

The Preamble to the Uniform Classification Guidelines was approved by the RCI Drug Testing and Quality Assurance Program Committee (now the Drug Testing Standards and Practices Program Committee) on August 26, 1991. Minor revisions to the Preamble were made by the Drug Classification Subcommittee (now the Veterinary Pharmacologists Subcommittee) on September 3, 1991.

"The Uniform Classification Guidelines printed on the following pages are intended to assist stewards, hearing officers and racing commissioners in evaluating the seriousness of alleged violations of medication and prohibited substance rules in racing jurisdictions. Practicing equine veterinarians, state veterinarians, and equine pharmacologists are available and should be consulted to explain the pharmacological effects of the drugs listed in each class prior to any decisions with respect to penalties to be imposed. The ranking of drugs is based on their pharmacology, their ability to influence the outcome of a race, whether or not they have legitimate therapeutic uses in the racing horse, or other evidence that they may be used improperly. These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses. The facts of each case are always different and there may be mitigating circumstances which should always be considered. These drug classifications will be reviewed frequently and new drugs will be added when appropriate."

### Notes Regarding Classification Guidelines

- Where the use of a drug is specifically permitted by a jurisdiction, then the jurisdiction's rule supersedes these penalty guidelines.
- Regulators should be aware that a laboratory report may identify a drug only by the name of its metabolite. The metabolite might not be listed here, but the parent compound may be.
- These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses.
- The facts of each case are different and there may be mitigating circumstances that should be considered.
- These drug classifications will be reviewed periodically. New drugs will be added or some drugs may be reclassified when appropriate.
- Found substances or drugs not included in these guidelines should be treated as Class 1 violations warranting a Class A penalty unless otherwise advised by consultation with Racing Commissioners International (RCI) and/or the Racing Medication and Testing Consortium (RMTC).



## Classification Criteria

The RCI Drug Classification Scheme is based on 1) pharmacology, 2) drug use patterns, and 3) the appropriateness of a drug for use in the racing horse. Categorization is decided using the following general guidelines:

- *Pharmacology.* Drugs that are known to be potent stimulants or depressants are placed in higher classes, while those that have (or would be expected to have) little effect on the outcome of a race are placed in lower classes.
- *Drug Use Patterns.* Some consideration is given to placement of drugs based on practical experience with their use and the nature of positive tests. For example, procaine positives have in the past been associated primarily with the administration of procaine penicillin, and this has been taken into consideration in the placement of procaine into Class 3 instead of Class 2 with other injectable local anesthetics.
- *Appropriateness of Drug Use.* Drugs that clearly are intended for use in equine therapeutics are placed in lower classes. Drugs that clearly are not intended for use in the horse are placed in higher classes, particularly if they might affect the outcome of a race. Drugs that are recognized as legitimately useful in equine therapeutics but could affect the outcome of a race are placed in the middle or higher classes.

The list includes most drugs that have been reported as detected by racing authority laboratories in the United States, Canada, the United Kingdom and other Association of Official Racing Chemists (AORC) laboratories, but does not include those which would seem to have no effect on the performance of the horse or drug detectability. For example, it does not include antibiotics, sulfonamides, vitamins, anthelmintics, or pangamic acid, all of which have been reported.

The list contains many drugs that have never been reported as detected. Usually, these are representatives of chemical classes that have the potential for producing an effect, and in many cases, for which at least one drug in that chemical class has been reported.

Most drugs have numerous effects, and each was judged on an individual basis. There are instances where there is a rather fine distinction between drugs in one category and those in the next. This is a reflection of a nearly continuous spectrum of effects from the most innocuous drug on the list to the drug that is the most offensive.

## Classification Definitions

- **Class 1:** Stimulant and depressant drugs that have the highest potential to affect performance and that have no generally accepted medical use in the racing horse. Many of these agents are Drug Enforcement Agency (DEA) schedule II substances. These include the following drugs and their metabolites: Opiates, opium derivatives, synthetic opioids and psychoactive drugs, amphetamines and amphetamine-like drugs as well as related drugs, including but not limited to apomorphine, nikethamide, mazindol, pemoline, and pentylenetetrazol. Though not used as therapeutic agents, all DEA Schedule I agents are included in Class 1 because they are potent stimulant or depressant substances with psychotropic and often habituating actions.
- **Class 2:** Drugs that have a high potential to affect performance, but less of a potential than drugs in Class 1. These drugs are 1) not generally accepted as therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse. Drugs in this class include: psychotropic drugs, certain nervous system and cardiovascular system stimulants, depressants, and neuromuscular blocking agents. Injectable local anesthetics are included in this class because of their high potential for abuse as nerve blocking agents.
- **Class 3:** Drugs that may or may not have generally accepted medical use in the racing horse, but the pharmacology of which suggests less potential to affect performance than drugs in Class 2. Drugs in this class include bronchodilators, anabolic steroids and other drugs with primary effects on the autonomic nervous system, procaine, antihistamines with sedative properties and the high-ceiling diuretics.
- **Class 4:** This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3. Drugs in this class include less potent diuretics; corticosteroids; antihistamines and skeletal muscle relaxants without prominent central nervous system (CNS) effects; expectorants and mucolytics; hemostatics; cardiac glycosides and anti-arrhythmics; topical anesthetics; antidiarrheals and mild analgesics. This class also includes the non-steroidal anti-inflammatory drugs (NSAIDs), at concentrations greater than established limits.
- **Class 5:** This class includes those therapeutic medications for which concentration limits have been established by the racing jurisdictions as well as certain miscellaneous agents and other medications as determined by the regulatory bodies. Included specifically are agents that have very localized actions only, such as anti-ulcer drugs, and certain anti-allergic drugs. The anticoagulant drugs are also included.

• **Prohibited Practices:**

- A) The possession and/or use of a drug, substance or medication, specified below, on the premises of a facility under the jurisdiction of the regulatory body for which a recognized analytical method has not been developed to detect and confirm the administration of such substance; or the use of which may endanger the health and welfare of the horse or endanger the safety of the rider or driver; or the use of which may adversely affect the integrity of racing:
- 1) Erythropoietin
  - 2) Darbepoietin
  - 3) Oxyglobin
  - 4) Hemopure
- B) The possession and/or use of a drug, substance, or medication on the premises of a facility under the jurisdiction of the regulatory body that has not been approved by the United States Food and Drug Administration (FDA) for use in the United States.
- C) The practice, administration, or application of a treatment, procedure, therapy or method identified below, which is performed on the premises of a facility under jurisdiction of a regulatory body and which may endanger the health and welfare of the horse or endanger the safety of the rider or driver, or the use of which may adversely affect the integrity of racing:

# Drug Classification Scheme

- **Class 1:** Opiates, opium derivatives, synthetic opioids, psychoactive drugs, amphetamines, and all DEA Schedule I substances (see <http://www.deadiversion.usdoj.gov/schedules/#list>), and many DEA Schedule II drugs. Also found in this class are drugs that are potent stimulants of the CNS. Drugs in this class have no generally accepted medical use in the racing horse and their pharmacologic potential for altering the performance of a racing horse is very high.
- **Class 2:** Drugs placed in this category have a high potential for affecting the outcome of a race. Most are not generally accepted as therapeutic agents in the racing horse. Many are products intended to alter consciousness or the psychic state of humans, and have no approved or indicated use in the horse. Some, such as injectable local anesthetics, have legitimate use in equine medicine, but should not be found in a racing horse. The following groups of drugs are placed in this class:
  - A. Opiate partial agonists, or agonist-antagonists.
  - B. Non-opiate psychotropic drugs. These drugs may have stimulant, depressant, analgesic or neuroleptic effects.
  - C. Miscellaneous drugs, which might have a stimulant effect on the CNS.
  - D. Drugs with prominent CNS depressant action.
  - E. Anti-depressant and antipsychotic drugs, with or without prominent CNS stimulatory or depressant effects.
  - F. Muscle blocking drugs - those that have a direct neuromuscular blocking action.
  - G. Local anesthetics that have a reasonable potential for use as nerve-blocking agents (except procaine).
  - H. Snake venoms and other biologic substances that may be used as nerve-blocking agents.
- **Class 3:** Drugs placed in this class may or may not have an accepted therapeutic use in the horse. Many are drugs that affect the cardiovascular, pulmonary and autonomic nervous systems. They all have the potential of affecting the performance of a racing horse. The following groups of drugs are placed in this class:
  - A. Drugs affecting the autonomic nervous system that do not have prominent CNS effects, but which do have prominent cardiovascular or respiratory system effects. Bronchodilators are included in this class.
  - B. A local anesthetic that has nerve-blocking potential but also has a high potential for producing urine residue levels from a method of use not related to the anesthetic effect of the drug (procaine).
  - C. Miscellaneous drugs with mild sedative action, such as the sleep-inducing antihistamines.
  - D. Primary vasodilating/hypotensive agents.
  - E. Potent diuretics affecting renal function and body fluid composition.
  - F. Anabolic and/or androgenic steroids and other drugs.

• Class 4: Drugs in this category comprise primarily therapeutic medications routinely used in racehorses. These may influence performance, but generally have a more limited ability to do so. Groups of drugs assigned to this category include the following:

- A. Non-opiate drugs that have a mild central antipyretic effect.
- B. Drugs affecting the autonomic nervous system that do not have prominent CNS, cardiovascular, or respiratory effects:
  - 1. Drugs used solely as topical vasoconstrictors or decongestants.
  - 2. Drugs used as gastrointestinal antispasmodics.
  - 3. Drugs used to void the urinary bladder.
  - 4. Drugs with a major effect on CNS vasculature or smooth muscle of visceral organs.
- C. Antihistamines that do not have a significant CNS depressant effect. This does not include the H2 blocking agents, which are in Class 5.
- D. Mineralocorticoid drugs.
- E. Skeletal muscle relaxants.
- F. Anti-inflammatory drugs. These drugs may reduce pain as a consequence of their anti-inflammatory action.
  - 1. Non-steroidal anti-inflammatory drugs (NSAIDs). (Aspirin-like drugs).
  - 2. Corticosteroids (glucocorticoids).
  - 3. Miscellaneous anti-inflammatory agents.
- G. Less potent diuretics.
- H. Cardiac glycosides and antiarrhythmic agents.
  - 1. Cardiac glycosides.
  - 2. Antiarrhythmic agents (exclusive of lidocaine, bretylium, and propranolol).
  - 3. Miscellaneous cardiotoxic drugs.
- I. Topical Anesthetics - agents not available in injectable formulations.
- J. Antidiarrheal drugs.
- K. Miscellaneous drugs:
  - 1. Expectorants with little or no other pharmacologic action.
  - 2. Stomachics.
  - 3. Mucolytic agents.

• Class 5: Drugs in this category are therapeutic medications for which concentration limits have been established by the racing jurisdictions as well as certain miscellaneous agents. Included specifically are agents that have very localized actions only, such as anti-ulcer drugs, and certain antiallergic drugs. The anticoagulant drugs are also included.

# Alphabetical Substance List

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
2-Aminoheptane	Tuamine	4	B
3,4-methylenedioxypropylpropranolone	MIDPV, "bath salts"	1	A
3-Methoxytyramine	3-MT	2	A
Acetazolol	Sectral	3	B
Acetabromal		2	A
Acenocoumarol		5	C
Aepromazine	Atrovet, Noteusil, PromAcc@	3	B
Acetaminophen (Paracetamol)	Tylenol, Tempra, etc.	4	C
Acetamidid		4	B
Acetazolamide	Diamox, Vetamox	4	B
Acetophenazine	Tindal	2	A
Acetophenetidin (Phenacetin)		4	B
Acetylsalicylic acid (Aspirin)		4	C
Alclomethasone	Aclovate	4	C
Adiazolam		2	A
Adrenochrome monosemicarbazone salicylate		4	B
Albuterol (Salbutamol)	Proventil, Ventolin	3	B
Alclofenac		2	A
Alcuronium	Alloferin	2	A
Aldosterone	Aldocortin, Electrococtin	4	B
Alfentanil	Alfenta	1	A
Almotriptan	Axert	3	A
Alphaprodine	Nisentil	2	A
Alplidern	Anaxyl	2	A
Alprazolam	Xanax	2	A
Alprenolol		3	A
Althesin	Saffan	2	A
Ambenonium	Mytelase, Myeuran	3	B
Ambroxol	Ambrol, etc.	4	C
Amechtonide	Cyclocort	4	C
Amiloride	Moduretic; Midamor	4	B
Aminocaproic acid	Amicar, Caprocid	4	C
Aminodarone		4	B
Aminophylline	Aminophyllin, etc.	3	B
Aminopyrine		4	B
Aminorex	Aminoxafen, Aminoxaphen, Apiquel, MeN-742, Menocel	1	A
Amisometadine	Relictron	4	B

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Amisulpride	Solian	2	A
Amifraz	Milaban	3	A
Amiripylic	Elavil, Amitril, Endep	2	A
Amlodipine	Amiviv, Norvasc	3	B
Aminobarbital	Amytal	2	A
Amoxapine	Asendin	2	A
Amperozide		2	A
Amptheramine		1	A
Amrinone		4	B
Amyl nitrite		3	A
Anileridine	Lentine	1	A
Anilopam	Anishe	2	A
Anisindione		5	C
Anisotropine	Valpin	4	B
Antipyrine		4	B
Apazone (Azapropazone)	Rheumox	4	B
Apomorphine		1	A
Aptindine		4	B
Aprobarbital	Alurate	2	A
Arecoline		3	A
Arformoterol		3	A
Articaine	Septocaine; Ultracaine, etc.	2	A
Atenolol	Tenormin	3	B
Alomoxetine	Strattera	2	A
Atracurium	Tractium	2	A
Atropine		3	B
Azacyclonol	Frenque	2	A
Azaperone	Siresnil, Suicalm, Fentaz (with Fentanyl)	2	A
Baclofen	Lioresal	4	B
Barbital	Veronal	2	A
Barbiturates		2	A
Beclomethasone	Propaderm	4	C
Bemegride	Megimide, Miledimide	2	A
Benazepril	Lotrel, Lotensin	3	B
Bendroflumethiazide	Naturetin	4	B
Benoxaprofen		2	A
Benzonate	Dorsacaine	4	C
Benperidol	Anquil	2	A
Bontazepam	Tiadipona	2	A

# Alphabetical Substance List (Cont)

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Benzacizine	Deprol, Bronchodilanten	2	A
Benzocaine		4	B
Benzocetamine		2	A
Benzodiazepines		2	A
Benzonate	Tessalon, Tessalon Perles, Zonatus	2	A
Benzhexamine	Didrex	2	A
Benzthiazide		4	B
Benztrihexide		2	A
Benztropine	Cogentin	2	A
Benzylpiperazine (BZP)		1	A
Bepridil	Bepadin	4	B
Betamethasone	Betasone, etc.	4	C
Betaxolol	Kerlone	3	B
Bethanechol	Urecholine, Duvoid	4	C
Bethanidine	Esbatal	3	A
Biperiden	Akineton	3	A
Briperone		2	A
Bisoprolol	Zebeta, Bisobloc, etc.	3	B
Bitolterol	Effectin	3	A
Bolasterone		3	A
Boldenone	Equipoise	3	B
Boldione		3	A
Bretylum	Bretylol	3	B
Brimonidine	Alphagan	2	A
Bromazepam	Lexotan, Lectopam	2	A
Bromfenac		3	A
Bromhexine	Oleto, etc.	4	B
Bromisovalum	Difficord, etc.	2	A
Bromocriptine	Parlodel	2	A
Bromodiphenhydramine		3	B
Bromperidol	Bromidol	2	A
Brompheniramine	Dimetane, Disomer	4	B
Brotizolam	Brotocol	2	A
Budesonide	Pulmacort, Rhinocort	4	C
Bufexamac		3	A
Bumetanide	Bumex	3	B
Bupivacaine	Marcaine	2	A
Buprenorphine	Temgesic	2	A
Bupropion	Wellbutin	2	A
Buspitron	Buspar	2	A
Butabarbital (Secbutobarbital)	Butacaps, Butasol, etc.	2	A
Butacaine	Butyn	4	B
Butalbital (Talbutal)	Fiorinal	2	A
Butamben (butyl aminobenzoate)	Butesin	4	C
Butanilcaine	Hostacain	2	A

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Butaperazine	Repoise	2	A
Butocamide	Lisformin	2	A
Butorphanol	Stadol, Torbugesic	3	B
Butoxyacaine	Stadacain	4	B
N-Butylisopropylamine		3	B
Caffeine		2	B
Calusterone	Methosorb	3	B
Canazepam	Paxor	2	A
Camphor		4	C
Candesartan	Atand	3	B
Capofidine	Covatine	2	A
Captopril	Capoten	3	B
Carazolol	Carbacel, Conduction	3	A
Carbachol	Lentim, Doryl	3	B
Carbamazepine	Tegretol	3	B
Carbazochrome		4	C
Carbidopa + levodopa	Sinemet	2	A
Carbinoxamine	Clislin	3	B
Carbromol	Mifudorm	2	A
Carfantanil		1	A
Carisoprodol	Rela, Soma	2	B
Carphenazine	Proketazine	2	A
Carpramite	Prazinil	2	A
Carprofen	Rinadyl	4	B
Cartrol	Cartrol	3	B
Carticaine (see articaine)	Septocaine; Ultracaine, etc.	2	A
Carvedilol	Coreg	3	B
Cathinone	Khat, kat, qat, quat, chat, catha, Abyssinian tea, African tea	1	A
Celecoxib	Celebrex	3	B
Cetirizine	Zyrtec	4	C
Chloral betaine	Beta-Chlor	2	A
Chloral hydrate	Naetes, Oridrate, etc.	2	A
Chloraldehyde (chloral)		2	A
Chloralose (Alpha-Chloralose)		2	A
Chlordiazepoxide	Librium	2	A
Chlorhexidol		2	A
Chlormerodrin	Neohydrin	2	A
Chlormezanone	Trancopal	2	A
Chloroform		2	A
Chlorophenesin	Maolate	4	C
Chloroprocaine	Nescaine	2	A
Chloroquine	Avloclor	4	C
Chlorothiazide	Diuril	4	B

# Alphabetical Substance List (Cont)

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Chlorpheniramine	Chlortrimeton, etc.	4	B
Chlorpropethazine	Newplege	2	A
Chlorpromazine	Thorazine, Largactil	2	A
Chlorprothixene	Taractan	2	A
Chlorthalidone	Hydrotan	4	B
Chlorthalozone	Paraflex	4	B
Ciclesonide		4	B
Cilostazol	Plental	5	C
Cimetrol		3	A
Cimetidine	Tagamet	5	D
Cinchocaine	Nupercaine	4	C
Citalopram	Celex	2	A
Clenbutin	Tavist	4	B
Clemastine	Ventipulmin	3	B
Clenbuterol	Batrax	3	B
Clibucaine		4	C
Clidinium	Quarezon, Clindex, etc.	3	B
Clobazam	Urbanyl	2	A
Clobetasol	Temovate	4	C
Clocapramine		2	A
Clocoortolone	Cloderm	4	C
Clofenamide		4	B
Clomethiazole (Chlormethiazole)		2	A
Clomipramine	Anafranil	2	A
Clonazepam	Klonopin	2	A
Clonidine	Catapres	3	B
Clorazepate	Tranxene	2	A
Clormecaine	Placacid	4	C
Clostebol		3	B
Clothiapine	Enternin	2	A
Clozapepam	Trecalmo, Rize	2	A
Clozazolam	Enadel, Sepazon, Tolestan	2	A
Clozapine	Clozaril, Leponex	2	A
Cobalt		3	B <sup>1</sup>
n-Cobratoxin		1	A
Cocaine <sup>2</sup>		1	B <sup>2</sup>
Codeine		1	A
Coflichicine		4	B
Conorphone		2	A

<sup>1</sup> For cobalt concentrations of less than 25 parts per billion (ppb) of blood serum or plasma no penalty is recommended. For concentrations of 25 ppb or greater but less than 50 ppb of blood plasma or serum the recommended penalty is a written warning, the placement of the horse on the Veterinarians List with removal from list only after a blood test confirms that the concentration is below 25 ppb of blood plasma or serum. Testing shall be paid by the owner(s) of the horse. Concentrations of 50 ppb or greater in blood plasma or serum have a recommended "B" penalty.

Association of Racing Commissioners International, Inc.

Uniform Classification Guidelines for Foreign Substances

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Corticaine	Ulfracain	2	A
Cortisone	Cortone, etc.	4	C
Cromolyn	Intal	5	C
Crozetamide		2	A
Cyamemazine	Tercian	2	A
Cyclandelate	Cyclospasmol	3	A
Cyclizine	Merazine	4	B
Cyclobarbitol	Phanodorm	2	A
Cyclobenzaprine	Flexeril	4	B
Cyclomethycaine	Surfacaine	4	C
Cyclothiazide	Anhydron, Renazide	4	B
Cyrimine	Papitane	3	B
Cyproheptadine	Perciatin	4	C
Danzol	Danoctine	3	B
Dantrolene	Dantrium	4	C
Darbopeetin	Aranesp	2	A
Decamethonium	Syncurine	2	A
Dehydrochloromethyltestosterone		3	B
Dembroxol (Dembrexine)	Sputolysin	4	C
Demoxepam		2	A
Deoxycorticosterone	Percorin, DOCA, Descotone, Dorcostirin	4	C
Deracoxib	Deramaxx	3	B
Dermorphin		1	A
Desipramine	Norpromine, Pertofrane	2	A
Desonite	Des Owen	4	C
Desoximeasone	Topicoort	4	C
Desoxymethyltestosterone		3	B
Detomidine		3	B
Dexamethasone	Dormosedan Azium, etc.	4	C
Dextromethorphan		4	B
Dextromoramide	Palfium, Navcolo	1	A
Dextropropoxyphene	Darvon	3	B
Dezocine	Dalgan	2	A
Dianorphan		1	A
Diazepam	Valium	2	B
Diazoxide	Proglyceen	3	B
Dibucaine	Nupercainal, Cinchocaine	4	C
Dichloralphenazone	Febenol, Isocoin	2	A

<sup>2</sup> Penalty class "A" recommended if regulators can prove an intentional administration.



# Alphabetical Substance List (Cont)

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Dichlorophenamide	Daramide	4	C
Diclofenac	Voltaren, Voltarol	4	C
Dicumarol	Dicumarol	5	C
Diethylpropion	Tepanil, etc.	2	A
Diethylthiambutene	Themalon	2	A
Diflorasone	Florone, Maxiflor	4	C
Difluocortolone	Flu-Cortinest, etc.	4	C
Diflunisal		3	B
Digloxin	Crystodigin	4	B
Digoxin	Lanoxin	4	B
Dihydrocodeine	Parcodin	2	A
Dihydroergotamine		4	B
Dihydroergotamine		2	A
Dihydroergotamine		2	A
Dilazepam	Briantum	4	B
Diltiazem	Cardizem	4	B
Dimefibo		3	A
Dimethisoquin	Quotane	4	B
Dimethylsulfoxide (DMSO)		4	C
Dimethylsulphone (MSM)		5	C
Diphenadione		5	C
Diphenhydramine	Benadryl	3	B
Diphenoxylate	Difenoxin, Lomotil	4	B
Diprenorphine	M50/50	2	A
Dipyridamole	Persantine	3	B
Dipyrrone	Novin, Methampyrone	4	C
Disopyramide	Norpace	4	B
Divalproex	Depakote	3	A
Dixyrazine	Esucos	2	A
Dobutamine	Dobutrex	3	B
Dopamine	Intropin	2	A
Donepezil	Aricept	1	A
Doxacurium	Nuromax	2	A
Doxapram	Dopram	2	A
Doxazosin		3	A
Doxefazepam	Doxans	2	A
Doxepin	Adapin, Sinequan	2	A
Doxylamine	Decepryn	3	B
Dromostanolone	Droiban	3	B
Droperidol	Inapsine, Droleptan, Innovar-Vet (with Fentanyl)	2	A
Duloxetine		2	A
Dyclonine	Dyclone	4	C
Dyphylline		3	B
Edrophonium	Tension	3	B
Efedipran	Relpax	3	A

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Efeneac		4	C
Enalapril (metabolite enalaprilat)	Vasotec	3	B
Enciprazine		2	A
Endorphins		1	A
Enkephalins		1	A
Ephedrine		2	A
Epibatidine		2	A
Epinephrine		2	A
Ergoloid mesylates (dihydroergocornine mesylate, dihydroergocristine mesylate, and dihydroergocypine mesylate)		2	A
Ergonovine	Ergotrate	4	C
Ergotamine	Gynergen, Cafergot, etc.	4	B
Ertirityl tetranitrate	Cardilate	3	A
Erythropoietin (EPO)	Epogen, Procrit, etc.	2	A
Esmolol	Brevibloc	3	B
Esomeprazole	Nexium	5	D
Estazolam	Domnamid, Eurodin, Nuctalon	2	A
Ethinylloin		3	B
Etanercept	Enbrel	4	B
Ethacrynic acid	Edecrin	3	B
Ethinamivan		2	A
Ethanol		2	A
Ethchlorvynol	Placidyl	2	A
Ethinamate	Valmid	2	A
Ethioheptazine	Zactane	4	B
Ethiopropazine	Parsidol	2	A
Ethosuximide	Zarontin	3	A
Ethofoin	Peganone	4	B
Ethoxzolamide	Cardrase, Ethamide	4	C
Ethylaminobenzoate (Benzocaine)	Senefts, etc.	4	C
Ethylestrenol	Maxibolin, Organon	3	B
Ethylisobutrazine	Diquel	2	A
Ethylmorphine	Dionin	1	A
Ethyldiorepinephrine	Bronkheprine	3	A
Etidocaine	Duraneset	2	A
Etifoxin	Siresun	2	A
Etizolam	Depas, Pasaden	2	A
Etidolac	Locidine	3	B
Etidroxizine	Indurox	2	A
Etomidate		2	A
Etorphine HCl	M99	1	A
Famotidine	Gasster, etc.	5	D

# Alphabetical Substance List (Cont)

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Felbamate	Felbatol	3	A
Felodipine	Pindil	4	B
Fenfluramine	Tymium	2	A
Fenbutafen	Cincopal	3	B
Fenclozic acid	Myalex	2	A
Fenfluramine	Pondimin	2	A
Fenoldopam	Corfopam	3	B
Fenpropafen	Naifon	3	B
Fenpropion	Berotec	3	B
Fenpropion	Respiride, Respan, etc	3	B
Fentanyl	Sublimaze	1	A
Fentanyl	Allegra	3	B
Fexofenadine		4	C
Firocoxib		4	C
Flecainide	Idalon	4	B
Flecainide	Idalon, Idarac	4	B
Fluctafonine	Sedalande	2	A
Fluazone	Synalar, etc.	4	C
Flucinolone	Erispam	2	A
Fludiazepam	Alforone, etc.	4	C
Fludrocortisone		4	C
Flufenamic acid		3	B
Flumequine	Flucort, etc.	4	C
Flumethiazide	Ademol	4	B
Flunarizine	Sibellum	4	B
Flunisolide	Bronilide, etc.	4	C
Flunitrazepam	Rohypnol, Narcozep, Darkene, Hypnodorm	2	A
Flunitrazepam	Banamine	4	C*
Flunitrazepam	Synalar	4	C
Fluocinolone	Licon, Lidex	4	C
Fluocinonide		4	C
Fluopromazine	Psyquil, Siquil	2	A
Fluorenone	Gaducid	2	A
Fluorometholone	FML	4	B
Fluoroprednisolone	Preddef-2X	4	C
Fluoxetine	Prozac	2	A
Fluoxymesterone	Halotestin	3	B
Flupentixol	Depixol, Fluaxol	2	A
Fluphenazine	Prolixin, Permittil, Anatenzol, etc.	2	A
Flupirtine	Katadolone	3	A
Fluprednisolone	Alphadrol	4	C
Flurandrenolide	Cordran	4	C
Flurazepam	Dalmane	2	A
Flurbiprofen	Froben	3	B
Fluspirtine	Imap, Redeptin	2	A

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Fluticasone	Flisonase, Flutide	4	C
Flutoprazepam	Restas	2	A
Fluvoxamine	Dumirox, Favein, etc.	2	A
Formebolone		3	B
Formoterol	Altram	3	B
Fosinopril	Monopril	3	A
Fosphenytoin	Corebyx	3	B
Furazabol		3	B
Furosemide	Lasix	N/A	
Gabapentin	Neurontin	3	B
Galaritamine	Reminyl	2	A
Gallamine	Flaxedil	2	A
Gamma Aminobutyric Acid (GABA)	Carolina Gold	3	B
Gepirone		2	A
Gesirone		3	A
Glutethimide	Doriden	2	A
Glycopyrrolate	Robipul	3	B
Gnaifenesin (glycerol galactolate)	Geolate	4	C
Guanadrel	Hylorol	3	A
Gunnethidine	Jamelin	3	A
Guanabenz	Wyntensin	3	B
Halazepam	Paxipam	2	A
Halcinonide	Halog	4	C
Halobetasol	Ultravate	4	C
Haloperidol	Haldol	2	A
Haloxazolam	Somelin	2	A
Hemoglobin glutamers	Oxyglobin Hemopure	2	A
Heptaminol	Corofundol	3	B
Heroin		1	A
Hexafluorenum	Myaloxen	2	A
Hexobarbital	Evipal	2	A
Hexoecelium	Tral	4	B
Hexylecaine	Cyclaine	4	C
Homatropine	Homapin	3	B
Homophenazine	Pelvicthol	2	A
Hydralazine	Apressoline	3	B
Hydrochlorothiazide	Hydrodiuril	4	B
Hydrocodone (dihydrocodenone)	Hyocodan	1	A
Hydrocortisone (Cortisol)	Cortef, etc.	4	C
Hydroflumethiazide	Sahuron	4	B
Hydromorphone	Dilaudid	1	A
Hydroxyamphetamines	Parandrine	1	A
4-Hydroxylestosterone		3	B
Hydroxyzine	Atarax	2	B
Ibomal	Noctal	2	A

# Alphabetical Substance List (Cont)

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Ibuprofen	Motrin, Advil, Nurofen, etc.	4	C
Ibutilide	Corvert	3	B
Iloprost	Ventavis	3	A
Imipramine	Innovate, Presamine, Tofranil	2	A
Indomethacin	Indocin	3	B
Infliximab	Remicade	4	B
Ipratropium		3	B
Irsesarten	Avapro	3	A
Isapirone		2	A
Isocarboxazid	Marplan	2	A
Isoetharine	Bronkosol	3	B
Isoflupredone	Predef	4	C
Isonethadone		2	A
Isometheptene	Ostin, Octon	4	B
Isopropamide	Darbid	4	B
Isoproterenol	Isoprel	2	A
Isosorbide dinitrate	Isordil	3	B
Isoxicam	Maxicam	2	A
Isosuprine	Vasodilan	4	C
Isradipine	DynaCirc	4	B
Kebuzone		3	B
Ketamine	Ketalar, Ketaset, Vetalar	2	B
Ketazolam	Anxon, Laftram, Solatran, Loftran	2	A
Ketoprofen	Orudis	4	C*
Ketorolac	Toradol	3	A
Labetalol	Normodyne	3	B
Lamotrigine	Lamictal	3	A
Lansoprazole		5	D
Lempirone	Elanone-V	2	A
Letosteine	Viscotol, Visiotol	4	C
Levamisole		2	B
Levobunolol	Betagan	3	B
Levonethorphan		2	A
Levorphanol	Levo-Dremoran	1	A
Lidocaine	Xylocaine	2	B
Lisinopril	Prinivil, Zestril	3	A
Lithium	Lithizine, Duralith, etc.	2	A
Lobeline		2	A
Lofentanil		1	A
Loflazepate, Ethyl	Victan	2	A
Loperamide	Inoodium	2	A
Loprazolam	Dormonot, Flavlane	2	A
Lorazepam	Clartin	4	B

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Lorazepam	Ativan	2	A
Lornetazepam	Noctamid	2	A
Losartan	Hyzaar	3	B
Loxapine	Laxtane	2	A
Mabuterol		3	A
Maprotiline	Ludomil	2	A
Mazindol	Sanorex	1	A
Mebutamate	Axiten, Dormate, Capla	2	A
Mecamylamine	Inversine	3	B
Mecizine	Antivert, Bonine	4	B
Meclofenamic acid	Arquel	4	C
Meclofenoxate	Luclidril, etc.	2	A
Medazepam	Nobrium, etc.	2	A
Medetomidine	Domitor	3	B
Mefenryone	Medrusar, etc.	4	C
Mefenamic acid	Ponstel	3	B
Mefexicam	Mobic	4	B
Melperone	Eunerpan	2	A
Memantine	Namenda	2	A
Meparfynol	Obivron	2	A
Mepazine	Pacatal	2	A
Mepenzolate	Canfil	3	A
Meperidine	Demerol	1	A
Mephencsin	Tolserol	4	B
Mephexalalone	Control, etc.	2	A
Mephentermine	Wyamine	1	A
Mepheryfoin	Mesantoin	2	A
Mephobarbital (Methylphenobarbital)	Mebaral	2	A
Mepivacaine	Carbocaine	2	B
Meprobamate	Equanil, Milltown	2	A
Menlluride	Mercurhydrin	4	B
Menbaphen	Novasural	4	B
Mercaptopimetin	Thiomertin	4	B
Microcarmalin	Cumertilin	4	B
Mersalyl	Salyrgan	4	B
Mesalamine	Asacol	5	C
Mesordazine	Sereniti	2	A
Mestanolone		3	B
Mesterolone		3	B
Metaclozepam	Talis	2	A
Metaproterenol	Alupent, Metaprel	3	B
Metaraminol	Aramine	1	A
Metaxalone	Skelaxin	4	B
Metazocine		2	A

# Alphabetical Substance List (Cont)

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Mefenolone		3	B
Mefenolone		3	A
Mefenolone	Dolophine	1	A
Mefenolone	Desoxylin	1	A
Mefenolone		3	B
Mefenolone	Probolic	3	B
Mefenolone	Djanabol	3	A
Mefenolone	Bantheline	3	B
Mefenolone	Histadyl, etc.	4	B
Mefenolone	Quaalude	1	A
Mefenolone	Gemonil	2	A
Mefenolone		3	A
Mefenolone	Naptazane	4	C
Mefenolone	Tacaryl	1	A
Mefenolone	Trest	4	B
Mefenolone		3	A
Mefenolone	Robaxin	4	C
Mefenolone	Brevital	2	A
Mefenolone	Folex, Nexate, etc.	4	B
Mefenolone	Levoprome, Neurocil, etc.	2	A
Mefenolone	Vasoxyl	3	A
Mefenolone	Orthoxide	3	A
Mefenolone	Pamine	4	B
Mefenolone	Celfontin	3	A
Mefenolone		3	B
Mefenolone	Enduron	4	B
Mefenolone		3	B
Mefenolone		3	A
Mefenolone	Aldomet	3	A
Mefenolone	Geranamine	1	A
Mefenolone		4	C
Mefenolone	Methergine	3	B
Mefenolone		1	A
Mefenolone	Ritalin	4	C
Mefenolone	Medrol	3	A
Mefenolone	Metandren	3	A
Mefenolone		3	A
Mefenolone	Noludar	2	A
Mefenolone	Sansert	4	B
Mefenolone		4	B
Mefenolone	Reglan	4	C
Mefenolone	Metubine	2	A
Mefenolone		3	B

<sup>3</sup> Recommended Penalty B if testing can prove presence of only levo-methamphetamine is present in sample.

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Mefenolone	Hypnodil	2	A
Mefenolone		1	A
Mefenolone	Lopressor	3	B
Mefenolone	Melex	2	A
Mefenolone	Mexill	4	B
Mefenolone	Posicor	3	B
Mefenolone		3	B
Mefenolone	Versed	2	A
Mefenolone	Pro-Amiline	3	B
Mefenolone		4	B
Mefenolone	Loniten	3	B
Mefenolone	Remeron	2	A
Mefenolone	Cytotec	5	C
Mefenolone	Mivacron	2	A
Mefenolone	Provigil	2	A
Mefenolone	Uniretic	3	B
Mefenolone	Moban	2	A
Mefenolone	Elocon	4	C
Mefenolone	Singulair	4	C
Mefenolone	Luvafren	2	A
Mefenolone		1	B <sup>4</sup>
Mefenolone		2	A
Mefenolone		3	A
Mefenolone		1	A
Mefenolone	Anthraxan, Relafen, Reliflex	3	A
Mefenolone	Corgard	3	B
Mefenolone	Amylsine	4	C
Mefenolone	Nubain	2	A
Mefenolone	Nalline, Lethidrone	2	A
Mefenolone	Narcan	3	A
Mefenolone	Revvia	3	A
Mefenolone	Nandrolin, Laurabolin, Durabolin	3	B
Mefenolone	Privine	4	B
Mefenolone	Equiproxen, Naprosyn	4	C
Mefenolone	AmERGE	3	B
Mefenolone		3	A
Mefenolone	Tilade	5	C
Mefenolone	Sezzone	2	A
Mefenolone		3	A

<sup>4</sup> Penalty class "A" recommended if regulator can prove an intentional administration.

# Alphabetical Substance List (Cont)

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Neostigmine	Prostigmine	3	B	Pantoprazole	Protonix	5	D
Nicardipine	Cardine	4	B	Papaverine	Pavagen, etc.	3	A
Nifedipine	Procardia	4	B	Paraldehyde	Paral	2	A
Niflumic acid	Nifluril	3	B	Paramethadione	Paradione	3	A
Niketamide	Coramine	1	A	Paraldehyde	Paraldehyde	4	C
Nimesulide		3	B	Pargyline	Eutonil	3	A
Nimetazepam	Erimin	2	A	Paroxetine	Paxil, Serostat	2	A
Nimetopine	Nemotop	4	B	Penbutolol	Cylert	1	A
Nitrazepam	Mogadon	2	A	Penfluridol	Levitol	3	B
Nitroglycerin		3	B	Pentafuridol	Cypron	2	A
Nizatidine	Axid	5	C	Pentamerythritol tetranitrate	Duotrate	3	A
19-Norandrostenediol		3	B	Pentazocine	Talwin	3	B
19-Norandrostenedione		3	B	Pentobarbital	Nembutal	2	A
Norbolethone		3	B	Pentoxifylline	Trental, Vazofrin	4	C
Norelthobol		3	B	Pentylenetetrazol	Metrazol, Nloric	1	A
Nordiazepam	Calmday, Nordaz, etc.	2	A	Perazine	Taxilan	2	A
Norepinephrine		2	A	Perfluorodecalin		2	A
Norethandrolone		3	A	Perfluorodecahydrodipthalene		2	A
Nortestosterone		4	C	Perfluoroethylbromide		2	A
Nortriptyline	Aventyl, Pamelor	2	A	Perfluorotripropylamine		2	A
Nylidrine	Arildin	3	A	Perfluorocarbonyls		2	A
Olanzapine	Zyprexa	2	A	Pergolide	Permax	3	B
Olmesartan	Benicar	3	A	Pericazine	Alodept, etc.	2	A
Olsalazine	Dipentum	4	B	Perindopril	Biprol	3	A
Omeprazole	Prilosec, Losec	5	D	Perlapine	Hypnodin	2	A
Orphenadrine	Norflex	4	B	Perphenazine	Trilafon	2	A
Oxabolone		3	B	Phenacemide	Phenutone	4	B
Oxandrolone	Anavar	3	B	Phenaglycodol	Acalo, Alcamid, etc.	2	A
Oxaprozih	Daypro, Deflam	4	C	Phenazocine	Narphen	1	A
Oxazepam	Serax	2	A	Phencyclidine (PCP)	Serxylan	1	A
Oxazolam	Serenal	2	A	Phentolamine	Bontril, etc.	1	A
Oxcarbazepine	Trileptal	3	A	Phenelzine	Nardelzine, Nardil	2	A
Oxloflorine (hydroxyephedrine)		2	A	Phenindione	Hedulin	5	C
Oxprenolol	Trasacor	3	B	Phenmetrazine	Prehudin	1	A
Oxycodone	Percodan	1	A	Phenobarbital	Luminal	2	A
Oxymesterone		3	B	Phenoxybenzamine	Dibenzylamine	3	B
Oxymetazoline	Afrin	4	B	Phenprocoumon	Liquanar	5	C
Oxymetholone	Adroyd, Anadrol	3	B	Phensuximide	Milonin	4	B
Oxymorphone	Numorphan	1	A	Phentermine	Ionamin	2	A
Oxyperitine	Fortit, Integrin	2	A	Phentolamine	Regitine	3	B
Oxyphenbutazone	Tandaeril	4	C	Phenybutazone	Butazolodin	4	C*
Oxyphenacetylimine	Daricon	4	B	Phenylephrine	Isophrin, Neo-Synephrine	3	B
Oxyphenonium	Antrenyl	4	B	Phenylpropanolamine	Propadrine	3	B
Paliperidone		2	A	Phenytolam	Dilantin	4	B
Pancuronium	Pavulon	2	A	Physostigmine	Eserine	3	B

# Alphabetical Substance List (Cont)

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Picrotoxin		1	A
Pimindone	Alvodine, Cimadon	2	A
Pimozide	Orep	2	A
Pinzepan	Domar	2	A
Pindolol	Viskin	3	A
Pipamperone	Djiperon	2	A
Piperacium	Arduan	2	A
Piperaciline		2	A
Piperacetazine	Psymod, Quide	2	A
Piperocaine	Metycaine	2	A
Pipotiazine	Lonseren, Piportil	2	A
Pipradrol	Dataril, Gerondyl, etc.	2	A
Piquindone		2	A
Pibuterol	Mnxair	3	A
Pirenzapine	Gastrozepin	5	C
Pretamide	Arelix, Tauliz	3	B
Pritramid		1	A
Piroxicam	Feldene	3	B
Polyethylene glycol		5	C
Polythiazide	Renese	4	B
Pravoxine	Tronothaine	4	C
Praxepam	Verstran, Centrux	2	A
Prazosin	Minipress	3	B
Prednisolone	Delta-Cortef, etc.	4	C
Prednisone	Meticorten, etc.	4	C
Prilocaline	Cltanest	2	A
Primidone	Mysoline	3	B
Probenecid		4	C
Procainamide	Pronestyl	4	B
Procaine		3	B
Procaterol	Pro Air	3	A
Prochlorperazine	Darbazine, Compazine	2	A
Procyllidine	Kemadrin	3	B
Promazine	Sparino	3	B
Promethazine	Phenergan	3	B
Propafenone	Rythmol	4	B
Propanidid		2	A
Propantheline	Pro-Banthine	3	A
Proparacaine	Ophthaine	4	C
Propentophylline	Karsivan	3	B
Propiomazine	Largon	2	A
Propionylpromazine	Tranvet	2	A
Propiram		2	A
Propofol	Djiprivan, Disoprivan	2	A
Propoxycaine	Ravocaine	2	A

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Propranolol	Inderal	3	B
Propylhexedrine	Benzedrex	4	B
Prostanazol		3	B
Prothipendyl	Dominal	2	A
Protoktyol	Ventaire	3	A
Protriptyline	Concordin, Triptil	2	A
Proxibarbitol	Axeon, Centralgol	2	A
Pseudoephedrine	Cenafed, Novafed	3	B
Pyridostigmine	Mestinon, Regonol	3	B
Pyrilamine	Neontergan, Equibhist	3	B
Pyriylidione	Hybersulfan, Sonodor	2	A
Quazipam	Doral	2	A
Quetiapine	Seroquel	2	A
Quinbolone		3	B
Quinapril, Quinaprilat	Accupril	3	A
Quinidine	Quinidex, Quinidine	4	B
Rabeprazole	Aciphex	5	D
Racemethorphan		2	A
Racemorphan		2	A
Raclopride		2	A
Racopamine	Paylean	2	A
Ramipril, metaboliite Ramiprilat	Altace	3	A
Ranitidine	Zantac	5	D
Remifentanyl	Ultiva	1	A
Remoxipride	Roxiam	2	A
Reserpine	Serpasil	2	A
Rilmazafone		2	A
Risperidone		2	A
Ritanserlin		2	A
Ritodrine	Yutopar	3	B
Rivastigmine	Exelon	2	A
Rizatriptan	Maxalt	3	B
Rocuronium	Zemuron	2	A
Rofecoxib	Vioxx	2	A
Romifidine	Sedivet	2	B
Ropivacaine	Naropin	2	A
Salicylamide		4	C
Salicylate		4	C
Salmeterol		3	B
Scopolamine (Hyoscine)	Triptone	3	B
Secobarbital (Quinalbarbitone)	Seconal	2	A
Selegiline	Eldepryl, Jumex, etc.	2	A
Sertraline	Lustral, Zolofl	2	A
Sibutramine	Meridia	3	B
Sildenafil	Viagra	3	A

# Alphabetical Substance List (Cont)

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Snake Venoms		2	A
Somatropin	Nutropin	2	A
Somatrem	Protropin	2	A
Sotalol	Beipace, Sotacor	3	B
Spiclomazine		2	A
Spiperone		2	A
Spirapril, metabolite Spiraprilat	Renomax	3	A
Spironolactone	Aldactone	4	B
Stanozolol	Winstrol-V	3	B
Stenbolone		3	B
Strychnine		1	B
Succinylcholine	Sucostrin, Quelin, etc.	2	A
Sufentanil	Sufenta	1	A
Sulfasalazine	Azulfidine, Azaline	4	C
Sulfondiallymethane		2	A
Sulfonmethane		2	A
Sulfuridazine		2	A
Sulindac	Inofal	2	A
Sulpiride	Clonril	3	A
Sulpropride	Aiglonyl, Sulptil	2	A
Sumatriptan	Barnetil	2	A
Synthetic cannabis	Imitrex	3	B
Tadalafil	Spice, K2, Kronic	1	A
Talbutal	Cialis	3	A
Tandospirone	Lotusato	2	A
Telmisartan		2	A
Temazepam	Micardis	3	B
Tenoxicam	Restoril	2	A
Tepoxalin	Aliganex, etc.	3	B
Terazosin		3	B
Terbutaline	Elytrin	3	A
Terfenadine	Brefine, Bricanyl	3	B
Testolactone	Seldane, Triludan	4	B
Testosterone	Teslac	3	B
Tetracaine		3	B
Tetrahydrogestrinone	Nifoman	2	A
Tetrazepam	Pontocaine	2	A
Thebaine		2	A
Theophylline	Tyzine	4	B
Thiobarbital	Musaril, Myolastin	2	A
Thiamylal		2	A
Thiethylperazine	Theobromine	4	B
	Theophylline	3	B
	Kemithal	2	A
	Surital	2	A
	Torecan	2	A
Thiopental	Pentobarb	2	A
Thiopropazate	Dartal	2	A
Thiopropazine	Majeptil	2	A
Thioridazine	Mellaril	2	A
Thiosalicylate		4	C
Thiothixene	Navane	2	A
Thiphenamil	Trocinat	4	B
Thiopride	Inalprid, Luxoben, etc.	2	A
Tiaprofenic acid	Surgain	3	B
Tiletamine	Component of Tolazol	2	A
Timiperone	Tolopelon	2	A
Timolol	Blocardrin	3	B
Toenitide	Tonocard	4	B
Tofisopam	Grandaxin, Seriel	2	A
Tolazoline	Priscoline	3	B
Tolmetin	Tolectin	3	B
Topiramate	Topamax	2	A
Torsenide (Torsasemide)	Demadex	3	A
Tramadol	Ultram	2	B
Trandolapril (and metabolite,trandolaprilat)	Tarka	3	B
Tranexamic acid		4	C
Tranylcypromine	Parnate	2	A
Trazodone	Desyrel	2	A
Trenbolone	Finoplix	2	B
Tretinoin	Inolin	2	A
Triamcinolone	Vetalog, etc.	4	C
Triamterene	Dyrenium	4	B
Triazolam	Halcion	2	A
Tribromethanol		2	A
Tricaine methanesulfonate	Finquel	2	A
Trichlormethiazide	Naqua, Naquasone	4	C
Trichloroethanol		2	A
Trichloethylene	Trilene, Trimar	2	A
Triclofos	Triclos	2	A
Tridhexethyl	Fathilon	4	B
Trifluomepazine	Norran	2	A
Trifluoperazine	Stelazine	2	A
Trifluoperidol	Triperidol	2	A
Trifluoromazine	Vetame, Vesprin	2	A
Trihexyphenidyl	Artane	3	A
Trimepazine	Temaril	4	B
Trimethadione	Tridione	3	B
Trimethaphan	Arfonad	3	A
Trimipramine	Surmontil	2	A

# Alphabetical Substance List (Cont)

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Typhelennamine	PBZ	3	B
Triprolidine	Acidil	4	B
Tubocurarine (Curare)	Metubin	2	A
Tybamate	Benvil, Nospan, etc.	2	A
Urethane		2	A
Valdecoxib		2	A
Valerianic acid		3	A
Valoctamide		2	A
Valsartan	Nirvanyl	3	B
Vardenafil	Djovan	3	A
Vedaprofen	Levitra	4	B
Venlafaxine	Effexor	2	A
Verapamil	Accionel, Verapipri	2	A
Vercuronium	Calaz, Isoptin	4	B
Viloxazine	Norcuron	2	A
Vinbarbital	Catrol, Vivalan, etc.	2	A
Vinylbital	Delvinol	2	A
Warfarin	Optinox, Speda	2	A
Xylometazoline	Coumadin, Coufarin	5	C
Xylometazoline	Rompun, Bay Va 1470	3	B
Yohimbine	Citrivin	4	B
Zafirlukast		2	A
Zaleplon	Accolate	4	C
Ziconotide	Sonata	2	A
Zileuton	Ralgro	4	C
Zilpaterol hydrochloride		1	A
Ziprasidone	Zyflo	4	C
Zolazepam	Zilpaterol	2	A
Zolmitriptan	Geoden	2	A
Zoflupicun		2	A
Zomepirac	Zornig	3	B
Zonisamide	Ambien, Stilnox	2	A
Zopiclone	Zomax	2	A
Zotepine	Zonegran	3	B
Zuclopenthixol	Imovan	2	A
A-1-androstene-3, 17-dione	Lodopin	2	A
A-1-dihydrotestosterone	Clatyl, Cesordinol	2	A
		3	A
		3	A

\*See Recommended Penalty Section of Document



## Listing by Classification

Class 1: Stimulant and depressant drugs that have the highest potential to affect performance and that have no generally accepted medical use in the racing horse. Many of these agents are Drug Enforcement Agency (DEA) Schedule II substances. These include the following drugs and their metabolites: Opiates, opium derivatives, synthetic opioids, psychoactive drugs, all DEA Schedule I\* substances (see <http://www.usdoj.gov/dea/pubs/scheduling.html>), amphetamines and amphetamine-like drugs as well as related drugs, including but not limited to apomorphine, nikethamide, mazindol, pemoline, and pentylenetetrazol.

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
3,4-methylenedioxypropylverone	MDPV, "Bath Salts"	1	A
Alfentanil	Alfenta	1	A
Aminorex	Aminoxafen, Aminoxaphen, Apiqueil, McN-742, Monocil	1	A
Amphetamine	Leritine	1	A
Amirididine		1	A
Apomorphine		1	A
Benzylpiperazine (BZP)		1	A
Carfentanil		1	A
Cathinone	khat, kat, quat, chat, catha, Abyssinian tea, African tea	1	A
a-Cobratoxin		1	A
Cocaine <sup>4</sup>		1	B <sup>4</sup>
Codeine		1	A
DEA Schedule I (all)*		1	A
Demorphin		1	A
Dextromoramide	Palfium, Narcolo	1	A
Diamorphine		1	A
Donepezil	Aricept	1	A
Endorphins		1	A
Bakaphalins		1	A
Ethylmorphine	Dionin	1	A
Etorphine HCl	M99	1	A
Fentanyl	Sublimaze	1	A
Heroin		1	A
Hydrocodone (dihydrocodienone)	Hydlocane	1	A
Hydromorphone	Dilaudid	1	A
Hydroxylamphetamine	Paraldine	1	A
Levorphanol	Levo-Dremoran	1	A
Lofantamyl		1	A

<sup>5</sup> Recommended Penalty B if testing can prove presence of only levo-methamphetamine is present in sample.

Association of Racing Commissioners International, Inc.

Uniform Classification Guidelines for Foreign Substances

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Mazindol	Sanorex	1	A
Meperidine	Demerol	1	A
Mephentermine	Wyamine	1	A
Metaraminol	Aramine	1	A
Methadone	Dolophine	1	A
Methamphetamine	Desoxyn	1	A <sup>3</sup>
Methaqualone	Quaalude	1	A
Methcathinone		1	A
Methylhexanamine (Methylhexanamine)	Geranamine	1	A
Methylphenidate	Ritalin	1	A
Metopon (methyldihydromorphinone)		1	A
Morphine <sup>6</sup>		1	B <sup>6</sup>
myo-inositol trispyrophosphate (ITPP)		1	A
Nikethamide	Coramine	1	A
Oxycodone	Percodan	1	A
Oxymorphone	Numorphen	1	A
Pemoline	Cylert	1	A
Pentylenetetrazol	Metrazol, Nioric	1	A
Phenazocine	Narphen	1	A
Phencyclidine (PCP)	Sernylan	1	A
Phendimetrazine	Bontril, etc.	1	A
Phenmetrazine	Preludin	1	A
Picloroxin		1	A
Piritramide		1	A
Remifentanyl	Ultiva	1	A
Strychnine		1	B
Sufentanil	Sufonia	1	A
Synthetic cannabis	Spice, K2, Kronik	1	A
Ziconotide		1	A

<sup>6</sup> Penalty class "A" recommended if regulators can prove an intentional administration.



## Listing by Classification (Continued)

**Class 2:** Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse.

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
3-Methoxytyramine	3-MT	2	A
Acetabromal		2	A
Acetophenazine	Tindal	2	A
Adiazolam		2	A
Alcufenac		2	A
Alcuronium	Alloferin	2	A
Alphaprodine	Nisentil	2	A
Alpidem	Anaxyl	2	A
Alprazolam	Xanax	2	A
Althesin	Saffan	2	A
Amisulpride	Solian	2	A
Amitriptyline	Elavil, Amitril, Endop	2	A
Amobarbital	Amytal	2	A
Amoxapine	Asendin	2	A
Amperozide		2	A
Anilopam	Anisine	2	A
Apröbarbital	Alurate	2	A
Articaine	Septocaine; Ultracaine, etc.	2	A
Atomoxetine	Strattera	2	A
Atacurium	Traetium	2	A
Azacylonol	Fraque	2	A
Azaparone	Stresnil, Suicalm, Fentaz (with Fentanyl)	2	A
Barbital	Veronal	2	A
Barbiturates		2	A
Bemegride	Megimide, Mikedimide	2	A
Benoxaprofen		2	A
Benperidol	Anquil	2	A
Benzepam	Tiadipona	2	A
Benzocazine	Deprol, Bronchodilietten	2	A
Benzocetamine		2	A
Benzodiazepines		2	A
Benzonatale	Tessalon, Tessalon Pettes, Zonatuss	2	A
Benzphetamine	Didrex	2	A
Benztropine	Cogentin	2	A
Birperone		2	A
Brimonidine	Alphagan	2	A
Bromazepam	Lexotan, Lectopam	2	A

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Bromisovalium	Difficord, etc.	2	A
Bromocriptine	Parlodol	2	A
Bromperidol	Bromidol	2	A
Brotizolam	Brotocol	2	A
Bupivacaine	Maracaine	2	A
Buprenorphine	Tengestic	2	A
Buspirone	Buspar	2	A
Bupropion	Wellbutrin	2	A
Butabarbital (Secbutobarbital)	Butacaps, Butasol, etc.	2	A
Butalbital (Talbutal)	Fiorinal	2	A
Butamlicaine	Hostacain	2	A
Butaperazine	Repoise	2	A
Butocetamide	Listomin	2	A
Caffeine		2	B
Camazepam	Paxor	2	A
Captofidame	Covafine	2	A
Carbidopa + levodopa	Sinemet	2	A
Carbromol	Mifudorm	2	A
Carisoprodol	Soma, Rele	2	B
Carphenazine	Proke-tazine	2	A
Carpirramine	Praznil	2	A
Carticaine (see articaine)	Septocaine; Ultracaine, etc.	2	A
Chloralose (Alpha-Chloralose)		2	A
Chloral betaine	Beta-Chlor	2	A
Chloral hydrate	Nactec, Oridrate, etc.	2	A
Chloraldehyde (chloral)		2	A
Chlordiazepoxide	Librium	2	A
Chlormezanone	Trancopal	2	A
Chloroform		2	A
Chlorhexidol		2	A
Chlorpropocaine	Nesacaino	2	A
Chlorprothiazine	Newplege	2	A
Chlorpromazine	Thorazine, Largactil	2	A
Chlorprothixene	Taractan	2	A
Citalopram	Celex	2	A
Clobazam	Urbanyl	2	A
Clocapramine		2	A
Clomethiazole (Chlormethiazole)		2	A
Clomipramine	Anafranil	2	A

## Listing by Classification (Continued)

**Class 2:** Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse.

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Clonazepam	Klonopin	2	A
Clorazepate	Tranxene	2	A
Clothiapine	Ertermin	2	A
Clofazepam	Trecalmo, Rize	2	A
Cloxazolam	Enadel, Sepazon, Tolestan	2	A
Clozapine	Clozaril, Leponex	2	A
Conorphone		2	A
Corticaine	Ultracain	2	A
Crotetamide		2	A
Cyamemazine	Terolan	2	A
Cyclobarbital	Phanodorm	2	A
Darboparin	Aranesp	2	A
Decamethonium	Syneurine	2	A
Demoxepam		2	A
Desipramine	Norpromine, Pertofrane	2	A
Dezocine	Dalgan®	2	A
Diazepam	Valium	2	B
Dichloralphenazone	Febenol, Isocom	2	A
Diethylpropion	Topanil, etc.	2	A
Diethylthiambutene	Theralon	2	A
Dihydrocodeine	Parcodin	2	A
Diltiazepam	Briantum	2	A
Diprenorphine	M50/50	2	A
Dixyrazine	Esucos	2	A
Dopamine	Intropin	2	A
Doxacurium	Nuromax	2	A
Doxapram	Dopram	2	A
Doxofazepam	Doxans	2	A
Doxepin	Adapin, Sinequan	2	A
Droperidol	Inapsine, Droleptan, Innovar-Vet (with Fentanyl)	2	A
Duloxetine		2	A
Enciprazine		2	A
Ephedrine		2	A
Epibatidine		2	A
Epinephrine		2	A
Ergoloid Mesylates (dihydroergocornine)		2	A

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Mesylate, dihydroergocristine mesylate and dihydroergocryptine mesylate)	Hydergine		
Erythropoietin (EPO)	Epoen, Proctif, etc.	2	A
Estazolam	Domnamid, Eurodin, Nuctalon	2	A
Ethamivan		2	A
Ethanol		2	A
Ethchlorvynol	Placidyl	2	A
Ethinamate	Vaimid	2	A
Ethopropazine	Paridol	2	A
Ethylisobutrazine	Diquel	2	A
Ethioecaine	Duranest	2	A
Etilfoxin	Stresam	2	A
Etizolam	Dopas, Pasaden	2	A
Etidroxizine	Indunox	2	A
Etomidate		2	A
Fenarbamate	Tymium	2	A
Fenclozic Acid	Cincopal	2	A
Fenfluramine	Pondimin	2	A
Fluanisone	Sedalande	2	A
Fludiazepam	Etisepam	2	A
Flunitrazepam	Rohypnol, Narcozep, Darkene, Hypnodorm	2	A
Flunitrazepam	Darkene, Hypnodorm	2	A
Flunitrazepam	Darkene, Hypnodorm	2	A
Flunitrazepam	Darkene	2	A
Flupromazine	Psyquil, Siquil	2	A
Fluoresone	Caducid	2	A
Fluoxetine	Prozac	2	A
Flupentixol	Depixol, Fluanxol	2	A
Fluphenazine	Prolixin, Permilti, Anatsensol, etc.	2	A
Flurazepam	Dalmane	2	A
Fluspirilene	Imep, Redeptin	2	A
Flutoprazepam	Restas	2	A
Flvoxamine	Dumirox, Faverin, etc.	2	A
Galantamine	Reminyl	2	A
Gallamine	Flaxedil	2	A
Gepirone		2	A
Glutethimide	Doriden	2	A

## Listing by Classification (Continued)

Class 2: Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse.

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Halazepam	Paxipam	2	A
Haloperidol	Haldol	2	A
Haloxazolam	Somelin	2	A
Hemoglobin glutamers	Oxyglobin, Hemopure	2	A
Hexafluorenum	Myaloxen	2	A
Hexobarbital	Evpal	2	A
Homophenzazine	Pelvichthol	2	A
Hydroxyzine	Aiarax	2	B
Ibomal	Noctal	2	A
Imipramine	Imavate, Presamine, Toframil	2	A
Isapirone		2	A
Isocarboxazid	Marplan	2	A
Isomethadone		2	A
Isoproterenol	Isoprel	2	A
Isoxetam	Maxicam	2	A
Ketamine	Ketalar, Ketaset, Vetalar	2	B
Ketazolam	Auxon, Loftram, Solatran, Loftran	2	A
Lenperone	Elanone-V	2	A
Levamisole		2	B
Levomethorphan		2	A
Lidocaine	Xyllocaine	2	B
Lithium	Lithizine, Duralith, etc.	2	A
Lobeline		2	A
Loflazepate, Ethyl	Victan	2	A
Loperamide	Imodium	2	A
Loprazolam	Dommonort, Havlene	2	A
Lorazepam	Ativan	2	A
Lornetazepam	Noctamid	2	A
Loxapine	Laxitene	2	A
Maprotiline	Ludiomil	2	A
Mebutamate	Axiten, Dormate, Capla	2	A
Meclofenoxate	Lucidril, etc.	2	A
Medazepam	Nobrium, etc.	2	A
Melperone	Eunerpan	2	A
Memantine	Namenda	2	A
Meparfynol	Oblivon	2	A
Mepazine	Pacatal	2	A
Mephexalono	Control, etc.	2	A

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Mephentermin	Mesantoin	2	A
Mephobarbital (Methylphenobarbital)	Mebaral	2	A
Mepivacaine	Carbocaine	2	B
Meprobamate	Equamil, Miltown	2	A
Mesoridazine	Sereniti	2	A
Metaclozepam	Thlis	2	A
Metazocine		2	A
Metharbital	Gemonil	2	A
Methohexital	Brevital	2	A
Methotrimeprazine	Levoprome, Neurocil, etc.	2	A
Methypyrrolon	Nolbidar	2	A
Metocurine	Metubine	2	A
Metomidate	Hypnodil	2	A
Mexazolam	Melex	2	A
Midazolam	Versed	2	A
Mirtazepine	Remeron	2	A
Mivacurium	Mivacuron	2	A
Modafinil	Provigil	2	A
Molindone	Moban	2	A
Mopetone	Luvatron	2	A
Mosaprimine		2	A
Nalbuphine	Nubain	2	A
Nalorphine	Nalaine, Lethidrone	2	A
Nefazodone	Serzone	2	A
Nimetazepam	Bimtin	2	A
Nitrazepam	Mogadon	2	A
Nordiazepam	Calmday, Nordaz, etc.	2	A
Norepinephrine		2	A
Nortriptyline	Aventyl, Pamelor	2	A
Olanzapine	Zyprexa	2	A
Oxazepam	Serax	2	A
Oxazolam	Serenal	2	A
Oxlofrine (hydroxyephedrine)		2	A
Oxyperitine	Forit, Integrin	2	A
Paliperidone		2	A
Pancuronium	Pavulon	2	A
Paraldehyde	Paral	2	A
Paroxetine	Paxil, Serostat	2	A
Penfluridol	Cyperon	2	A

## Listing by Classification (Continued)

Class 2: Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse.

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Pentobarbital	Nembutal	2	A
Petazine	Taxilan	2	A
Perfluorodecalin		2	A
Perfluorodecahydrophthalene		2	A
Perfluorooctylbromide		2	A
Perfluorotripropylamine		2	A
Perfluorocarbons		2	A
Pericazine	Alodept, etc.	2	A
Perlapine	Hypnodin	2	A
Perphenazine	Trilafon	2	A
Phenaglycodol	Acalo, Alcamid, etc.	2	A
Phenolizinc	Nardelzine, Nardil	2	A
Phenobarbital	Luminal	2	A
Phentermine	Ionamin	2	A
Pimindone	Alvodine, Cimadon	2	A
Pimozide	Orap	2	A
Phazepam	Domar	2	A
Pipamperone	Dipiperon	2	A
Pipecuronium	Arduan	2	A
Pipecqualine		2	A
Pipercetazine	Pymod, Quidé	2	A
Piperocaine	Metycaine	2	A
Pipotiazine	Lonseren, Piportil	2	A
Pipradrol	Dataril, Gerondyl, etc.	2	A
Piquindone		2	A
Praxepam	Verstran, Centrex	2	A
Prilocaine	Citanest	2	A
Prochlorperazine	Darbazine, Compazine	2	A
Propandiol		2	A
Propiomazine	Largon	2	A
Propionylpromazine	Tranvet	2	A
Propirram		2	A
Propofol	Diprivan, Disoprivan	2	A
Propoxycaïne	Ravocaine	2	A
Prothipendyl	Dominal	2	A
Protriptyline	Concordin, Triptil	2	A
Proxibarbitol	Axcen, Centralfol	2	A
Pyvithyldione	Hybersulfan, Sonodor	2	A
Quazipam	Doral	2	A
Quetiapine	Seroquel	2	A

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Racemethorphan		2	A
Racemorphan		2	A
Raclopride		2	A
Raclopramine	Payleam	2	A
Remoxipride	Roxiam	2	A
Reserpine	Serpasil	2	A
Rilimazafone		2	A
Risperidone		2	A
Ritanserlin		2	A
Rivastigmine	Exelon	2	A
Rocuronium	Zemuron	2	A
Rofecoxib	Vioxx	2	A
Romifidine	Sedivet	2	B
Ropyracaine	Naropin	2	A
Secobarbital (Quinalbarbitone)	Seconal	2	A
Selegiline	Eldepryl, Jumex	2	A
Sertaline	Lustral, Zolof	2	A
Snake Venoms		2	A
Somatrem	Protropin	2	A
Somatropin	Nutropin	2	A
Spiclomazine		2	A
Spiperone		2	A
Succinylcholine	Sucostrin, Quelin, etc.	2	A
Sulfondietilimethane		2	A
Sulfonmethane		2	A
Sulforidazine	Inofal	2	A
Sulpiride	Algonyl, Sulpitol	2	A
Sulfopride	Bametil	2	A
Talbutal	Lotusate	2	A
Tandospirone		2	A
Temazepam	Restoril	2	A
Tetrabenazine	Nitomax	2	A
Tetracaine	Pontocaine	2	A
Tetrazeepam	Musaril, Mycolastin	2	A
Thebaine		2	A
Thiobarbital	Kemithal	2	A
Thiamylal	Surital	2	A
Thiethylperazine	Torecan	2	A
Thiopental	Pentothal	2	A
Thiopropazate	Dartal	2	A

## Listing by Classification (Continued)

**Class 2:** Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse.

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Thiopropazine	Majeril	2	A
Thioridazine	Mellaril	2	A
Thiothixene	Navane	2	A
Thiipride	Italprid, Luxoben, etc.	2	A
Tiletamine	Component of Telazol	2	A
Timiperone	Tolopelon	2	A
Tofisopam	Grandaxain, Sericl	2	A
Topiramate	Topamax	2	A
Tramadol	Ultram	2	B
Tranylcypromine	Pernate	2	A
Trazodone	Desyrel	2	A
Tretinoin	Inolin	2	A
Triazolam	Halcion	2	A
Tribromethanol		2	A
Tricaine methanesulfonate	Finguel	2	A
Trichloroethanol		2	A
Trichloroethylene	Trilene, Trimer	2	A
Triclofos	Triclos	2	A
Trifluomethazine	Nortran	2	A
Trifluoperazine	Stelazine	2	A
Trifluoperidol	Tripertidol	2	A
Triflupromazine	Yctame, Vesprin	2	A
Trimipramine	Surmontil	2	A
Tubocurarine (Curare)	Metubin	2	A
Tybamate	Benvil, Nospau, etc.	2	A
Urethane		2	A
Valdecoxib		2	A
Valoctamide	Nirvanyl	2	A
Venlafaxine	Effexor	2	A
Veralipride	Accional, Veralipril	2	A
Vecuronium	Norcuron	2	A
Viloxazine	Catrol, Vivalan, etc.	2	A
Vinbarbital	Delvinol	2	A
Vinylicital	Optanox, Speda	2	A
Yohimbine		2	A
Zaleplon	Sonata	2	A
Zilpaterol hydrochloride	Zilpaterol	2	A
Ziprasidone	Geodon	2	A
Zolazepam		2	A
Zolpidem	Ambien, Stilnox	2	A

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Zomepirac	Zomax	2	A
Zopiclone	Imovan	2	A
Zotepine	Lodopin	2	A
Zuclopentixol	Claty!, Cesordinol	2	A

## Listing by Classification (Continued)

Class 3: Drugs that may or may not have generally accepted medical use in the racing horse, but the pharmacology of which suggests less potential to affect performance than drugs in Class 2.

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Acetubolol	Sectral	3	B
Acepromazine	Atrovat, Notensil, PromAce®	3	B
Albuterol (Salbutamol)	Proventil, Ventolin	3	B
Almotriptan	Axert	3	A
Alprenolol		3	A
Ambenoprium	Mytelase, Myeuran	3	B
Aminophylline	Aminophyllin, etc.	3	B
Amitraz	Mitaban	3	A
Amlodipine	Norvasc	3	B
Amyl nitrite		3	A
Arcoquine		3	A
Arformoterol		3	A
Atenolol	Tenormin	3	B
Atropine		3	B
Benazepril	Lotrel, Lotensin	3	B
Betaxolol	Kerlone	3	B
Bethanidine	Esbatol	3	A
Biperiden	Akineon	3	A
Bisoprolol	Zebeta, Bisobloc, etc.	3	B
Bifolterol	Effectin	3	A
Bolasterone		3	A
Boldenone	Equipoise	3	B
Boldione		3	A
Bretylolol	Bretylol	3	B
Bromfenac	Durnact	3	A
Bromodiphenhydramine		3	B
Bumetanide	Bumex	3	B
Butorphanol	Stadol, Torbugesic	3	B

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
N-Butylscopolamine		3	B
Calusterone		3	B
Candesartan	Atacand	3	B
Captopril	Capoten	3	B
Carazolol	Carbael, Conduction	3	A
Carbachol	Lentini, Doryl	3	B
Carbamazepine	Tegretol	3	B
Carbinoxamine	Clistin	3	B
Carfentolol	Carrol	3	B
Carvedilol	Coreg	3	B
Celecoxib	Celebrex	3	B
Cimetrolol		3	A
Clemastine	Tavist	3	B
Clenbuterol	Ventipulmin	3	B
Citidinum	Quarezan, Cilindex, etc.	3	B
Cionidine	Catapres	3	B
Cisfebrol		3	B
Cobalt		3	B <sup>7</sup>
Cyclandelate	Cyclospasmol	3	A
Cycrimine	Pagifone	3	B
Danazol	Danoocrine	3	B
Dehydrochloromethyltestosterone		3	B
Deracoxib	Deremaxx	3	B
Desoxymethyltestosterone		3	B
Deformidine	Dormosedan	3	B
Dextropropoxyphene	Darvon	3	B
Diazoxide	Proglycem	3	B
Diflunisal		3	B
Dimeflin		3	A
Diphenhydramine	Bendryl	3	B

<sup>7</sup> For cobalt concentrations of less than 25 parts per billion (ppb) of blood serum or plasma no penalty is recommended. For concentrations of 25 ppb or greater but less than 50 ppb of blood plasma or serum the recommended penalty is a written warning, the placement of the horse on the Veterinarians List with removal from list only after a blood test confirms that the concentration is below 25 ppb of blood plasma or serum. Testing shall be paid by the owner(s) of the horse. Concentrations of 50 ppb or greater in blood plasma or serum have a recommended "P" penalty.



## Listing by Classification (Continued)

Class 3: Drugs that may or may not have generally accepted medical use in the racing horse, but the pharmacology of which suggests less potential to affect performance than drugs in Class 2.

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Dipyridamol	Persantine	3	B
Divalproex	Depakote	3	A
Dobutamine	Dobutrex	3	B
Doxazosin	Decapryn	3	A
Doxylamine	Drolban	3	B
Dromostanolone	Tensilon	3	B
Dyphylline	Relpax	3	A
Etiopium	Vasotec	3	B
Eletipran	Cardilate	3	A
Enalapril (metabolite enalaprilat)	Brevibloc	3	B
Ethinyl tetrahydrate	Ederin	3	B
Esmolol	Zarontin	3	B
Ethamiphylline	Maxibolin, Organon	3	B
Ethacrynic acid	Bronkophrine	3	A
Ethosuximide	Lodino	3	B
Ethylestrenol	Felbato	3	A
Ethylinorepinephrine	Cincopal	3	B
Etidolol	Corlopan	3	B
Felbamate	Nalfon	3	B
Fenbuten	Perotec	3	B
Fenoldopam	Respiride, Respan, etc	3	B
Fenpropfen	Froben	3	B
Fenoterol	Froben	3	B
Fenspride	Halotestin	3	B
Fentiazac	Katadolone	3	A
Flurbiprofen	Altram	3	B
Flufenamic Acid	Monopril	3	A
Fluoxymesterone	Cerebyx	3	B
Flupirtine	Neurontin	3	B
Formebolone	Carolina Gold	3	B
Fornolator	Robinul	3	B
Fosinopril	Hyloral	3	A
Fosphenytoin	Ismelin	3	A
Furazabol	Wytensin	3	B
Gabapentin			
Gamma Aminobutyric Acid (GABA)			
Gestrinone			
Glycopyrrolate			
Guanadrel			
Guanethidine			
Guanabenz			

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Heptaminol	Corofundol	3	B
Homatropine	Etiopium	3	B
Hydralazine	Apresoline	3	B
4-Hydroxytestosterone			
Ibutilide	Corvet	3	B
Iloprost	Vontavis	3	B
Indomethacin	Indocin	3	A
Ipratropium			
Iribesarten	Avapro	3	B
Isoetharine	Bronkosol	3	A
Isosorbide dinitrate	Isordil	3	B
Kebuzone			
Ketorolac	Toradol	3	B
Labetalol	Normodyne	3	A
Lamotrigino	Lamictal	3	B
Levobunolol	Belagan	3	A
Lisinopril	Prinivil, Zestril	3	B
Losartan	Hyzaar	3	A
Mabuterol			
Mecamylamine	Inversine	3	A
Medetomidine	Domitor	3	B
Mefenamic Acid	Fonstel	3	B
Mepenzolate	Cantil	3	B
Mestanolone			
Mesterolone			
Metaproterenol	Alupent, Metaprel	3	A
Metenolone			
Methacholine			
Methandienone			
Methandriol	Probolc	3	B
Methandrostenolone	Dianabol	3	B
Methanetheline	Banflin	3	A
Methasterone			
Methixene	Trest	3	B
Methoxamine	Vasoxyl	3	A
Methoxyphenamine	Orthoxide	3	A
Methauximide	Celontin	3	A
Methylatropine			
Methyldienolone			
Methylidopa	Aldomet	3	B
Methylnortestosterone			

## Listing by Classification (Continued)

Class 3: Drugs that may or may not have generally accepted medical use in the racing horse, but the pharmacology of which suggests less potential to affect performance than drugs in Class 2.

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Methyltestosterone	Metandren	3	A
Methyl-1-testosterone		3	A
Metolazone		3	B
Metoprolol	Lopressor	3	B
Mibefradil	Posicor	3	B
Mibolerone		3	B
Midodrine	Pro-Amidine	3	B
Minoxidil	Loniten	3	B
Moexipril (metabolite, moexiprilat)	Uniretic	3	B
Muscarine		3	A
Nabumetone	Anthraxan, Relafen, Reliflex	3	A
Nadolol	Corgard	3	B
Naloxone	Narcan	3	A
Naltrexone	Revia	3	A
Nandrolone	Nandrolin, Laurabolin, Durabolin	3	B
Naratriptan		3	B
Nebivolol	Amerge	3	A
Nefopam		3	A
Neostigmine	Prostigmine	3	B
Niflumic Acid	Nifluril	3	B
Nimesulide		3	B
Nitroglycerin		3	B
19-Norandrosteronediol		3	B
19-Norandrostenedione		3	B
Norbolethone		3	B
Norelgestobol		3	B
Norethandrolone		3	A
Nylidrine	Artidin	3	A
Olmesartan	Benicar	3	A
Oxabolone		3	B
Oxandrolone	Anavar	3	B
Oxcarbazepine	Trileptal	3	A
Oxprenolol	Trasicor	3	B
Oxymesterone		3	B
Oxymetholone	Adroyd, Anadrol	3	B
Papaverine	Pavagen, etc.	3	A
Paramethadione	Paraldione	3	A
Pargyline	Butonyl	3	A
Penbutolol	Levatol	3	B

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Peniterythritol tetrakisphosphate	Duotrate	3	A
Pentazocine	Talwin	3	B
Pergolide	Permax	3	B
Perindopril		3	A
Phenoxymethylamine	Dibenzylamine	3	B
Phentolamine	Regitine	3	B
Phenylephrine	Isophrin, Neo-Synephrine	3	B
Phenylpropanolamine	Propadrine	3	B
Physostigmine	Eserine	3	B
Pindolol	Viskin	3	A
Piibutero	Maxair	3	A
Piretanide	Arelx, Tauliz	3	B
Piroxicam	Feldene	3	B
Prazosin	Minipress	3	B
Primidone	Mysoline	3	B
Procaine		3	B
Procaerol	Pro Air	3	A
Procyclidine	Kemadim	3	B
Promazine	Sparine	3	B
Promethazine	Phenergan	3	B
Propranolol	Pro-Banathine	3	A
Propentophylline	Karsivan	3	B
Propranolol	Inderal	3	B
Prostanazol		3	B
Protoktyol	Ventaire	3	A
Pseudoephedrine	Cenafed, Novafed	3	B
Pyridostigmine	Mestinon, Regonol	3	B
Pyrimamine	Neoantergan, Equibhist	3	B
Quinapril, Quinaprilat	Accupril	3	A
Quinbolone		3	B
Ramipril, metabolite Ramiprilat	Altace	3	A
Ritodrine	Yutopar	3	B
Rizatriptan	Maxalt	3	B
Salmeterol		3	B
Scopolamine (Hyoscine)	Triptonc	3	B
Sibutramine	Meridia	3	B
Sildenafil	Viagra	3	A
Sotalol	Betapace, Solacor	3	B
Spirapril, metabolite Spiraprilat	Renomax	3	A
Stanozolol	Winstrol-V	3	B
Stenbolone		3	B

## Listing by Classification (Continued)

Class 3: Drugs that may or may not have generally accepted medical use in the racing horse, but the pharmacology of which suggests less potential to affect performance than drugs in Class 2.

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Sulindac	Climoril	3	A
Sumatriptan	Imitrex	3	B
Tadalafil	Cialis	3	A
Telmisartan	Micardis	3	B
Tenoxicam	Alganex, etc.	3	B
Tepoxalin		3	B
Tenzosin	Hytrin	3	A
Terbutaline	Brethine, Bricanyl	3	B
Testolone	Testlac	3	B
Testosterone		3	B
Tetrahydrogestrinone		3	A
Theophylline	Aqualylin, etc.	3	B
Tiaprofenic Acid	Surgam	3	B
Timolol	Blocardrin	3	B
Tolazoline	Priscoline	3	B
Tolmetin	Tolectin	3	B
Torsemide (Torsemide)	Demadex	3	A
Trandolapril (and metabolite, Trandolaprilat)	Tarka	3	B
Trenbolone	Finoplix	3	B
Trihexyphenidyl	Artane	3	A
Trimethadione	Tridione	3	B
Trimethaphan	Arfonad	3	A
Triptelennamine	PBZ	3	B
Valeric acid		3	A
Valsartan	Diovan	3	B
Vardenafil	Levitra	3	A
Xylazine	Rompun, Bay Va 1470	3	B
Zolmitriptan	Zomig	3	B
Zonisamide	Zonegran	3	B
$\Delta$ -1-androstene-3, 17-diol		3	A
$\Delta$ -1-androstene-3, 17-dione		3	A
$\Delta$ -1-dihydrotestosterone		3	A

## Listing by Classification (Continued)

Class 4: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3.

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
2-Aminoheptane	Tuamine	4	B
Acetaminophen (Paracetamol)	Tylenol, Tempra, etc.	4	C
Acetanilid		4	B
Acetazolamide	Diamox, Vetamox	4	B
Acetophenetidin (Phenacetin)		4	B
Acetylsalicylic acid (Aspirin)		4	C
Alclomethasone	Aclovate	4	C
Adrenochrome monosemicarbazone salicylate		4	B
Aldosterone	Aldocortin, Electro cortin	4	B
Ambroxol	Ambrol, etc.	4	C
Amichonide	Cyclocort	4	C
Amiloride	Moduretic, Midamor	4	B
Aminocaproic acid	Amicar, Caprocid	4	C
Amiodarone		4	B
Aminopyrine		4	B
Amisotriadine	Rolictron	4	B
Amlodipine	Norvasc, Ammiviv	4	B
Amrhone		4	B
Anisotropine	Valpin	4	B
Antipyrine		4	B
Apazone (Azapropazone)	Rheumox	4	B
Aprindine		4	B
Baclofen	Lioresal	4	B
Beclomethasone	Propadorm	4	C
Bendroflumethiazide	Naturetin	4	B
Benoxinate	Dorsacaine	4	C
Benzocaine		4	B
Benzthiazide		4	B
Bepidil	Bepadil	4	B
Betamethasone	Betasone, etc.	4	C
Bethanechol	Urecholine, Duvoid	4	C
Bromhexine	Oleto, etc.	4	B
Brompheniramine	Dimetane, Disomer	4	B
Budesonide	Pulmacort, Rhinocort	4	C
Butacaine	Butyn	4	B
Butamben (butyl aminobenzoate)	Butesin	4	C
Butoxyacaine	Studecain	4	B
Camphor		4	C
Carbazochrome		4	C
Carprofen	Rimadyl	4	B
Cetirizine	Zyrtec	4	C

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Chlormerodrin	Neohydrin	4	B
Chlorophenesin	Macolate	4	C
Chloroquine	Avloclor	4	C
Chlorothiazide	Diuril	4	B
Chlorpheniramine	Chlortrimeton, etc.	4	B
Chlorthalidone	Hydron	4	B
Chlorzoxazone	Paraflex	4	B
Ciclesonide		4	B
Cinchocaine	Nupercaine	4	C
Cinacalcin		4	B
Cilobutrin		4	C
Citibucaine	Barax	4	C
Clobetasol	Temovate	4	C
Clocortolone	Cloderm	4	C
Clofenamide		4	B
Clormecaine	Placacid	4	C
Colchicine		4	B
Cortisone	Cortone, etc.	4	C
Cyclizine	Mrazine	4	B
Cyclobenzaprine	Flexeril	4	B
Cyclomethylcaine	Surfacaine	4	C
Cyclofliazide	Anhydron, Renazide	4	B
Cyproheptadine	Perticin	4	C
Dantrolene	Dantrium	4	C
Dembroxol (Dumbroxine)	Sputolysin	4	C
Deoxycorticosterone	Pevortin, DOCA, Descotone, Dorcostrin	4	C
Desonite	Des Owen	4	C
Desoximetasone	Topicort	4	C
Dexamethasone	Azium, etc.	4	C
Dextromethorphan		4	B
Dibucaine	Nupercainal, Cincocaine	4	C
Dichlorophenamide	Daramide	4	C
Diclofenac	Volifen, Voltarol	4	C
Diflorasone	Florons, Maxiflor	4	C
Difluocortolone	Flu-Cortines, etc.	4	C
Digitoxin	Crystodigin	4	B
Digoxin	Lanoxin	4	B
Dihydroergotamine		4	B
Diltiazem	Cardizem	4	B
Dimethisoquin	Quotane	4	B
Dimethylsulfoxide (DMSO)	Domoso	4	C
Diphenoxylate	Difenoxin, Lomotil	4	B

## Listing by Classification (Continued)

Class 4: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3.

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Dipyrene	Novin, Methampyrone	4	C
Disopyramide	Norpace	4	B
Dyclonine	Dyclone	4	C
Eifenac		4	C
Ergonovine	Ergotrate	4	C
Ergolamine	Gynergen, Cafergot, etc.	4	B
Etenacet	Embrel	4	B
Ethioheptazine	Zactano	4	B
Ethotolol	Peganone	4	B
Ethoxzolamide	Cardiase, Ethamide	4	C
Ethylamino benzoate (Benzocaine)	Sernets, etc.	4	C
Felodipine	Plendil	4	B
Fexofenadine	Allegra	4	C
Firocoxib		4	C
Flecainide	Idalon	4	B
Floctafenine	Idalon, Idarac	4	B
Fludionolone	Synalar, etc.	4	C
Fludrocortisone	Alforone, etc.	4	C
Flumethasone	Flucort, etc.	4	C
Flumethiazide	Ademol	4	B
Flunarizine	Sibelium	4	B
Flunisolide	Bronilide, etc.	4	C
Flunixin	Benamine	4	C*
Fluocinolone	Synalar	4	C
Fluocinonide	Licon, Lidex	4	C
Fluorometholone	FML	4	B
Fluoroprednisolone	Predef-2X	4	C
Fluprednisolone	Alphadrol	4	C
Flurandrenolide	Cordran	4	C
Fluticasone	Flixonase, Flutide	4	C
Guaifenesin (glycerol guaiacolate)	Gecolate	4	C
Halichonide	Halog	4	C
Halobetasol	Ultravate	4	C
Hexocyclium	Tyal	4	B
Hexylamine	Cyclaine	4	C
Hydrochlorothiazide	Hydrodiuril	4	B
Hydrocortisone (Cortisol)	Cortef, etc.	4	C
Hydroflumethiazide	Satoron	4	B
Ibuprofen	Motrin, Advil, Nurpin, etc.	4	C
Infliximab	Remicade	4	B
Isoflupredone	Predef	4	C

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Isometheptene	Ocain, Octon	4	B
Isopropamide	Dartbid	4	B
Isoxsuprine	Vasodilan	4	C
Isradipine	DynaCirc	4	B
Ketoprofen	Orudis	4	C*
Letosteine	Viscotol, Visiotal	4	C
Loratidine	Claritin	4	B
Mecizine	Antivert, Bonine	4	B
Meclofenamic acid	Arquel	4	C
Medrysone	Medriusat, etc.	4	C
Meloxicam	Mobic	4	B
Mephesisin	Tolserol	4	B
Meralluride	Mercubhydrin	4	B
Merbaphen	Novasural	4	B
Mercaptopimerin	Thiomerin	4	B
Mercumailin	Cumerfilin	4	B
Mersalyl	Salyrgan	4	B
Metaxalone	Skelaxin	4	B
Methapyrilone	Histadyl, etc.	4	B
Methazolamide	Napiazane	4	C
Methidiazine	Tacaryl	4	B
Methiocarbamol	Robaxin	4	C
Methotrexate	Folex, Nexate, etc.	4	B
Methscopolamine	Pamine	4	B
Methylchlorothiazide	Enduron	4	B
Methysergionovine	Methergine	4	C
Methylprednisolone	Mecrol	4	C
Methysergide	Sansert	4	B
Metamide		4	B
Metoclopramide	Reglan	4	C
Mexilitine	Mexillil	4	B
Milrinone		4	B
Mometasone	Elocon	4	C
Montelukast	Singulair	4	C
Naepaine	Amylsine	4	C
Naphazoline	Privine	4	B
Naproxen	Equiproxen, Naprosyn	4	C
Nicardipine	Cardine	4	B
Nifedipine	Procardia	4	B
Nimodipine	Nemotop	4	B
Noticosterone		4	C
Olsalazine	Dipentum	4	B

## Listing by Classification (Continued)

Class 4: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3.

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Orphenadrine	Nortifex	4	B
Oxaprozin	Daypro, Deflam	4	C
Oxymetazoline	Afrin	4	B
Oxyphenbutazone	Tandearl	4	C
Oxyphenyemimine	Daricon	4	B
Oxyphenonium	Antrenyl	4	B
Paramethasone	Haldrone	4	C
Pentoxifylline	Trental, Vazofirin	4	C
Phenacemide	Phenurone	4	B
Phensuximide	Milonitin	4	B
Phenylbutazone		4	C*
Phenyletoin	Dilantin	4	B
Polythiazide	Retese	4	B
Pranoxine	Tronothaline	4	C
Prednisolone	Delta-Cortef, etc.	4	C
Prednisone	Meticorten, etc.	4	C
Probenecid		4	C
Procinamide	Pronestyl	4	B
Propafenone	Rythmol	4	B
Proparacaine	Ophthalmine	4	C
Propylhexedrine	Bonzedrox	4	B
Quinidine	Quinidex, Quinicoardine	4	B
Salicylamide		4	C
Salicylate		4	C
Spironolactone	Aldactone	4	B
Sulfasalazine	Azulfidine, Azaline	4	C
Terfenadine	Seldane, Trihidan	4	B
Tetrahydrozoline	Tyzine	4	B
Theobromine		4	B
Thiosalicylate		4	C
Thiophenamil	Troxinate	4	B
Tocainide	Tonocard	4	B
Tranexamic acid		4	C
Triamcinolone	Vertalog, etc.	4	C
Triamterene	Dyrenium	4	B
Trichloromethiazide	Naqua, Naquasone	4	C
Tridihexethyl	Pathilon	4	B
Trimeprazine	Temaril	4	B
Triprolidine	Acidil	4	B
Vedaprofen		4	B
Verapamil	Calan, Isoptin	4	B
Xylometazoline	Otrivin	4	B

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Zafirlukast	Accolate	4	C
Zenanol	Ralgro	4	C
Zileuton	Zyflo	4	C

\* See Recommended Penalty Section of Document

## Listing by Classification (Continued)

Class 5: This class includes those therapeutic medications for which concentration limits have been established by the racing jurisdictions as well as certain miscellaneous agents and other medications as determined by the regulatory bodies.

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class
Acenocoumarol		5	C
Anisidione		5	C
Cilostazol	Pletal	5	C
Cimetidine	Tagamet	5	D
Cromolyn	Intel	5	C
Dicumarol	Dicumarol	5	C
Dimethylsulphone (MSM)		5	C
Diphenadione		5	C
Esomeprazole	Nexium	5	D
Famotidine	Gastef, etc.	5	D
Lansoprazole		5	D
Mesalamine	Asacol	5	C
Misoptotel	Cytotec	5	C
Nedocromil	Tilade	5	C
Nizatidine	Axid	5	C
Omeprazole	Prilosec, Losec	5	D
Pantoprazole	Protonix	5	D
Phenindione	Hedulin	5	C
Phenprocoumon	Liquamar	5	C
Pitrazepine	Gastrozepin	5	C
Polyethylene glycol		5	C
Reheprazole	Aciphex	5	D
Ranitidine	Zantac	5	D
Warfarin	Coumadin, Coufarin	5	C

## Non-Classified Substances

Substances that are considered to have no effect on the physiology of a racing animal except to improve nutrition or treat or prevent infections or parasite infestations, are not classified. These Substances normally include antimicrobials, antiparasitic drugs, and nutrients such as vitamins. Examples of such substances include the following:

Sulfonamides and trimethoprim

Bufotenine

1. Note: Bufotenine is not commercially available in any form.

Antibiotics:

Penicillins  
Cephalosporins  
Chloramphenicol  
Aminoglycosides  
Tetracyclines  
Nitrofurans  
Metronidazole

2. Note: Bufotenine is a metabolite of 5-methoxy-N,N-dimethyltryptamine, found in reed canary grass (and potentially other food source plants). It may be found in the urine of horses eating this grass (and potentially other plant foods), and has been reported as a positive finding. Findings of bufotenine in equine urine should not be considered for regulatory action.

Anthelmintics:

Avermectins  
Benzimidazoles  
Piperazines  
Pyrantel  
A, D, E, K, B vitamins  
Vitamin C

Antifungals  
Vitamins



## Recommended Penalty and Model Rule

The following are recommended penalties for violations due to the presence of a drug carrying a Category "A" penalty and for violations of ARCI-011-015 and ARCI-025-015; Prohibited Practices:

<b>LICENSED DRIVERS</b>		
1 <sup>st</sup> Offense	2 <sup>nd</sup> LIFETIME offense in any jurisdiction	3 <sup>rd</sup> LIFETIME offense in any jurisdiction
<ul style="list-style-type: none"> <li>Minimum one-year suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a three-year suspension</li> </ul> <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> <li>Minimum fine of \$10,000 or 10% of total purse (greater of the two) absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of \$25,000 or 25% of purse (greater of the two).</li> </ul> <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> <li>May be referred to the Commission for any further action deemed necessary by the Commission.</li> </ul>	<ul style="list-style-type: none"> <li>Minimum three-year suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of license revocation with no reapplication for a three-year period.</li> </ul> <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> <li>Minimum fine of \$25,000 or 25% of total purse (greater of the two) absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of \$50,000 or 50% of purse (greater of the two).</li> </ul> <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> <li>May be referred to the Commission for any further action deemed necessary by the Commission.</li> </ul>	<ul style="list-style-type: none"> <li>Minimum five-year suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of license revocation with no reapplication for a five-year period.</li> </ul> <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> <li>Minimum fine of \$50,000 or 50% of total purse (greater of the two) absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of \$100,000 or 100% of purse (greater of the two).</li> </ul> <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> <li>May be referred to the Commission for any further action deemed necessary by the Commission.</li> </ul>
<b>LICENSED OWNER</b>		
1 <sup>st</sup> Offense	2 <sup>nd</sup> LIFETIME offense in owner's stable any jurisdiction	3 <sup>rd</sup> LIFETIME offense in owner's stable in any jurisdiction
<ul style="list-style-type: none"> <li>Disqualification and loss of purse</li> </ul> <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> <li>Horse shall be placed on the Veterinarian's List for 90 days and must pass a commission-approved examination before becoming eligible to be entered.</li> </ul>	<ul style="list-style-type: none"> <li>Disqualification and loss of purse</li> </ul> <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> <li>Horse shall be placed on the Veterinarian's List for 120 days and must pass a commission-approved examination before becoming eligible to be entered.</li> </ul>	<ul style="list-style-type: none"> <li>Disqualification, loss of purse and \$50,000 fine</li> </ul> <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> <li>Horse shall be placed on the Veterinarian's List for 180 days and must pass a commission-approved examination before becoming eligible to be entered.</li> </ul> <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> <li>Referral to the Commission with a recommendation of a suspension for a minimum of 90 days.</li> </ul>

## Recommended Penalty and Model Rule (Continued)

The following are recommended penalties for violations due to the presence of a drug carrying Category "B" penalty, for the presence of more than one NSAID in a plasma/serum sample, subject to the provisions set forth in ARCI-011-020(E) and ARCI-025-020(E) and for violations of the established levels for total carbon dioxide:

<b>LICENSED OWNER</b>	<b>2<sup>nd</sup> offense (365-day period) in any jurisdiction</b>	<b>3<sup>rd</sup> offense (365-day period) in any jurisdiction</b>
<b>1<sup>st</sup> Offense</b>	<b>2<sup>nd</sup> offense (365-day period) in any jurisdiction</b>	<b>3<sup>rd</sup> offense (365-day period) in any jurisdiction</b>
<ul style="list-style-type: none"> <li>• Minimum 15-day suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a 60-day suspension</li> </ul> <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> <li>• Minimum fine of \$500 absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum fine of \$1,000.</li> </ul>	<ul style="list-style-type: none"> <li>• Minimum 30-day suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a 180-day suspension</li> </ul> <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> <li>• Minimum fine of \$1,000 absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum fine of \$2,500.</li> </ul>	<ul style="list-style-type: none"> <li>• Minimum 60-day suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a one-year suspension.</li> </ul> <ul style="list-style-type: none"> <li>• Minimum fine of \$2,500 absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of \$5,000 or 5% purse (greater of the two).</li> </ul> <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> <li>• May be referred to the Commission for any further action deemed necessary by the Commission.</li> </ul>
<b>LICENSED OWNER</b>	<b>2<sup>nd</sup> offense (365-day period) in owner's stable any jurisdiction</b>	<b>3<sup>rd</sup> offense (365-day period) in owner's stable in any jurisdiction</b>
<b>1<sup>st</sup> Offense</b>	<b>2<sup>nd</sup> offense (365-day period) in owner's stable any jurisdiction</b>	<b>3<sup>rd</sup> offense (365-day period) in owner's stable in any jurisdiction</b>
<ul style="list-style-type: none"> <li>• Disqualification and loss of purse [in the absence of mitigating circumstances]*</li> </ul> <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> <li>• Horse must pass a commission-approved examination before becoming eligible to be entered.</li> </ul>	<ul style="list-style-type: none"> <li>• Disqualification and loss of purse [in the absence of mitigating circumstances]*</li> </ul> <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> <li>• Horse must pass a commission-approved examination before becoming eligible to be entered.</li> </ul>	<ul style="list-style-type: none"> <li>• Disqualification, loss of purse, and in the absence of mitigating circumstances a \$5,000 fine.*</li> </ul> <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> <li>• Horse shall be placed on the Veterinarian's List for 45 days and must pass a commission-approved examination before becoming eligible to be entered.</li> </ul>

\*The RMTTC recommendation called for loss of purse to happen in absence of mitigating circumstances. The Joint Model Rules Committee has made loss of purse mandatory in their proposal.

## Recommended Penalty and Model Rule (Continued)

The following are recommended penalties for violations due to the presence of a drug carrying a Category "C" penalty and overages for permitted NSAIDs and furosemide: *(All concentrations are for measurements in serum or plasma.)*

<b>LICENSEE/TRAINER</b>	Phenylbutazone ( $\geq 2.0$ - $5.0$ mcg/ml) Flunixin ( $\geq 20$ - $100$ ng/ml) Ketoprofen ( $\geq 2$ - $50$ ng/ml) Furosemide ( $\geq 100$ ng/ml) and/or no furosemide when identified as administered	Phenylbutazone ( $\geq 5.0$ mcg/ml) Flunixin ( $\geq 100$ ng/ml) Ketoprofen ( $\geq 50$ ng/ml) and GLASS C Violations
1 <sup>st</sup> Offense (365-day period) in any jurisdiction	Minimum of a written warning to maximum fine of \$500	Minimum fine of \$1,000 absent mitigating circumstances
2 <sup>nd</sup> Offense (365-day period) in any jurisdiction	Minimum of a written warning to maximum fine of \$750	Minimum fine of \$1,500 and 15-day suspension absent mitigating circumstances
3 <sup>rd</sup> Offense (365-day period) in any jurisdiction	Minimum fine of \$500 to a maximum fine of \$1,000	Minimum fine of \$2,500 and 30-day suspension absent mitigating circumstances
<b>LICENSEE/OWNER</b>	Phenylbutazone ( $\geq 2.0$ - $5.0$ mcg/ml) Flunixin ( $\geq 20$ - $100$ ng/ml) Ketoprofen ( $\geq 2$ - $50$ ng/ml) Furosemide ( $\geq 100$ ng/ml) and/or no furosemide when identified as administered	Phenylbutazone ( $\geq 5.0$ mcg/ml) Flunixin ( $\geq 100$ ng/ml) Ketoprofen ( $\geq 50$ ng/ml) and GLASS C Violations
1 <sup>st</sup> Offense (365-day period) in any jurisdiction	Horse may be required to pass commission-approved examination before being eligible to run	Loss of purse. Horse must pass commission-approved examination before being eligible to run
2 <sup>nd</sup> Offense (365-day period) in any jurisdiction	Horse may be required to pass commission-approved examination before being eligible to run	Loss of purse. If same horse, placed on veterinarian's list for 45 days, must pass commission-approved examination before being eligible to run
3 <sup>rd</sup> Offense (365-day period) in any jurisdiction	Disqualification and loss of purse. Horse must pass commission-approved examination before being eligible to run	Loss of purse. Minimum \$5,000 fine. If same horse, placed on veterinarian's list for 60 days, must pass commission-approved examination before being eligible to run

\*If the trainer has not had more than one violation within the previous two years, the Stewards/Judges are encouraged to issue a warning in lieu of a fine provided the reported level is below 3.0 mcg/ml absent of aggravating factors.

After a two-year period, if the licensee has had no further violations, any penalty due to an overage in the 2.0-5.0 category will be expunged from the licensee's record for penalty purposes.

## Recommended Penalty and Model Rule (Continued)

The recommended penalty for a violation involving a drug that carries a Category "D" penalty is a written warning to the trainer and owner. Multiple violations may result in fines and/or suspension.

## Recent Document Revisions

Version	Date	Drug/Substance	Notes	Approx. Page(s)
12.00	March 2016	Methamphetamine	Added footnote language recommending Penalty B if testing can prove presence of only levo-methamphetamine is present in sample.	7, 13
12.00	March 2016	Tramadol	Changed from Penalty A to Penalty B	11, 19
12.00	March 2016	Cetirizine	Changed from Penalty B to Penalty C after inclusion into ARCI Controlled Therapeutic Medication Schedule	2, 24
12.00	March 2016	Morphine	Added footnote language recommending Penalty A if intentional administration can be proven by regulators.	8, 13
12.00	March 2016	Cocaine	Added footnote language recommending Penalty A if intentional administration can be proven by regulators.	3, 13
12.00	March 2016	Methacholine	Corrected spelling error in Alphabetical Listing by Substance Section and Listing by Classification Section	7, 20
12.00	March 2016	myo-inositol trispyrophosphate (ITPP)	Corrected spelling error in Alphabetical Listing by Substance Section and Listing by Classification Section	8, 13
11.00	December 2015	2-Aminoheptane	Corrected typographical error to reflect Class 4, Penalty B Substance	1, 23
11.00	December 2015	Xylometazoline	Corrected typographical error to reflect Class 4, Penalty B Substance	11, 25
11.00	December 2015	Rivastigmine	Corrected typographical error to reflect Class 2, Penalty A Substance	10, 17
11.00	December 2015	Rabeprazole	Corrected typographical error to reflect Class 5, Penalty D Substance	10 26
11.00	December 2015	Prilocaine	Corrected typographical error to reflect Class 2, Penalty A Substance	9, 17
11.00	December 2015	Hexocyclium	Corrected typographical error to reflect Class 4, Penalty B Substance	6, 24
11.00	December 2015	Gabapentin	Corrected typographical error to reflect Class 3, Penalty B Substance	5, 20
11.00	December 2015	Ergoloid Mesylates	Corrected typographical error to reflect Class 2, Penalty A Substance	4, 15

Version	Date	Drug/Substance	Notes	Approx. Page(s)
11.00	December 2015	Butacaine	Corrected typographical error to reflect Class 4, Penalty B Substance	2, 23
11.00	December 2015	Budesonide	Corrected typographical error to reflect Class 4, Penalty C Substance	2, 23
11.00	December 2015	Brimonidine	Corrected typographical error to reflect Class 2, Penalty A Substance	2, 14
11.00	December 2015	Benazepril	Corrected typographical error to reflect Class 3, Penalty B Substance	2, 19
11.00	December 2015	Amlodipine	Corrected typographical error to reflect Class 3, Penalty B Substance	1, 19
11.00	December 2015	3-Methoxytyramine	Added as Class 2, Penalty A Substance	1, 14
10.00	July 2015	Methylhexanamine	Added alternative spelling	7, 13
10.00	July 2015	Gamma Aminobutyric Acid (GABA)	Added as Class 3, Penalty B Substance	5, 19
9.00	April 2015	Cobalt	Added as Class 3, Penalty B with note to refer to ARCI Endogenous, Dietary, or Environmental Substances Schedule for threshold and penalty information for contractions of less than 50 parts per billion (ppb) in blood serum or plasma	3, 18
8.00	December 2014	Firocoxib	Changed Penalty Class from "B" to "C" to conform to the ARCI Controlled Therapeutic Medication Schedule	5, 23
8.00	December 2014	Acenocoumarol	Had been previously omitted from Listing by Classification Section, Added to section	25
8.00	December 2014	Deracoxib	Corrected Spelling in Alphabetical Listing by Substance Section	3
8.00	December 2014	Norclostebol	Corrected Spelling in Alphabetical Listing by Substance Section	8
8.00	December 2014	Rizatriptan	Corrected Spelling in Alphabetical Listing by Substance Section	10
8.00	December 2014	Dehydrochloromethyltestosterone	Corrected Spelling in Alphabetical Listing by Substance Section	3
8.00	December 2014	Amiodarone	Corrected Spelling in Listing by Classification Section	22
8.00	December 2014	2-Aminoheptane	Corrected Spelling in Listing by Classification Section	22
8.00	December 2014	Bupropion	Corrected Spelling in Listing by Classification Section	13
8.00	December 2014	Alclofenac	Assigned Penalty Class A	1, 13

Version	Date	Drug/Substance	Notes	Approx. Page(s)
8.00	December 2014	Recommended Penalties for Ketoprofen	Updated the recommended penalty for Ketoprofen to comply with the primary threshold established in the ARCI Controlled Therapeutic Medication Schedule.	29
8.00	December 2014	Class B Recommended Penalties	Corrected typographical error on recommended penalties for Class B substances for licensed owners. Version 7.00 incorrectly recommended penalties for second or third offense in the owner's lifetime. Version 8.00 corrects error and recommends penalty for second or third offense in 365-day period.	28
8.00	December 2014	Aminorex	Addition is not a change of the Uniform Classification Guidelines. Aminorex has been a DEA Schedule 1 substance. All DEA Schedule 1 substances are considered Class 1, Penalty A substances by reference. By request, Aminorex has been listed to avoid confusion.	1, 13
8.00	December 2014	Bufotenine	Corrected the precursor to 5-methoxy-N-N dimethyltryptamine	26
7.00	January 2014	Pergolide	Added as Class 3, Penalty B	8, 20
6.00	December 2013	Methylhexanamine	Added as Class 1, Penalty A	7, 12
5.00	December 2012	Zilpaterol hydrochloride	Moved from Class 3 to Class 2 Substance, Penalty Remains Unchanged	11, 17
5.00	December 2012	Tetramisole hydrochloride	Removed from Non-Classified Substance list	26
5.00	December 2012	Ambroxol	Moved from Class 4, Penalty B to Class 4, Penalty C	1, 22
4.01	October 2012	Ractopamine	Corrected typographical error in Drug Class (Incorrectly listed as a Class 3 substance)	9, 16
4.01	October 2012	Pyrilamine	Corrected typographical error on Penalty Class (Listed as Penalty Class A in "Listing by Classification" section.	9, 20
4.00	July 2012	myo-inositol trispyrophosphate (ITPP)	Added as Class 1, Penalty A	7, 12
4.00	July 2012	Benzonate	Added as Class 2, Penalty A	2, 13
3.00	December 2011	Almotriptan	Corrected Penalty Class omission in Alphabetical Listing section of document	1, 18
3.00	December 2011	Naltrexone	Corrected Penalty Class omission in Alphabetical Listing section of document	7, 20
3.00	December 2011	Amiloride	Corrected Penalty Class omission in Alphabetical Listing section of document	1, 22

Version	Date	Drug/Substance	Notes	Approx. Page(s)
3.00	December 2011	Butanilcaine	Corrected Penalty Class omission in Alphabetical Listing section of document	2, 13
3.00	December 2011	3,4-methylenedioxy-pyrovalerone, aka MDPV, "Bath Salts"	Corrected typographical error in Trade Name sections	1, 12
3.00	December 2011	Carbazochrome	Added as Class 4, Penalty C	2, 22
2.01	August 2011	Dimethylsulfoxide (DMSO)	Edited Drug Classification definitions to remove mention of DMSO from Class 5 definition	vii
2.00	July 2011	<<Drugs Not Listed>>	Language pertaining to all drugs/substances not found in this document shall be considered a Class I, Penalty A Substance	ii
2.00	July 2011	Phenylbutazone	Penalties for tests over 2.0 micrograms per milliliter of plasma or serum but less than 5.0 micrograms per milliliter of plasma or serum added.	29
2.00	July 2011	Dermorphin	Added as Class 1, Penalty A	3, 12
2.00	July 2011	3,4-methylenedioxy-pyrovalerone, aka MDPV, "Bath Salts"	Added as Class 1, Penalty A	1, 12
2.00	July 2011	Synthetic cannabis	Added as Class 1, Penalty A	10, 12
2.00	July 2011	Alclomethasone	Corrected typographical error in spelling	1, 22
1.01	January 2011	Methocarbamol	Corrected typographical error on Penalty Class from Class B to Class C	7, 23
1.00	December 2010	Zilpaterol	Added as Class 3, Penalty a	11, 17
1.00	December 2010	Dimethylsulfoxide (DMSO)	Changed from Class 5 to Class 4	4, 23





E200939

TRACK/ EVENT Indiana Downs

Dawn Martin, RVT  
Collection Supervisor

Date 9/10/16

INDUSTRIAL LABORATORIES  
Sample Submission Card

DUPLICATE SAMPLE



E200939

TRACK Indiana Downs

Dawn Martin, RVT  
Collection Supervisor

Date 9/10/16

Split Sample Card

INDUSTRIAL LABORATORIES



E200939

Date 9/10/16

Horse	<input checked="" type="checkbox"/>	Dog	<input type="checkbox"/>	Other	<input type="checkbox"/>
Blood	<input checked="" type="checkbox"/>	Urine	<input checked="" type="checkbox"/>	Other	<input type="checkbox"/>
Bute	<input type="checkbox"/>	Furosemide	<input checked="" type="checkbox"/>	Flunixin	<input type="checkbox"/>
		TC02	<input type="checkbox"/>	Keto	<input type="checkbox"/>

Name American Furr

Tattoo No. 31905

Color Sor Sex G Age 2

Finish 1 Race 1

Track Indiana Downs

Trainer John McCreary

Urine Sampled By [Signature] (Signature)

Blood Sampled By [Signature] (Signature)

Witness Jordan Hersh (Signature Trainer, Owner or Representative)

Witness License # 271497

Remarks \_\_\_\_\_

Client Copy

KEEP FOR YOUR RECORDS

E200939 9/10/16 Date


E200939 9/10/16 Date

EXHIBIT  
3

COMMISSION TEST BARN REPORT  
INDIANA GRAND

SALUTE CONTROL #	RACE #	HORSE #	TATTOO #	NAME OF HORSE	SEX	OCCUPATION	TRAINER	TIME HORSE ARRIVED/ DISMISSED	URINE	TIME	Blood Drawn By	Blood Sealed By	TIME	WELTS YES/NO/NAME				
															Day:	Date:		
1	X	E200989	1	5	31905	American Run	G	X	John McCreary	6:19	6:43	Michael	6:39	BH	DM	6:42	NO	BH
2	X	E200940	2	1	08709	Beyond Ivory	F	X	Randy Smith	6:47	7:12	Jodi	7:08	BH	DM	7:11	NO	BH
3	X	E200941	3	6	224C3	Folly N Dash	G	X	Saul Perez	6:45	7:28	Beth	7:23	BH	DM	7:26	NO	BH
4		E200942	3	10	409D2	Fear This Wave	G	X	Anthony Dunningham	7:19	8:00	Nichelle	7:56	BH	DM	7:59	NO	BH
5	X	E200943	3	8	717C1	Of Painting Legacy	G	X	Christina Duff Z checker	7:18	7:43	Jodi	7:39	BH	DM	7:41	NO	BH
6	X	E200944	4	6	113D5	Sixes Turn	F	X	Eno Thompson	7:44	8:11	Beth	8:07	BH	DM	8:10	NO	BH
7	X	E200945	4	1	910D8	Kids Bright Image	G	X	Paul Martin	7:43	8:06	Jodi	8:03	BH	DM	8:05	NO	BH
8	X	E200946	5	8	302C0	The Cartel Concept	G	X	Randy Smith	8:13	8:19	Nichelle	8:26	BH	DM	8:47	NO	BH
9	X	E200947	6	3	578C9	Love Beach	F	X	Randy Smith	8:39	9:00	Beth	8:55	BH	DM	8:59	NO	BH
10	X	E200948	6	7	350D2	Janus De Rey	G	X	Mathraizer	8:37	9:04	Jodi	8:58	BH	DM	9:02	NO	BH
11	Y	E200949	7	7	533C9	Fantastic Six Back	G	X	Mathraizer	9:07	9:34	Beth	9:29	BH	DM	9:32	NO	BH
12	X	E200950	7	4	395D2	Beach Bum Medie	G	X	Anthony Dunningham	9:08	10:05	Nichelle	10:00	BH	DM	10:04	NO	BH
13	X	E200951	8	6	041C6	Seize The Nin	H	X	Mathraizer	9:34	10:01	Jodi	9:57	BH	DM	9:59	NO	BH
14	Y	E200952	9	8	912D8	Cartel Justice	G	X	Randy Smith	10:01	10:45	Beth	10:41	BH	DM	10:43	NO	BH

Signature of Veterinarian: 

Vet Tech: 

G - Gelding  
H - Stud/Colt  
F - Mare/Filly

tabbies

EXHIBIT

4



# Chain of Custody Form


(Page 1 of 2)

Track or Event Name: Indiana Grand Collection Date: 9/10/14

Shipping Container Seal #: 9191067 Sample Collection Supervisor: Dawn Martin, RVT

Sample Number	Sample Type			Gender	Notes (Ex: Lasix use, special test requests, euthanasia, Claim, etc.)	For Lab use: check if sample is present and in good condition, verify tube total #
	Urine (Check if collected)	Serum /Plasma (Check if collected, record # of tubes sent)	Other (please specify)			
E200939 <u>9/10/14</u> Date	✓	✓ 2		G	Lasix	
E200940 <u>9/10/14</u> Date	✓	✓ 2		F	Lasix	
E200941 <u>9/10/14</u> Date	✓	✓ 2		G	Lasix	
E200942 <u>9/10/14</u> Date	✓	✓ 2		G	—	
E200943 <u>9/10/14</u> Date	✓	✓ 2		G	Lasix	
E200944 <u>9/10/14</u> Date	✓	✓ 2		F	Lasix	
E200945 <u>9/10/14</u> Date	✓	✓ 2		G	Lasix	
E200946 <u>9/10/14</u> Date	✓	✓ 2		G	Lasix	
E200947 <u>9/10/14</u> Date	✓	✓ 2		F	Lasix	
E200948 <u>9/10/14</u> Date	✓	✓ 2		G	Lasix	
Total # of samples on this page: <u>10</u>	<u>10</u>	<u>20</u>				Checked by:  On:

~~DM~~ DM









# Chain of Custody Form


(Page 2 of 2)

Track or Event Name: Indiana Grand Collection Date: 9/10/16

Shipping Container Seal #: 9191067 Sample Collection Supervisor: Dawn Martin, RVT

Sample Number	Sample Type			Gender	Notes (Ex: Lasix use, special test requests, euthanasia, Claim, etc.)	For Lab use: check if sample is present and in good condition, verify tube total #
	Urine (Check if collected)	Serum /Plasma (Check if collected), record # of tubes sent	Other (please specify)			
 E200949 <i>9/10/16</i> Date	✓	✓ <sub>2</sub>		G	Lasix	
 E200950 <i>9/10/16</i> Date	✓	✓ <sub>2</sub>		G	Lasix	
 E200951 <i>9/10/16</i> Date	✓	✓ <sub>2</sub>		H	Lasix	
 E200952 <i>9/10/16</i> Date	✓	✓ <sub>2</sub>		G	Lasix	
<del><i>DMA</i></del>						
Total # of samples on this page: <i>4</i>	<i>4</i>	<i>8</i>				Checked by:  On:

*BAB DM*



**industrial  
LABORATORIES**

Industrial Laboratories is your full-service  
independent third party analytical laboratory

Report # Rpt-16092919

Indiana Horse Racing Commission  
1302 N. Meridian Street  
Suite 175  
Indianapolis, IN 46202

**AFFIDAVIT**

I hereby certify that The Industrial Laboratories Company, 4046 Youngfield Street,  
Wheat Ridge, Colorado; has analyzed the sample identified below:

E200939  
Indiana Grand  
September 10, 2016

The sample was received in Acceptable/Secure condition on: September 15, 2016

SampleCode: 16091507-034

The sample was analyzed using:

Liquid Chromatography - Tandem Mass Spectrometry (LC-MS/MS)

Results : Mepivacaine Confirmed in Serum  
(approx. 81 pg/mL)

Comment :

SIGNED:


Petra Hartmann  
Petra Hartmann  
Director, DTS

SETH WONG  
NOTARY PUBLIC  
STATE OF COLORADO  
NOTARY ID # 20044017679  
MY COMMISSION EXPIRES 05-21-2020

Sworn to me this day:  
29 day of September, 2016.

Date: September 29<sup>th</sup>, 2016

[Signature]  
NOTARY PUBLIC



UNIVERSITY OF CALIFORNIA, DAVIS

*old*

BERKELEY • DAVIS • IRVINE • LOS ANGELES • RIVERSIDE • SAN DIEGO • SAN FRANCISCO



SANTA BARBARA • SANTA CRUZ

CALIFORNIA ANIMAL HEALTH & FOOD SAFETY  
LABORATORY SYSTEM  
P.O. BOX 1770  
DAVIS, CALIFORNIA 95617

PHONE: (530) 752-8700  
FAX: (530) 752-6253

December 15, 2016

Dawn Martin, RVT  
Indiana Horse Racing Commission  
1302 N. Meridian, Suite 175  
Indianapolis, IN 46202

RE: IHRC No. E200939

Received: November 08, 2016  
Laboratory No.: EACL-161108-11  
No. of Samples: 1  
Veterinarian Tech: Dawn Martin

INVESTIGATION: Split Sample Analysis: Prohibited (Mepivacaine)

Dear Ms. Martin,

The one blood (serum) samples submitted from the IHRC, Indiana Grand, #E200939, was delivered on November 08<sup>th</sup>, 2016 by FedEx #8726 5361 1200. The sample was in good condition upon arrive.

The one blood (serum) sample was subjected to quantitative analysis for the presence of mepivacaine. Detection, identification and quantitation were completed utilizing liquid chromatography - mass spectrometry. Mepivacaine was confirmed in sample (#E200939). No further testing has been assigned.

If you have any questions or require additional information, please don't hesitate to contact me.

The remainder of the original sample will be storage at the Maddy Lab and disposed of after 1 months.

Sincerely,


Handwritten signature of Scott D. Stanley in black ink.

Scott D. Stanley, PhD  
Professor  
University of California – Davis

Cc: Deena Pitman



LICENSEES



Licensee Search

Licensee: JOHN MCCREARY

Reports on JOHN MCCREARY  
Comprehensive Ruling Report  
Comprehensive Licensee Report



Identification Information

Date of Birth	Federal ID/SSN	Country	Sex	<a href="#">Add a New Identification Record</a>
4/25/1961	5753	USA	Unknown	

Name Information

Name Type	Prefix	First Name	Middle Name	Last Name	Suffix	<a href="#">Add a New Name Record</a>
Current Legal Name		JOHN		MCCREARY		
Previous Legal		JOHN	M.	MCCREARY		

Address Information


Address Type	Street Address	City	State	Zip Code
Mailing	470 KEG BRANCH RD.	CUMBERLAND GAP	TN	37724

Phone Information

Phone Number Type	Phone Number
Home	4238512053

License Information

License Number	License Type	Issued Date	Expiration Date	Licensing Commission	<a href="#">Add a New License Record</a>
241859	Owner/Trainer	4/15/2016	12/31/2016	Indiana Racing Commission	
	Trainer	6/30/2015	12/31/2015	Indiana Racing Commission	
	Owner/Trainer	4/15/2015	12/31/2015	Indiana Racing Commission	
	Owner/Trainer	4/24/2014	12/31/2014	Indiana Racing Commission	
	Owner/Trainer	4/11/2013	12/31/2013	Indiana Racing Commission	
	Owner/Trainer	4/4/2012	12/31/2012	Indiana Racing Commission	
	Owner/Trainer	4/7/2011	12/31/2011	Indiana Racing Commission	
	Trainer	3/30/2010	12/31/2010	Indiana Racing Commission	
	Owner/Trainer	4/9/2009	12/31/2009	Indiana Racing Commission	
	Owner/Trainer	7/4/2008	12/31/2008	Indiana Racing Commission	
	Trainer	7/4/2008	12/31/2008	Indiana Racing Commission	
	Owner/Trainer	9/11/2007	12/31/2007	Indiana Racing Commission	



1/30/2017

ARCI Online Licensee Information

	Groom	6/30/2007	12/31/2007	Indiana Racing Commission
510233	Vendor	4/25/2007	12/31/2007	Michigan Racing Commission
	Owner/Trainer	4/25/2007	12/31/2007	Michigan Racing Commission
241859	Owner	4/29/2006	12/31/2006	Indiana Racing Commission
	Owner	9/3/2005	12/31/2005	Indiana Racing Commission
	Owner	9/4/2004	12/31/2004	Indiana Racing Commission
*N*1534156	Owner	8/4/2004	12/31/2004	Ohio Racing Commission

Fingerprint Information

[Add a New Fingerprint Record](#)

Processing Commission	Date Taken	Status	Notes	RCI Card Submitted Date
Michigan Racing Commission	4/29/2004	Unknown		
Indiana Racing Commission	5/6/2008	Unknown		
Racing Commissioners International	5/6/2008	Unknown	RCI Multi-Jurisdiction Card	5/6/2008

Ruling Number	Ruling Type	Ruling Date	Fine	Fine Paid?	Suspension Start	Suspension End
11600	Medication/Drug Violation - Animal	6/13/2011	250	Yes		
29569	Medication/Drug Violation - Animal	8/5/2009	250	Yes		

Applicable Reports

- Comprehensive Ruling Report
- Comprehensive Licensee Report




## Comprehensive Ruling Report

Rulings Against: JOHN MCCREARY

Legal Name: JOHN MCCREARY

Birth Date: 4/25/1961



2 Total Ruling(s) Listed

"Multiple medication violation points and point totals are for advisory and informational purposes only to indicate the existence of regulatory medication violation determinations made by racing regulatory entities in order to notify officials of possible aggravating factors that should be reviewed by officials prior to taking regulatory action. Confirmation of violations should be made directly with the racing regulatory entity responsible."

## Ruling #: 1

Ruling Number:	11600	Date:	6/13/2011
Issued By:	Indiana Racing Commission	Facility:	Indiana Downs
Ruling Type:	Medication/Drug Violation - Animal		
Division:	Horse	Breed:	Thoroughbred
Effective Date:	N/A	Race Date:	N/A
Infraction Date:	N/A	Infraction Facility:	N/A
Race Number:	N/A	Animal Name:	N/A
Under Appeal:	False	Appeal Date:	N/A
Drug:	Flunixin		
Fine Amount:	\$ 250	Fine Paid:	Yes
Suspension Start:	None	Suspension End:	None
Actions:			

Alpha Ruling: 11600

Action Type: Initial Ruling

Issue Date: 6/13/2011

## Action Text:

On June 23, 2011, the Board of Stewards at Indiana Downs received notice from Tuedsail Laboratories INC. that blood sample #103710 had tested 80 nanograms per milliliter which is above the allowable amount for flunixin. It was determined that blood sample #103710 had been taken from "How Cool Is She" winner of the tenth (10th) race on June 13, 2011. The trainer of "How Cool Is She", John McCreary, was notified of the flunixin overage and advised of his rights to a hearing and to have the blood sample tested by an independent laboratory approved by the Indiana Horse Racing Commission prior to the Stewards conducting a hearing in the matter. Trainer McCreary chose to have the split sample sent to the Pennsylvania Equine Toxicology and Research Laboratory. On July 15, 2011 the Pennsylvania Equine Toxicology and Research Laboratory confirmed the overage of flunixin at a level of 42.775 nanograms per milliliter. Trainer McCreary was notified of the confirmation and he waived his rights to a hearing. Based on the evidence available to them the Stewards find the following: 1.) Blood sample #103710 belongs to "How Cool Is She", winner of the tenth (10th) race on June 13, 2011. 2.) Pursuant to 71 IAC 8.5-2-1, the findings in blood sample #103710 is prima facie evidence that "How Cool Is She" carried flunixin in its system in the tenth (10th) race on June 13, 2011 above the limit of 20 nanograms per milliliter of blood as allowed in 71 IAC 8.5-1-4.1 (a)(1)(B). 3.) The blood in sample #103710

tested 80 nanograms per milliliter by Truesdail Laboratories and 42.775 per milliliter by Pennsylvania Equine Toxicology and Research Laboratory, both in excess of the allowable limit. 4.) Pursuant to 71 IAC 5.5-3-2 (a)(1) (2) the trainer of record, John McCreary, was responsible for any medication received by the horse. 5.) Pursuant to 71 IAC 8.5-1-7, The Stewards have considered the Uniform Classification Guidelines of Foreign Substances and Recommended Penalties in determining the penalties to be imposed. The Stewards hereby ORDER the following: 1.) Trainer John McCreary is fined two hundred and fifty dollars (\$250). 2.) "How Cool Is She" is disqualified from the first (1st) and unplaced for the purpose of receiving purse money. 3.) The Horsemen's Bookkeeper is directed to redistribute the purse for the tenth (10th) race on June 13, 2011 as follows: 1.) Jess Luci D 2.) Cash For Braggs 3.) Bigbobcrawford 4.) Zoom N Crash 5.) Jonah Corona 6.) Apollo Two Socks 7.) Flyin A Mooney 8.) Moon Over Corona This ruling does not affect the pari-mutuel payoffs.

---

**Ruling #: 2**

Ruling Number:	29569	Date:	8/5/2009
Issued By:	Indiana Racing Commission	Facility:	Hoosier Park
Ruling Type:	Medication/Drug Violation - Animal		
Division:	Horse	Breed:	Thoroughbred
Effective Date:	N/A	Race Date:	N/A
Infraction Date:	N/A	Infraction Facility:	N/A
Race Number:	N/A	Animal Name:	N/A
Under Appeal:	False	Appeal Date:	N/A
Drug:	Flunixin		
Fine Amount:	\$ 250	Fine Paid:	Yes
Suspension Start:	None	Suspension End:	None
Actions:			

Alpha Ruling: 29569

Action Type: Initial Ruling

Issue Date: 8/5/2009

## Action Text:

Two hundred fifty dollars (\$250) fine, loss of purse. Upon receipt from the official chemist for the Indiana Horse Racing Commission indicated that sample #89213 taken from "A Polar Cat", second (2nd) place finisher in the ninth (9th) race on June 22, 2009, contained an overage of Flunixin. A split sample requested by the trainer confirmed the results. "A Polar Cat" is hereby disqualified and the purse ordered redistributed for the ninth (9th) race on June 22, 2009. "Perrys Copper Penny", first (1st) "First Flyin Fish", second (2nd) "Right Said Fred", third (3rd) "Runs And Roses", fourth (4th) "Im Tryin", fifth (5th) "Royal Snow Angel", sixth (6th) "Hoosier La Golla", seventh (7th) "RI Indian Trick", eighth (8th) "Privy To Cash", ninth (9th)

BEFORE AN ADMINISTRATIVE LAW JUDGE  
APPOINTED BY THE INDIANA HORSE RACING COMMISSION

INDIANA HORSE RACING COMMISSION  
STAFF,

Petitioner,

v.

JOHN MCCREARY,

Respondent.

2017 JUN 14 A 9:59

INDIANA  
HORSE RACING COMMISSION  
In Re: ADMINISTRATIVE COMPLAINT  
NO.: 217002

AFFIDAVIT OF PETRA HARTMANN

Comes now the undersigned, and being duly sworn upon her oath, alleges and says as follows:

1. I am an adult, over eighteen (18) years of age, of sound mind, and have personal knowledge of and am competent to testify as to the matters contained herein.

2. I am and was at all times relevant employed as the Drug Testing Services Director of Industrial Laboratories ("Industrial"). At all times relevant, Industrial has regularly conducted tests of samples taken from race horses to detect the presence of any foreign substance in the horse's system at the time of a race.

3. At all times relevant, Industrial Laboratories was engaged by the Indiana Horse Racing Commission to analyze serum and urine samples from horses participating in pari-mutuel racing in Indiana.

4. On or about September 15, 2016, urine and blood/serum Samples No. E200939 taken from Indiana Grand on September 10, 2016, were received by Industrial Laboratories in good and secure condition.

5. Industrial Laboratories was engaged to perform an analysis of serum and urine Samples No. E200939, which were collected after a race at Indiana Grand Racing and Casino on September 10, 2016.

6. In my role as the Drug Testing Services Director at Industrial, the testing of serum and urine Samples No. E200939 were conducted under my supervision and control.

7. Industrial testing determined that serum Sample No. E200939 contained mepivacaine. Detection, identification and confirmation of the presence of mepivacaine was performed utilizing liquid chromatography mass spectrometry-mass spectrometry (LC-MS/MS).

8. I sent an Affidavit to the Indiana Horse Racing Commission confirming these results on September 29, 2016. A true and accurate copy of that document is attached to this Affidavit and identified as Exhibit 8.

9. Attached Exhibit 8 reflects entries, reports, records and/or data compilations that were made at or near the time of the occurrence of the matters set forth in each of the records, by or from information transmitted by a person with knowledge of the existence of the matters recorded therein.

10. Attached Exhibit 8 and the entries, reports, records and/or data compilations that it reflects are, and were, kept in the course of regularly conducted business activities of the Commission.


11. Attached Exhibit 8 and the entries, reports, records and/or data compilations that it reflects are, and were, made and gathered as a part of the regular business practice and activity of the Commission.

12. I certify the authenticity of Exhibit 8 pursuant to the provision of Indiana Rules of Evidence 803(6).

Further Affiant Sayeth Not.

I affirm under the penalties for perjury that the foregoing representations are true and correct to the best of my knowledge.





Report # Rpt-16092919

Indiana Horse Racing Commission  
1302 N. Meridian Street  
Suite 175  
Indianapolis, IN 46202

AFFIDAVIT

I hereby certify that The Industrial Laboratories Company, 4046 Youngfield Street, Wheat Ridge, Colorado; has analyzed the sample identified below:

E200939  
Indiana Grand  
September 10, 2016

The sample was received in Acceptable/Secure condition on: September 15, 2016

SampleCode: 16091507-034

The sample was analyzed using:

Liquid Chromatography - Tandem Mass Spectrometry (LC-MS/MS)

Results : Mepivacaine Confirmed in Serum  
(approx. 81 pg/mL)

Comment :

SIGNED:

Petra Hartmann  
Petra Hartmann  
Director, DTS

Date: September 29<sup>th</sup>, 2016

SETH WONG  
NOTARY PUBLIC  
STATE OF COLORADO  
NOTARY ID # 20044017879  
MY COMMISSION EXPIRES 05-21-2020

Sworn to me this day:

29 day of September, 2016.

[Signature]  
NOTARY PUBLIC

EXHIBIT  
8

BEFORE AN ADMINISTRATIVE LAW JUDGE  
APPOINTED BY THE INDIANA HORSE RACING COMMISSION

INDIANA HORSE RACING COMMISSION  
STAFF,

Petitioner,

v.

JOHN MCCREARY,

Respondent.

In Re: ADMINISTRATIVE COMPLAINT  
NO.: 217002

**AFFIDAVIT OF SCOTT STANLEY**

Comes now the undersigned, and being duly sworn upon her oath, alleges and says as follows:

1. I am an adult, over eighteen (18) years of age, of sound mind, and have personal knowledge of and am competent to testify as to the matters contained herein.

2. I am and was at all times relevant employed as the Equine Analytical Chemistry Section Head of University of California – Davis (“UC Davis”). At all times relevant, UC Davis has regularly conducted tests of samples taken from race horses to detect the presence of any foreign substance in the horse's system at the time of a race.

3. At all times relevant, UC Davis was engaged by the Indiana Horse Racing Commission to analyze serum and urine samples from horses participating in pari-mutuel racing in Indiana.

4. On or about November 8, 2016, urine and blood/serum Samples No. E200939 taken from Indiana Grand on September 10, 2016, was received by UC Davis in good and secure condition.

5. UC Davis was engaged to perform an analysis of serum and urine Samples No. E200939, which were collected after a race at Indiana Grand Racing and Casino on September 10, 2016.

6. In my role as the Equine Analytical Chemistry Section Head at UC Davis, the testing of serum and urine Samples No. E200939 were conducted under my supervision and control.

7. UC Davis testing determined that serum Sample No. E200939 contained mepivacaine. Detection, identification and confirmation of the presence of mepivacaine was performed utilizing liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS).

8. I sent an Affidavit to the Indiana Horse Racing Commission confirming these results on December 15, 2016. A true and accurate copy of that document is attached to this Affidavit and identified as Exhibit 13.

9. Attached Exhibit 13 reflects entries, reports, records and/or data compilations that were made at or near the time of the occurrence of the matters set forth in each of the records, by or from information transmitted by a person with knowledge of the existence of the matters recorded therein.

10. Attached Exhibit 13 and the entries, reports, records and/or data compilations that it reflects are, and were, kept in the course of regularly conducted business activities of the Commission.

11. Attached Exhibit 13 and the entries, reports, records and/or data compilations that it reflects are, and were, made and gathered as a part of the regular business practice and activity of the Commission.

12. I certify the authenticity of Exhibit 13 pursuant to the provision of Indiana Rules of Evidence 803(6).

Further Affiant Sayeth Not.

I affirm under the penalties for perjury that the foregoing representations are true and correct to the best of my knowledge.





UNIVERSITY OF CALIFORNIA, DAVIS

BERKELEY • DAVIS • IRVINE • LOS ANGELES • RIVERSIDE • SAN DIEGO • SAN FRANCISCO



SANTA BARBARA • SANTA CRUZ

CALIFORNIA ANIMAL HEALTH & FOOD SAFETY  
LABORATORY SYSTEM  
P.O. BOX 1770  
DAVIS, CALIFORNIA 95617

PHONE: (530) 752-8700  
FAX: (530) 752-6253

December 15, 2016

Dawn Martin, RVT  
Indiana Horse Racing Commission  
1302 N. Meridian, Suite 175  
Indianapolis, IN 46202

RE: IHRC No. E200939

Received: November 08, 2016  
Laboratory No.: EACL-161108-11  
No. of Samples: 1  
Veterinarian Tech: Dawn Martin

INVESTIGATION: Split Sample Analysis: Prohibited (Mepivacaine)

Dear Ms. Martin,

The one blood (serum) samples submitted from the IHRC, Indiana Grand, #E200939, was delivered on November 08<sup>th</sup>, 2016 by FedEx #8726 5361 1200. The sample was in good condition upon arrive.

The one blood (serum) sample was subjected to quantitative analysis for the presence of mepivacaine. Detection, identification and quantitation were completed utilizing liquid chromatography - mass spectrometry. Mepivacaine was confirmed in sample (#E200939). No further testing has been assigned.

If you have any questions or require additional information, please don't hesitate to contact me.

The remainder of the original sample will be storage at the Maddy Lab and disposed of after 1 months.

Sincerely,

A handwritten signature in black ink, appearing to read "Scott Stanley".

Scott D. Stanley, PhD  
Professor  
University of California – Davis

Cc: Deena Pitman

EXHIBIT

tabbies

13

INDIANA HORSE RACING COMMISSION  
BEFORE AN ADMINISTRATIVE LAW JUDGE

INDIANA HORSE RACING )  
COMMISSION STAFF, )  
 )  
Petitioner, )  
 )  
v. )  
 )  
JOHN McCREARY, )  
 )  
Respondent. )

2017 FEB 27 P 4: 18

INDIANA  
HORSE RACING COMM.

ADMINISTRATIVE COMPLAINT # 217002

**SCHEDULING ORDER**


On February 23, 2017, Respondent filed his Preliminary Witness and Exhibit List. Therein, Respondent requested that the Administrative Law Judge ("ALJ") order U.C. Davis to provide a quantification of the split serum sample of American Purr.

On February 24, 2017, the Indiana Horse Racing Commission Staff ("Staff") filed its Objection to Respondent's request.

It is now ORDERED that, if Respondent wishes to make any reply to the Staff's Objection, he must do so within seven (7) days of this Order, or on or before Friday, March 2, 2017. Per agreement of the parties, Respondent may submit his reply, if any, by email to the ALJ.

The ALJ will rule promptly.

So ordered, on February 24, 2017.



Kelly R. Eskew,  
Administrative Law Judge  
1309 East 10<sup>th</sup> Street, HH4080  
Bloomington IN 47401  
(317) 600-8798  
[horseracingalj@gmail.com](mailto:horseracingalj@gmail.com)

**Distribution by 1<sup>st</sup> class mail:**  
John McCreary  
8080 Knapp Road  
Indianapolis IN 46259

**And via email to:** [john\\_mccreary@comcast.net](mailto:john_mccreary@comcast.net)

**Lea Ellingwood**  
**General Counsel**  
**Indiana Horse Racing Commission**  
**1302 N. Meridian, Suite 175**  
**Indianapolis IN 46202**

*And via email to: [lellingwood@hrc.in.gov](mailto:lellingwood@hrc.in.gov)*

**INDIANA HORSE RACING COMMISSION  
BEFORE AN ADMINISTRATIVE LAW JUDGE**

INDIANA HORSE RACING	)	
COMMISSION STAFF,	)	
	)	
Petitioner,	)	
	)	
v.	)	ADMINISTRATIVE COMPLAINT # 217002
	)	
JOHN McCREARY,	)	
	)	
Respondent.	)	

**RECOMMENDED ORDER GRANTING COMMISSION STAFF'S  
MOTION FOR SUMMARY JUDGMNET**

This matter came before Administrative Law Judge ("ALJ") Kelly Eskew on Administrative Complaint #217002, issued by the Indiana Horse Racing Commission Staff ("Commission Staff") as to Respondent John McCreary ("McCreary" or "Respondent"). The ALJ, having considered the arguments of the parties, and being in all respects duly advised, now issues the following Findings of Fact, Conclusions of Law, Ultimate Finding, and Recommended Order granting summary judgment in favor of the Commission Staff.

To the extent that any of the Findings of Fact are more appropriately considered Conclusions of Law, or conversely, they shall be so treated.

**Findings of Fact**

1. Mr. McCreary was licensed as a trainer in 2016 and was at all times relevant subject to the jurisdiction of the Indiana Horse Racing Commission.
2. Mr. McCreary was the trainer of American Purr, a quarter horse racehorse that competed in the first race at Indiana Grand on September 10, 2016. American Purr placed first in the race and was awarded a purse of \$8,800.
3. After the September 10th race, post-race blood and urine specimens were taken from American Purr. Those specimens were sent to the Industrial Laboratories Company ("Industrial Labs"), a Commission-approved laboratory, for analysis pursuant to Commission regulations.
4. On September 29, 2016, Industrial Labs reported to the Commission that the sample taken from American Purr tested positive for the presence of mepivacaine in its blood serum sample.

5. After being advised of the positive test results, Mr. McCreary requested that University of California Davis (UC Davis) test the split sample.

6. On December 15, 2016, UC Davis reported that the split sample taken from American Purr was positive for the presence of mepivacaine.

7. Mepivacaine is classified by the ARCI Uniform Classification Guidelines for Foreign Substances and Recommended Penalties and Model Rule (Version 12.00 revised on or about April 8, 2016, hereinafter "ARCI Uniform Guidelines"), as a Class 2 drug with a category "B" penalty classification ("Class 2-B foreign substance").

8. On January 31, 2017, the Commission Staff by its Executive Director, Mike Smith, issued Administrative Complaint # 217002 and recommended that Mr. McCreary be assessed an administrative penalty of a fifteen (15) day suspension, fined Five Hundred Dollars (\$500.00), and that American Purr be disqualified from the first race at Indiana Grand and the purse at issue be forfeited and redistributed. Mr. McCreary timely requested a hearing.

9. On February 23, 2017, Mr. McCreary requested that the ALJ "directly request Dr. Scott Stanley of UC Davis to provide" a report with the quantification of the split serum sample tested at that lab. This was construed by the ALJ without objection as a request for a subpoena for the quantification report. The Commission Staff filed its Objection on February 24, 2017. Mr. McCreary replied in support of his request on March 2, 2017.

10. In 71 IAC 8.5-1-4.2(18), the Commission establishes that mepivacaine shall not be present in a horse at any level that exceeds "the LOD [level of detection] ... in serum or plasma." Thus, any detectable amount of mepivacaine in a serum sample is sufficient for the Commission Staff to meet its burden of establishing a Rule violation.

11. Mr. McCreary has argued, however, that the Racing Medication and Testing Consortium ("RMTC") sets a threshold for mepivacaine that is different than the "level of detection" threshold set forth in the Commission Rule and asserted that a quantification report would confirm that the RMTC threshold was not violated.

12. The Commission does not follow and thus is not bound by RMTC guidelines.

13. A party is only entitled to discover "documents and other tangible things" that are relevant to the subject matter of the action and not privileged. *See*, Ind. T.R. 26(B)(1). Where the information requested is not relevant, then discovery is prohibited. *Robertson v. Bd. of Zoning Appeals, Town of Chesterton*, 699 N.E. 2d 310, 317 (Ind. App. 1998), *citing Bishop v. Goins*, 586 N.E. 2d 905, 907 (Ind. Ct. App. 1992).

14. Accordingly, the ALJ denied Mr. McCreary's request for a subpoena directing US Davis to produce a quantification report as the report is immaterial to the question of whether the presence of mepivacaine in American Purr exceeded the level of detection. Two labs detected its presence in the blood sample and split sample.

15. On June 16, 2017, the Commission Staff filed its motion for summary judgment based on the presence of mepivacaine exceeding the level of detection.

16. Mr. McCreary timely replied on July 5, 2017, and again raised the issue of the UC Davis quantification report and "threshold limits."

### **Conclusions of Law**

- A. By testing positive for the presence of mepivacaine following the first race at Indiana Grand on September 10, 2016, American Purr was in violation of the prohibition against the presence of prohibited substances at the time of the race. 71 IAC 8.5-1-2.
- B. As trainer of American Purr, the Respondent, John McCreary, was responsible for the care and custody of the horse with the duty to prevent the administration of any drug or medication or other prohibited substance that may cause a violation of Indiana Horse Racing rules. 71 IAC 8.5-1-2(a) and 71 IAC 5.5-3-2.
- C. A suspension for a period of fifteen (15) days, a fine of five hundred dollars (\$500.00), and forfeiture of the awarded purse are consistent with the ARCI Uniform Guidelines' recommended minimum penalties and Indiana statute, and are therefore both reasonable and appropriate.

### **Ultimate Finding of Fact**


The findings by Industrial Laboratories and University of California Davis clearly establish that John McCreary violated Commission equine medication rule 71 IAC 8.5-1-2 and the Trainer Responsibility Rule 71 IAC 5.5-3-2.

### **Recommended Order**

Upon the foregoing Findings of Fact and Conclusions of Law, the ALJ now determines there are no genuine issues of any material fact and the Commission Staff is entitled to judgment as a matter of law. Motion for Summary Judgment is granted pursuant to IC 4-21.5-3-23(b). The proposed penalties are affirmed in their entirety.

Pursuant to IC 4-21.5-3-29(d), either party has 15 days following receipt of this Recommended Order to file written exceptions with the Indiana Horse Racing Commission.

**IT IS SO ORDERED this 17<sup>th</sup> day of July, 2017.**



Kelly R. Eskew  
Administrative Law Judge

**Distribution by 1<sup>st</sup> class mail:**

**John McCreary  
8080 Knapp Road  
Indianapolis IN 46259**

***And via email to: [john\\_mccreary@comcast.net](mailto:john_mccreary@comcast.net)***

**Lea Ellingwood  
General Counsel  
Indiana Horse Racing Commission  
1302 N. Meridian, Suite 175  
Indianapolis IN 46202**

***And via email to: [lellingwood@hrc.in.gov](mailto:lellingwood@hrc.in.gov)***



John McCreary  
8080 Knapp Rd.  
Indianapolis, IN 46259

2017 JUL 28 A 9:37

July 25, 2017

Indiana Horse Racing Commission  
1302 N. Meridian  
Suite 175  
Indianapolis, IN 46202

**Administrative Complaint No. 217002: Response to Recommended Order Granting commission Staff's Motion for Summary Judgment**

The Respondent respectfully objects to the summary judgement issued on July 17, 2017 and as such requests a review by the ultimate authority. The basis of the objection is that pertinent evidence has not been released or reviewed by the parties. This evidence consists of the detailed results of the UC Davis Quantification of the split serum sample of American Purr, Sample number E200939. The following is additional background to clarify the need for this report.

***RMTC threshold for Mepivacaine in Plasma (50 pg/ml) instead of LOD thresholds***

The Scientific Advisory Committee of the Racing Medication and Testing Consortium (RMTC) has reviewed the limit of detection (LOD) limits for Mepivacaine and the RMTC is now recommending that LOD limits no longer be used for this drug. The RMTC Board approved a threshold for mepivacaine instead of a LOD as there have been recent improvements in testing that could result in false positives. The RMTC Board of Directors approved the threshold for Mepivacaine of 50 pg/ml in plasma or serum. As can be seen in the letter in Exhibit 1, a threshold approach for mepivacaine should be used instead of the LOD as there may be instances where the LOD approach could detect levels that are not producing pharmacological or performance altering effects ie, false positives. The letter states that if LOD limits instead of threshold limits are used, trainers who follow the withdrawal guidelines for mepivacaine (72 hours) may get a false positive in serum or plasma. As both testing laboratories used by IHRC (UC Davis and Industrial) received the RMTC letter, it is likely that they are no longer reporting mepivacaine levels in plasma less than 50 pg/ml.

To date, the serum sample from American Purr which was analyzed by UC Davis has only been reported as confirmed for the presence of mepivacaine with no quantification amount given even though the serum sample was analyzed quantitatively. It has been confirmed that the UC Davis laboratory has the results of this quantification. The respondent believes that this information is critical to determine if the level in American Purr's serum was above or below the threshold of 50 pg/ml. If the level is below the established threshold of 50 pg/ml, this would be considered a trace amount and would not be considered a sufficient amount to alter the horse's racing performance.

As drug testing methods have increased in sensitivity, many jurisdictions have moved away from LOD thresholds for therapeutic drugs as newer instruments are increasingly able to detect minute quantities of more drugs resulting "positives" when LOD limits are used. When LOD limits were established,

instruments were not able to pick up pg/ml levels in biological fluids. However, newer mass spectrometers can now detect these low levels which can occur from drug administration weeks before samples were taken in test barn or from contamination. Thus, thresholds are being adopted instead of LOD limits as is now the case for the RMTC threshold for mepivacaine.

Prominent racing states such as Oklahoma have adopted this new mepivacaine threshold of 50 pg/ml. This approach has also been adopted by the International Federation of Horseracing Authorities. Please note that this exhibit states 0.05 ng/ml which equals 50 pg/ml.

The Respondent believes that this quantification report is critical so that experts on the witness list can discuss the results from American Purr and evaluate whether levels are above or below the RMTC threshold and whether they are sufficient to result in performance altering effects.

In the summary judgement issued by Judge Eskew, item 12 states that the Commission does not follow and thus is not bound by RMTC guidelines. However, in communications from the Commission sent to race horse trainers (Hooser Horsepower, April 2016, Flat Racing Issue 1), the RMTC is stated as having the 'most up to date information' and directs horsemen to a link on the IHRC's website to the RMTC withdrawal guidelines and database. This clearly implies that the Commission is respecting RMTC's guidelines. Other Commission communications also point to RMTC as a credible agency associated with the IHRC.

The respondent thanks Judge Eskew and Lea Ellingwood for their consideration and professionalism in this case.

Respectfully submitted,

John McCreary



The IHRC Stewards notified McCreary of the positive tests and offered him the opportunity to request that split samples be tested. McCreary requested that the split be tested, and the University of California-Davis (“UC-Davis”) laboratory confirmed the presence of mepivacaine in the split sample. Mepivacaine is classified by the ARCI Uniform Classification Guidelines for Foreign Substances and Recommended Penalties and Model Rule (Version 12.00 revised on or about April 8, 2016, hereinafter “ARCI Uniform Guidelines”), as a Class 2 drug with a category “B” penalty classification (“Class 2-B foreign substance”).

On January 31, 2017, Commission Staff issued Administrative Complaint No. 217002 against McCreary, and the matter was assigned to be heard by ALJ Eskew.

On February 23, 2017, McCreary submitted a request asking the ALJ “directly request Dr. Scott Stanley of UC-Davis to provide” a report with the quantification (amount) of mepivacaine found in the split serum sample tested at that lab. Pursuant to 71 IAC 8.5-1-4.2(18), the Commission establishes that mepivacaine shall not be present in a horse at **any level** that exceeds “the LOD [level of detection] ... in serum or plasma.” (emphasis added). Thus, “any detectable amount of mepivacaine in a serum sample is sufficient for the Commission Staff to meet its burden of establishing a Rule violation.” (Recommended Order Granting Commission Staff’s Motion for Summary Judgment, pg. 2) Accordingly, ALJ Eskew denied McCreary’s request.

Commission Staff filed its Motion for Summary Judgment on June 16, 2017. McCreary timely replied. On July 17, 2017, ALJ Eskew issued her Recommended Order granting Staff’s Motion for Summary Judgment. Petitioner timely filed his objections, and the matter was scheduled for consideration during the Commission’s August 25, 2017 meeting. IHRC Chairman Philip Borst gave parties the opportunity to brief the issues.

Each of the Petitioner's objections to ALJ Eskew's Recommended Order is without merit. It is appropriate for the Commission to approve the ALJ's Recommended Order, and issue a Final Order in accordance therewith.

## II. RELEVANT LAW

The Indiana Horse Racing enabling statute is at Title 4, Article 31 of the Indiana Code (Pari-mutuel Wagering on Horse Races). Pursuant to the authority established in Title 4, Article 31, the IHRC has promulgated rules to regulate horse racing in Indiana. Those rules are codified at Title 71 of the Indiana Administrative Code. As an administrative agency, the IHRC also derives authority from and is restricted by the Administrative Orders and Procedures Act ("AOPA") (Indiana Code Title 4, Article 21.5).

In 1989, the Indiana state legislature charged the IHRC with ensuring that pari-mutuel wagering on horse races in Indiana will be conducted with the highest of standards and the greatest level of integrity. (*See* I.C. 4-31-1-2). The legislature further codified a restriction on foreign substances, stating that except as permitted by Commission rules, a horse participating in a race may not carry in its body any foreign substance. (*See* I.C. 4-31-12-2 (emphasis added)).

The following IHRC rules are most relevant to the McCreary disciplinary action:

### **71 IAC 5.5-3-2 Trainer responsibility**

Sec. 2. (a) The trainer is responsible for:

...;

(2) the presence of any prohibited drug, medication, or other substance, including permitted medication in excess of the maximum allowable level, in horses he or she trains; regardless of the acts of third parties. A positive test for a prohibited drug, medication, or substance, including permitted medication in excess of the maximum allowable level, as reported by a commission-approved laboratory, is prima facie evidence of a violation of this rule. In the absence of substantial evidence to the contrary, the trainer shall be responsible.

(b) A trainer shall prevent the administration of any drug or medication or other prohibited substance that may cause a violation of these rules.

...

### **71 IAC 8.5-1-2 Foreign substances prohibited**

Sec. 2. (a) No horse participating in a race shall carry in its body any foreign substance except as provided by these rules. A finding by the chemist or commission designee that a foreign substance is present in the test sample shall be prima facie evidence that such foreign substance was administered and carried in the body of the horse while participating in a race. Such a finding shall also be taken as prima facie evidence that the trainer and his or her agents responsible for the care or custody of the horse have been negligent in the handling or care of the horse.

(b) Upon a finding of a violation of this section, the owners or lessees of the horse from which the specimen was obtained shall forfeit any purse money and any trophy or award. However, forfeiture of any purse, trophy, or award for an overage of phenylbutazone, flunixin, ketoprofen, or furosemide in violation of these rules shall be consistent with Recommended Penalties of the Association of Racing Commissioners, International, as revised by the ARCI in 2014 and any other subsequent revision effective after said date, which are incorporated by reference herein, copies of which are available at the commission office.

**71 IAC 8.5-1-4.2 Threshold levels**

Authority: IC 4-31-3-9

Affected: IC 4-31-12

Sec. 4.2. The official blood (serum or plasma) and urine samples may contain only the following therapeutic medications, their metabolites or analogues, and shall not exceed the threshold concentrations specified in this rule:

...

(18) The use of mepivacaine shall be permitted under the following conditions: Not to exceed ten (10) nanograms per milliliter of total 3-hydroxymepivacaine in urine or the LOD of mepivacaine in serum or plasma. (emphasis added).

**III. ANALYSIS**

When McCreary applied for an Indiana Horse Racing Commission license in 2016, he subjected himself to the jurisdiction of the Indiana Horse Racing Commission, and explicitly agreed to know and abide by the rules of pari-mutuel horse racing in Indiana. Doping rules are paramount to the regulation of pari-mutuel horse racing. It was McCreary's obligation to know the IHRC medication rules, and to not run afoul of those rules. Yet in August of 2016, the McCreary-trained horse American Purr tested positive for mepivacaine. McCreary has presented no facts that successfully refute either of the positive tests. Mepivacaine is not allowed to be

present in a horse participating in pari-mutuel racing in Indiana at any level that can be detected in blood serum. If the substance is in the horse in an amount that can be detected in the blood serum, the trainer is in violation of 71 IAC 8.5-1-4.2, irrespective of whether the presence of the substance in the horse has had an impact on the horse's performance in a race. IHRC rules make the trainer responsible for the presence of a foreign substance in excess of maximum allowable limits (71 IAC 5.5-3-2(a)(2)).

#### IV. ARGUMENTS

##### **A. McCreary's Objections to the ALJ's Findings of Facts and Conclusions of Law**

The basis of McCreary's objections to the Recommended Order is that "pertinent evidence has not been released or reviewed by the parties." Specifically, McCreary states:

"To date, the serum sample from American Purr ... has only been reported as confirmed for the presence of mepivacaine with no quantification amount given even though the serum sample was analyzed quantitatively. It has been confirmed that the UC Davis laboratory has the result of this quantification. The respondent believes that this information is critical to determine if the level in American Purr's serum was above or below the threshold of 50 pg/ml. If the level is below the established threshold of 50 pg/ml, this would be considered a trace amount and would not be considered a sufficient amount to alter the horse's racing performance."

Mr. McCreary's argument fails on a number of points. First, the quantification report that McCreary seeks does not exist. Although the UC Davis laboratory has, during the course of its analysis, determined the quantity of mepivacaine in the pertinent blood serum sample, UC Davis has not created a report containing that information. Mr. McCreary is asking for a document that neither the Commission Staff nor UC Davis has.

Next, Respondent argues that the information is critical to determine if the level of the prohibited drug in American Purr's serum sample was above or below **the threshold of 50 pg/ml.** (emphasis added). As the ALJ found, there is no threshold of 50 pg/ml that is relevant to this case. Assuming *arguendo* that the RMTTC endorses a threshold of 50 pg/ml, that suggested

change to the existing drug limits has not been adopted by the Association of Racing Commissions International (“ARCI”), **nor has it been approved by the Indiana Horse Racing Commission.** The Commission does not follow, and therefore is not bound by the RMTC’s suggested guidelines for medication thresholds. The only relevant question at issue is whether a detectable amount of mepivacaine is present in the samples; the presence of mepivacaine has been identified both by Industrial Laboratory and UC Davis. Accordingly, any further quantification data from UC Davis is irrelevant to this case.

McCreary also argues that if the level of mepivacaine is below 50 pg/ml, the presence of the prohibited substance would be “considered a trace amount and would not be considered a sufficient amount to alter the horse’s racing performance.” In this case, for a determination that the Commission’s medication rules have been violated, Staff must prove by a preponderance of the evidence that the prohibited substance exists in the blood serum sample. In other words, Staff must prove that it is more likely than not that the primary lab, and the split lab, if appropriate has found enough of the prohibited drug in the sample to identify it. Staff is not required to prove the effect the drug had on the horse at the time of the race. The presence of mepivacaine is prohibited from being in a horse’s blood serum **at any detectable level** at the time of a race. McCreary’s horse had these substances in its system.

The rule in Indiana is clear: the finding by a chemist is prima facie evidence that the horse carried the substance in its system at the time of the race. McCreary has at no time presented any evidence that would suggest that either test was incorrect or that mepivacaine wasn’t in the horse’s system. Commission Staff met its burden, and the ALJ’s Ultimate Findings of Fact and Conclusions of Law are appropriate and should remain undisturbed.

## V. CONCLUSION



McCreary's objections to the ALJ's well reasoned and fully supported Recommended Order are without merit. Accordingly, Commission Staff respectfully requests that the Commission enter a Final Order affirming in all respects ALJ Eskew's Recommended Order of July 17, 2017, and that it impose the penalties recommended therein.

Respectfully submitted,



Lea Ellingwood, #22346-49  
Counsel to Indiana Horse Racing Commission Staff  
1302 North Meridian, Suite 175  
Indianapolis, IN 46204

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing has been served via electronic mail and deposited in the U.S. mail, first-class postage prepaid, on the 18<sup>th</sup> day of August, 2017, to:

Holly Newell  
Indiana Horse Racing Commission  
Deputy General Counsel  
1302 N. Meridian St. Ste. 175  
Indianapolis, IN 46204

John McCreary  
470 Keg Branch Rd.  
Cumberland Gap, TN 37724

Mike Smith  
Executive Director  
Indiana Horse Racing Commission  
1302 N. Meridian St. Ste. 175  
Indianapolis, IN 46204



Lea Ellingwood